WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

C12N 15/31, C07K 14/22, C12Q 1/68, G01N 33/53, A61K 39/095

A2

(11) International Publication Number:

WO 00/66741

- 1

(43) International Publication Date:

9 November 2000 (09.11.00)

(21) International Application Number:

PCT/IB00/00642

(22) International Filing Date:

28 April 2000 (28.04.00)

(30) Priority Data:

9910168.5 0005728.1 30 April 1999 (30.04.99) 9 March 2000 (09.03.00) GB GB

(71) Applicant (for all designated States except US): CHIRON S.P.A. [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): RAPPUOLI, Rino [IT/IT]; Chiron S.p.A., Via Fiorentina, 1, I-53100 Siena (IT).

(74) Agents: HALLYBONE, Huw, George et al.; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

Without international search report and to be republished upon receipt of that report.

(54) Title: CONSERVED NEISSERIAL ANTIGENS

(57) Abstract

To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of Neisseria, particularly N. meningitidis and N.gonorrhoeae.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
ΑT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Моласо	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	ÜA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of Americ
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand	٥.,	Zimonowe
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	. KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CONSERVED NEISSERIAL ANTIGENS

The contents of all documents cited herein are incorporated by reference in their entirety.

FIELD OF THE INVENTION

This invention relates to conserved antigens from the Neisseria bacteria.

5 BACKGROUND ART

Neisseria meningitidis and Neisseria gonorrhoeae are non-motile, gram negative diplococci that are pathogenic in humans.

Based on the organism's capsular polysaccharide, 12 serogroups of *N. meningitidis* have been identified. Group A is the pathogen most often implicated in epidemic disease in sub-Saharan Africa. Serogroups B and C are responsible for the vast majority of cases in the United States and in most developed countries. Serogroups W135 and Y are responsible for the rest of the cases in the United States and developed countries.

The meningococcal vaccine currently in use is a tetravalent polysaccharide vaccine composed of serogroups A, C, Y and W135. This approach cannot be used for Meningococcus B, however, because the menB capsular polysaccharide is a polymer of α(2-8)-linked N-acetyl neuraminic acid that is also present in mammalian tissue. One approach to a menB vaccine uses mixtures of outer membrane proteins (OMPs) To overcome the antigenic variability, multivalent vaccines containing up to nine different porins have been constructed [eg. Poolman (1992) Development of a meningococcal vaccine. Infect. Agents Dis. 4:13-28]. Additional proteins to be used in outer membrane vaccines have been the opa and opc proteins, but none of these approaches have been able to overcome the antigenic variability [eg. Ala'Aldeen & Borriello (1996) The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine 14(1):49-53].

A large number of Neisserial protein and nucleotide sequences are disclosed in WO99/24578, WO99/36544, WO99/57280 and WO00/22430. The contents of these four applications are incorporated herein by reference. Comprehensive sequence data from strain MC58 is disclosed in Tettelin *et al.* [Science (2000) 287:1809-1815], the contents of which are also incorporated herein by reference.

BNSDOCID: <WO_____0066741A2_I_>

5

DESCRIPTION OF THE INVENTION

To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention therefore provides proteins which comprise stretches of amino acid sequence that are shared across the majority of *Neisseria*, particularly *N. meningitidis* and *N. gonorrhoeae*.

The invention provides a protein comprising a fragment of a Neisserial protein, wherein said fragment consists of n consecutive conserved amino acids, with the proviso that the invention does not include within its scope full-length Neisserial proteins. Depending on the particular protein, n is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20 or more). The fragment preferably comprises an antigenic or immunogenic region of the Neisserial protein.

A "conserved" amino acid is one that is present in a particular Neisserial protein in at least x% or Neisseria. The value of x may be 50% or more eg. 66%, 75%, 80%, 90%, 95% or even 100% (ie. the amino acid is found in the protein in question in all Neisseria).

In order to determine whether an amino acid is "conserved" in a particular Neisserial protein, it is necessary to compare that amino acid residue in the sequences of the protein in question from a plurality of different Neisseria (a "reference population"). The reference population may include a number of different Neisseria species (preferably N.meningitidis and N.gonorrhoeae) or may include a single species. The reference population may include a number of different serogroups of a particular species (such as the A, B, C, W135, X, Y, Z and 29E serogroups of N.meningitidis) or a single serogroup. The reference population may also include a number of different strains from a particular serogroup (such as the NG6/88, BZ198, NG3/88, 297-f) BZ147, BZ169, 528, BZ133, NGE31, NGH38, NGH15, BZ232, BZ83, and 44/76 strains of N.meningitidis B). A preferred reference population consists of the 5 most common strains of N. meningitidis and/or the 5 most common strains of N.gonorrhoeae.

- The reference population preferably comprises k strains taken from k different branches of a suitable phylogenetic tree, such as those disclosed in (a) Ni et al. (1992) Epidemiol Infect 109:227-239 (b) Wolff et al. (1992) Nucleic Acids Res 20:4657 (c) Bygraves & Maiden (1992) J. Gen. Microbiol. 138:523-531 (d) Caugant et al. (1987) J. Bacteriol. 69:2781-2792. Another phylogenetic tree that can be used is shown in Figure 8 herein, and another in Figure 9b.
- 30 It will be appreciated that a particular species, serogroup or strain should only be included in the reference population if it encodes the protein in which the amino acid in question is located. In

the case of amino acids within ORF40 described below, for instance, the reference population should not include N. gonorrhoeae because this species does not contain ORF40.

For proteins found in both N.meningitidis and N.gonorrhoeae, therefore, a preferred reference population comprises:

- 5 N.meningitidis A, strain Z2491
 - N.meningitidis B, strains NG6/88
 - N.meningitidis W, strains A22
 - N.gonorrhoeae, strain Ng F62

These are described in (a) Seiler A. et al. (1996) Mol. Microbiol. 19(4):841-856 (b) Maiden et al. (1998) Proc. Natl. Acad. Sci. USA 95:3140-3145 (c) Virji et al. (1992) Mol. Microbiol. 6:1271-1279 (d) Dempsey et al. (1991) J. Bacteriol. 173:5476-5486.

For proteins found only in N. meningitidis, however, a preferred reference population comprises:

- N.meningitidis A, strain Z2491
- N.meningitidis B, strains NG6/88
- 15 N.meningitidis W, strains A22

Amino acid sequences of different Neissieriae can easily be compared using computers. This will typically involve the alignment of a number of sequences using an algorithm such as CLUSTAL [Thompson et al. (1994) Nucleic Acids Res 22:4673-4680; Trends Biochem Sci (1998) 23:403-405] or, preferably, PILEUP [part of the GCG Wisconsin package, preferably version 9.01.

Conserved amino acids are readily apparent in a multiple sequence alignment – at the amino acid position in question a majority of the aligned sequences will contain a particular amino acid. Conserved amino acids can be made more visually apparent by using a program such as BOXSHADE [available, for instance, at the NIH on-line], PRETTYBOX [GCG Wisconsin, version 10] or JALVIEW [available on-line at EBI].

25

The protein preferably comprises a fragment of one of the proteins disclosed in WO99/24578, WO99/36544, WO99/57280 or WO00/22430, or of one of the 2158 ORFs disclosed in Tettelin et al. [Science (2000) 287:1809-1815]. More particularly, it preferably comprises a fragment of one or more of ORF4, ORF40, ORF46, protein 225, protein 235, protein 287, protein 519, protein 726, protein 919 and protein 953 disclosed therein (see examples herein). Typically, the

30

protein of the invention will not comprise a protein sequence explicitly disclosed in WO99/24578, WO99/36544, WO99/57280, WO00/22430, or Tettelin et al.

The invention also provides a protein comprising one of the sequences shown in the Figures.

The proteins of the invention can, of course, be prepared by various means (eg. recombinant expression, native expression, purification from cell culture, chemical synthesis etc.) and in various forms (eg. native, fusions etc.). They are preferably prepared in substantially pure form (ie. substantially free from other Neisserial or host cell proteins)

According to a further aspect, the invention provides antibodies which bind to these proteins. These may be polyclonal or monoclonal and may be produced by any suitable means.

10 According to a further aspect, the invention provides nucleic acid encoding the proteins of the invention. It should also be appreciated that the invention provides nucleic acid comprising sequences complementary to these (eg. for antisense or probing purposes).

Furthermore, the invention provides nucleic acid which can hybridise to the *N.meningitidis* nucleic acid disclosed in the examples, preferably under "high stringency" conditions (eg. 65°C in a 0.1xSSC, 0.5% SDS solution).

Nucleic acid according to the invention can, of course, be prepared in many ways (eg. by chemical synthesis, from genomic or cDNA libraries, from the organism itself etc.) and can take various forms (eg. single stranded, double stranded, vectors, probes etc.).

In addition, the term "nucleic acid" includes DNA and RNA, and also their analogues, such a those containing modified backbones, and also peptide nucleic acids (PNA) etc.

According to a further aspect, the invention provides vectors comprising nucleotide sequences of the invention (eg. expression vectors) and host cells transformed with them.

According to a further aspect, the invention provides compositions comprising protein, antibody, and/or nucleic acid according to the invention. These compositions may be suitable as vaccines, for instance, or as diagnostic reagents, or as immunogenic compositions.

The invention also provides nucleic acid, protein, or antibody according to the invention for use as medicaments (eg. as vaccines) or as diagnostic reagents. It also provides the use of nucleic acid, protein, or antibody according to the invention in the manufacture of: (i) a medicament for treating or preventing infection due to Neisserial bacteria; (ii) a diagnostic reagent for detecting

the presence of Neisserial bacteria or of antibodies raised against Neisserial bacteria; and/or (iii) a reagent which can raise antibodies against Neisserial bacteria. The use is preferably applicable to all species of *Neisseria*.

Where a Neisserial protein contains more than q% conserved amino acids, the invention provides the use of the Neisserial protein, or a fragment thereof, as a non-strain-specific protein that exhibits cross-reactivity between many species, serogroups and strains. The value of q may be 50%, 60%, 75%, 80%, 90%, 95% or even 100%.

The invention also provides a method of treating a patient, comprising administering to the patient a therapeutically effective amount of nucleic acid, protein, and/or antibody according to the invention.

According to further aspects, the invention provides various processes.

A process for producing proteins of the invention is provided, comprising the step of culturing a host cell according to the invention under conditions which induce protein expression.

A process for producing protein or nucleic acid of the invention is provided, wherein the protein or nucleic acid is synthesised in part or in whole using chemical means.

A process for detecting polynucleotides of the invention is provided, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting said duplexes.

A process for detecting proteins of the invention is provided, comprising the steps of: (a) contacting an antibody according to the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes.

A summary of standard techniques and procedures which may be employed in order to perform the invention (eg. to utilise the disclosed sequences for vaccination or diagnostic purposes) follows. This summary is not a limitation on the invention but, rather, gives examples that may be used, but are not required.

General

25

 $(\dot{})$

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature eg. Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and ii (D.N Glover ed. 1985); Oligonucleotide

PCT/IB00/00642

Synthesis (M.J. Gait ed, 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); Transcription and Translation (B.D. Hames & S.J. Higgins eds. 1984); Animal Cell Culture (R.I. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Mayer and Walker, eds. (1987), Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); Scopes, (1987) Protein Purification: Principles and Practice, Second Edition (Springer-Verlag, N.Y.), and Handbook of Experimental Immunology, Volumes I-IV (D.M. Weir and C. C. Blackwell eds 1986).

10 Standard abbreviations for nucleotides and amino acids are used in this specification.

All publications, patents, and patent applications cited herein are incorporated in full by reference. In particular, the contents of international patent applications WO99/24578, WO99/36544, WO99/57280 and WO00/22430 are incorporated herein.

Definitions

A composition containing X is "substantially free of" Y when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95% or even 99% by weight.

The term "comprising" means "including" as well as "consisting" eg. a composition "comprising" X may consist exclusively of X or may include something additional to X, such as X+Y.

The term "heterologous" refers to two biological components that are not found together in nature. The components may be host cells, genes, or regulatory regions, such as promoters. Although the heterologous components are not found together in nature, they can function together, as when a promoter heterologous to a gene is operably linked to the gene. Another example is where a Neisserial sequence is heterologous to a mouse host cell. A further examples would be two epitopes from the same or different proteins which have been assembled in a single protein in an arrangement not found in nature.

An "origin of replication" is a polynucleotide sequence that initiates and regulates replication of polynucleotides, such as an expression vector. The origin of replication behaves as an autonomous unit of polynucleotide replication within a cell, capable of replication under its own control. An origin of replication may be needed for a vector to replicate in a particular host cell. With certain origins of replication, an expression vector can be reproduced at a high copy number in the presence of the appropriate

5

10

20

25

()

proteins within the cell. Examples of origins are the autonomously replicating sequences, which are effective in yeast; and the viral T-antigen, effective in COS-7 cells.

A "mutant" sequence is defined as DNA, RNA or amino acid sequence differing from but having sequence identity with the native or disclosed sequence. Depending on the particular sequence, the degree of sequence identity between the native or disclosed sequence and the mutant sequence is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more, calculated using the Smith-Waterman algorithm as described above). As used herein, an "allelic variant" of a nucleic acid molecule, or region, for which nucleic acid sequence is provided herein is a nucleic acid molecule, or region, that occurs essentially at the same locus in the genome of another or second isolate, and that, due to natural variation caused by, for example, mutation or recombination, has a similar but not identical nucleic acid sequence. A coding region allelic variant typically encodes a protein having similar activity to that of the protein encoded by the gene to which it is being compared. An allelic variant can also comprise an alteration in the 5' or 3' untranslated regions of the gene, such as in regulatory control regions (eg. see US patent 5,753,235).

Expression systems

15 The Neisserial nucleotide sequences can be expressed in a variety of different expression systems; for example those used with mammalian cells, baculoviruses, plants, bacteria, and yeast.

i. Mammalian Systems

Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence (eg. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation [Sambrook et al. (1989) "Expression of Cloned Genes in Mammalian Cells." In Molecular Cloning: A Laboratory Manual, 2nd ed.].

Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallotheionein gene, also provide useful promoter sequences. Expression may be either

constitutive or regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.

The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) Science 236:1237; Alberts et al. (1989) Molecular Biology of the Cell, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer [Dijkema et al (1985) EMBO J. 4:761] and the enhancer/promoters derived from the long terminal repeal (LTR) of the Rous Sarcoma Virus [Gorman et al. (1982b) Proc. Natl. Acad. Sci. 79:6777] and from human cytomegalovirus [Boshart et al. (1985) Cell 41:521]. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion [Sassone-Corsi and Borelli (1986) Trends Genet. 2:215; Maniatis et al. (1987) Science 236:1237].

A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus triparite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.

Usually, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation [Birnstiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of eukaryotic RNA. In Transcription and splicing (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105]. These sequences direct the

transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminater/polyadenylation signals include those derived from SV40 [Sambrook et al (1989) "Expression of cloned genes in cultured mammalian cells." In *Molecular Cloning: A Laboratory Manual*].

Usually, the above described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40 [Gluzman (1981) Cell 23:175] or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replicaton systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a prokaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al. (1989) Mol. Cell. Biol. 9:946] and pHEBO [Shimizu et al. (1986) Mol. Cell. Biol. 6:1074].

The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (eg. Hep G2), and a number of other cell lines.

ii. Baculovirus Systems

The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art. Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous

15

20

25

recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.

After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant plaques are identified and purified. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *inter alia*, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555* (1987) (hereinafter "Summers and Smith").

Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription, termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector). This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its owned set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.

Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373.

20 Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a Bamle cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, Virology (1989) 17:31.

The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) *Ann. Rev. Microbiol.*, 42:177) and a prokaryotic ampicillin-resistance (amp) gene and origin of replication for selection and propagation in *E. coli*.

Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a coding sequence (eg. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A

baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.

Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) "The Regulation of Baculovirus Gene Expression," in: *The Molecular Biology of Baculoviruses* (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlak et al., (1988), *J. Gen. Virol.* 69:765.

DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988) *Gene*, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, leaders of non-insect origin, such as those derived from genes encoding human α-interferon, Maeda et al., (1985), *Nature 315*:592; human gastrin-releasing peptide, Lebacq-Verheyden et al., (1988), *Molec. Cell. Biol. 8*:3129; human IL-2, Smith et al., (1985) *Proc. Nat'l Acad. Sci. USA*, 82:8404; mouse IL-3, (Miyajima et al., (1987) *Gene 58*:273; and human glucocerebrosidase, Martin et al. (1988) *DNA*, 7:99, can also be used to provide for secretion in insects.

A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by *in vitro* incubation with cyanogen bromide.

Alternatively, recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.

After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus -- usually by co-transfection. The promoter and transcription termination sequence of the construct will usually comprise a 2-5kb section of the baculovirus genome.

desired site in the baculovirus viru

Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith *supra*; Ju et al. (1987); Smith et al., *Mol. Cell. Biol.* (1983) 3:2156; and Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), *Bioessays 4*:91. The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.

The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual scree allowing recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15 µm in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith, *supra*; Miller et al. (1989).

Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, *inter alia*: Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni (WO 89/046699; Carbonell et al., (1985) J. Virol. 56:153; Wright (1986) Nature 321:718; Smith et al., (1983) Mol. Cell. Biol. 3:2156; and see generally, Fraser, et al. (1989) In Vitro Cell. Dev. Biol. 25:225).

Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. See, eg. Summers and Smith supra.

The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to high density, and expression induced. Alternatively,

where expression is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, eg. HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a product which is at least substantially free of host debris, eg. proteins, lipids and polysaccharides.

In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.

iii. Plant Systems

There are many plant cell culture and whole plant genetic expression systems known in the art. Exemplary plant cellular genetic expression systems include those described in patents, such as: US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 30:3861-3863 (1991). Descriptions of plant protein signal peptides may be found in addition to the references described above in Vaulcombe et al., *Mol. Gen. Genet.* 209:33-40 (1987); Chandler et al., *Plant Molecular Biology* 3:407-418 (1984); Rogers, *J. Biol. Chem.* 260:3731-3738 (1985); Rothstein et al., *Gene* 55:353-356 (1987); Whittier et al., Nucleic Acids Research 15:2515-2535 (1987); Wirsel et al., *Molecular Microbiology* 3:3-14 (1989); Yu et al., *Gene* 122:247-253 (1992). A description of the regulation of plant gene expression by the phytohormone, gibberellic acid and secreted enzymes induced by gibberellic acid can be found in R.L. Jones and J. MacMillin, Gibberellins: in: *Advanced Plant Physiology*, Malcolm B. Wilkins, ed., 1984 Pitman Publishing Limited, London, pp. 21-52. References that describe other metabolically-regulated genes: Sheen, *Plant Cell*, 2:1027-1038(1990); Maas et al., *EMBO J.* 9:3447-3452 (1990); Benkel and Hickey, *Proc. Natl. Acad. Sci.* 84:1337-1339 (1987)

Typically, using techniques known in the art, a desired polynucleotide sequence is inserted into an expression cassette comprising genetic regulatory elements designed for operation in plants. The expression cassette is inserted into a desired expression vector with companion sequences upstream and downstream from the expression cassette suitable for expression in a plant host. The companion sequences will be of plasmid or viral origin and provide necessary characteristics to the vector to permit the vectors to move DNA from an original cloning host, such as bacteria, to the desired plant host. The basic bacterial/plant vector construct will preferably provide a broad host range prokaryote replication origin; a

25

prokaryote selectable marker; and, for Agrobacterium transformations, T DNA sequences for Agrobacterium-mediated transfer to plant chromosomes. Where the heterologous gene is not readily amenable to detection, the construct will preferably also have a selectable marker gene suitable for determining if a plant cell has been transformed. A general review of suitable markers, for example for the members of the grass family, is found in Wilmink and Dons, 1993, *Plant Mol. Biol. Reptr.*, 11(2):165-185.

Sequences suitable for permitting integration of the heterologous sequence into the plant genome are also recommended. These might include transposon sequences and the like for homologous recombination as well as Ti sequences which permit random insertion of a heterologous expression cassette into a plant genome. Suitable prokaryote selectable markers include resistance toward antibiotics such as ampicillin or tetracycline. Other DNA sequences encoding additional functions may also be present in the vector, as is known in the art.

The nucleic acid molecules of the subject invention may be included into an expression cassette for expression of the protein(s) of interest. Usually, there will be only one expression cassette, although two or more are feasible. The recombinant expression cassette will contain in addition to the heterologous protein encoding sequence the following elements, a promoter region, plant 5' untranslated sequences, initiation codon depending upon whether or not the structural gene comes equipped with one, and a transcription and translation termination sequence. Unique restriction enzyme sites at the 5' and 3' ends of the cassette allow for easy insertion into a pre-existing vector.

A heterologous coding sequence may be for any protein relating to the present invention. The sequence encoding the protein of interest will encode a signal peptide which allows processing and translocation of the protein, as appropriate, and will usually lack any sequence which might result in the binding of the desired protein of the invention to a membrane. Since, for the most part, the transcriptional initiation region will be for a gene which is expressed and translocated during germination, by employing the signal peptide which provides for translocation, one may also provide for translocation of the protein of interest. In this way, the protein(s) of interest will be translocated from the cells in which they are expressed and may be efficiently harvested. Typically secretion in seeds are across the aleurone or scutellar epithelium layer into the endosperm of the seed. While it is not required that the protein be secreted from the cells in which the protein is produced, this facilitates the isolation and purification of the recombinant protein.

Since the ultimate expression of the desired gene product will be in a eucaryotic cell it is desirable to determine whether any portion of the cloned gene contains sequences which will be processed out as introns by the host's splicosome machinery. If so, site-directed mutagenesis of the "intron" region may be

5

10

15

conducted to prevent losing a portion of the genetic message as a false intron code, Reed and Maniatis, *Cell* 41:95-105, 1985.

The vector can be microinjected directly into plant cells by use of micropipettes to mechanically transfer the recombinant DNA. Crossway, *Mol. Gen. Genet*, 202:179-185, 1985. The genetic material may also be transferred into the plant cell by using polyethylene glycol, Krens, et al., *Nature*, 296, 72-74, 1982. Another method of introduction of nucleic acid segments is high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface, Klein, et al., *Nature*, 327, 70-73, 1987 and Knudsen and Muller, 1991, *Planta*, 185:330-336 teaching particle bombardment of barley endosperm to create transgenic barley. Yet another method of introduction would be fusion of protoplasts with other entities, either minicells, cells, lysosomes or other fusible lipid-surfaced bodies, Fraley, et al., *Proc. Natl. Acad. Sci. USA*, 79, 1859-1863, 1982.

The vector may also be introduced into the plant cells by electroporation. (Fromm et al., *Proc. Natl Acad. Sci. USA* 82:5824, 1985). In this technique, plant protoplasts are electroporated in the presence of plasmids containing the gene construct. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and form plant callus.

All plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be transformed by the present invention so that whole plants are recovered which contain the transferred gene. It is known that practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugarcane, sugar beet, cotton, fruit and other trees, legumes and vegetables. Some suitable plants include, for example, species from the genera Fragaria, Lotus, Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Datura, Hyoscyamus, Lycopersion, Nicotiana, Solanum, Petunia, Digitalis, Majorana, Cichorium, Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Hererocallis, Nemesia, Pelargonium, Panicum, Pennisetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Glycine, Lolium, Zea, Triticum, Sorghum, and Datura.

Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts containing copies of the heterologous gene is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced from the protoplast suspension. These embryos germinate as natural embryos to form plants. The culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and

alfalfa. Shoots and roots normally develop simultaneously. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is fully reproducible and repeatable.

In some plant cell culture systems, the desired protein of the invention may be excreted or alternatively, the protein may be extracted from the whole plant. Where the desired protein of the invention is secreted into the medium, it may be collected. Alternatively, the embryos and embryoless-half seeds or other plant tissue may be mechanically disrupted to release any secreted protein between cells and tissues. The mixture may be suspended in a buffer solution to retrieve soluble proteins. Conventional protein isolation and purification methods will be then used to purify the recombinant protein. Parameters of time, temperature pH, oxygen, and volumes will be adjusted through routine methods to optimize expression and recovery of heterologous protein.

iv. Bacterial Systems

Bacterial expression techniques are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (eg. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in Escherichia coli (E. coli) [Raibaud et al. (1984) Annu. Rev. Genet. 18:173]. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (*lac*) [Chang *et al.* (1977) *Nature 198*:1056], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (*trp*) [Goeddel *et al.* (1980) *Nuc. Acids Res. 8*:4057; Yelverton *et al.* (1981) *Nucl. Acids Res. 9*:731; US patent 4,738,921; EP-A-0036776 and EP-A-0121775]. The g-laotamase (*bla*) promoter system [Weissmann (1981) "The cloning of interferon and other mistakes."

5

15

In *Interferon 3* (ed. I. Gresser)], bacteriophage lambda PL [Shimatake *et al.* (1981) *Nature 292*:128] and T5 [US patent 4,689,406] promoter systems also provide useful promoter sequences.

In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [US patent 4,551,433]. For example, the *tac* promoter is a hybrid *trp-lac* promoter comprised of both *trp* promoter and *lac* operon sequences that is regulated by the *lac* repressor [Amann *et al.* (1983) *Gene 25*:167; de Boer *et al.* (1983) *Proc. Natl. Acad. Sci. 80*:21]. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier *et al.* (1986) *J. Mol. Biol. 189*:113; Tabor *et al.* (1985) *Proc Natl. Acad. Sci. 82*:1074]. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an *E. coli* operator region (EPO-A-0 267 851).

In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In *E. coli*, the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [Shine *et al.* (1975) *Nature 254*:34]. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' and of *E. coli* 16S rRNA [Steitz *et al.* (1979) "Genetic signals and nucleotide sequences in messenger RNA." In *Biological Regulation and Development: Gene Expression* (ed. R.F. Goldberger)]. To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site [Sambrook *et al.* (1989) "Expression of cloned genes in Escherichia coli." In *Molecular Cloning: A Laboratory Manual*].

- A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide or by either *in vivo* on *in vitro* incubation with a bacterial methionine N-terminal peptidase (EPO-A-0 219 237).
- Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid

sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing

enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene [Nagai et al. (1984) Nature 309:810]. Fusion proteins can also be made with sequences from the lacZ [Jia et al. (1987) Gene 60:197],

trpE [Allen et al. (1987) J. Biotechnol. 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:11], and Chey

[EP-A-0 324 647] genes. The DNA sequence at the junction of the two amino acid sequences may or may

not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made

with the ubiquitin region that preferably retains a site for a processing enzyme (eg. ubiquitin specific

processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign

protein can be isolated [Miller et al. (1989) Bio/Technology 7:698].

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules the encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria [US patent 4,336,336]. The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either *in vivo* or *in vitro* encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the *E. coli* outer membrane protein gene (*ompA*) [Masui et al. (1983), in: Experimental Manipulation of Gene Expression; Ghrayeb et al. (1984) EMBO J. 3:2437] and the E. coli alkaline phosphatase signal sequence (*phoA*) [Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212]. As an additional example, the signal sequence of the alpha-amylase gene from various Bacillus strains can be used to secrete heterologous proteins from B. subtilis [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EP-A-0 244 042].

Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the *trp* gene in *E. coli* as well as other biosynthetic genes.

Usually, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various Bacillus strains integrate into the Bacillus chromosome (EP-A- 0 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies et al. (1978) Annu. Rev. Microbiol. 32:469]. Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable market that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, *inter alia*, the following bacteria: Bacillus subtilis [Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA 79*:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541], Escherichia coli [Shimatake *et al.* (1981) *Nature 292*:128; Amann *et al.* (1985) *Gene 40*:183; Studier *et al.* (1986) *J. Mol. Biol. 189*:113; EP-A-0 036 776,EP-A-0 136 829 and EP-A-0 136 907], Streptococcus cremoris [Powell *et al.* (1988) *Appl.*

25

 $(\)$

Environ. Microbiol. 54:655]; Streptococcus lividans [Powell et al. (1988) Appl. Environ. Microbiol. 54:655], Streptomyces lividans [US patent 4,745,056].

Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl₂ or other agents, such as divalent cations and DMSO. 5 DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See eg. [Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EP-A-0 036 259 and EP-A-0 063 953; WO 84/04541, Bacillus], [Miller et al. (1988) Proc. Natl. Acad. Sci. 85:856; Wang et al. (1990) J. Bacteriol. 172:949, Campylobacter], [Cohen et al. (1973) Proc. Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic 10 Acids Res. 16:6127; Kushner (1978) "An improved method for transformation of Escherichia coli with ColE1-derived plasmids. In Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering (eds. H.W. Boyer and S. Nicosia); Mandel et al. (1970) J. Mol. Biol. 53:159; Taketo (1988) Biochim. Biophys. Acta 949:318; Escherichia], [Chassy et al. (1987) FEMS Microbiol. Lett. 44:173 Lactobacillus]; [Fiedler et al. (1988) Anal. Biochem 170:38, Pseudomonas]; [Augustin et al. (1990) FEMS Microbiol. Lett. 66:203, Staphylococcus, [Barany et al. (1980) J. Bacteriol. 144:698; Harlander (1987) "Transformation of Streptococcus lactis by electroporation, in: Streptococcal Genetics (ed. J. Ferretti and R. Curtiss III); Perry et al. (1981) Infect. Immun. 32:1295; Powell et al. (1988) Appl. Environ. Microbiol. 54:655; Somkuti et al. (1987) Proc. 4th Evr. Cong. Biotechnology 1:412, Streptococcusl.

v. Yeast Expression

Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (eg. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.

Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EP-A-0 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO-A-0 329 203). The yeast *PHO5* gene, encoding

5

20

acid phosphatase, also provides useful promoter sequences [Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1].

In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (US Patent Nos. 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, OR PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EP-A-0 164 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter alia, [Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) "The Expression of Bacterial Antibiotic Resistance Genes in the Yeast Saccharomyces cerevisiae," in: Plasmids of Medical, Environmental and Commercial Importance (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109;].

A DNA molecule may be expressed intracellularly in yeast. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, baculovirus, and bacterial expression systems. Usually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See eg. EP-A-0 196 056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (eg. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (eg. WO88/024066).

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for

WO 00/66741 PCT/IB00/00642

secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EP-A-0 012 873; JPO. 62,096,086) and the A-factor gene (US patent 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (EP-A-0 060 057).

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well a truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (US Patents 4,546,083 and 4,870,008; EP-A-0 324 274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (eg. see WO 89/02463.)

Usually, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.

Usually, the above described components, comprising a promoter, leader (if desired), coding sequence (interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (eg. plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a prokaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 [Botstein et al. (1979) Gene 8:17-24], pCl/1 [Brake et al. (1984) Proc. Natl. Acad. Sci USA 81:4642-4646], and YRp17 [Stinchcomb et al. (1982) J. Mol. Biol. 158:157]. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Enter a high or low copy number

30

vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See eg. Brake et al., supra.

Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver et al. (1983) Methods in Enzymol. 101:228-245]. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver et al., supra. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced [Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750]. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of CUP1 allows yeast to grow in the presence of copper ions [Butt et al. (1987) Microbiol, Rev. 51:351].

Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts:Candida albicans [Kurtz, et al. (1986) Mol. Cell. Biol. 6:142], Candida maltosa [Kunze, et al. (1985) J. Basic Microbiol. 25:141]. Hansenula polymorpha [Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302], Kluyveromyces fragilis
[Das, et al. (1984) J. Bacteriol. 158:1165], Kluyveromyces lactis [De Louvencourt et al. (1983) J. Bacteriol. 154:737; Van den Berg et al. (1990) Bio/Technology 8:135], Pichia guillerimondii [Kunze et al. (1985) J. Basic Microbiol. 25:141], Pichia pastoris [Cregg, et al. (1985) Mol. Cell. Biol. 5:3376; US Patent

()

Nos. 4,837,148 and 4,929,555], Saccharomyces cerevisiae [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163], Schizosaccharomyces pombe [Beach and Nurse (1981) Nature 300:706], and Yarrowia lipolytica [Davidow, et al. (1985) Curr. Genet. 10:380471 Gaillardin, et al. (1985) Curr. Genet. 10:49].

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See eg. [Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141; Candida]; [Gleeson et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; Hansenula]; [Das et al. (1984) J. Bacteriol. 158:1165; De Louvencourt et al. (1983) J. Bacteriol. 154:1165; Van den Berg et al. (1990) Bio/Technology 8:135; Kluyveromyces]; [Cregg et al. (1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985) . Basic Microbiol. 25:141; US Patent Nos. 4,837,148 and 4,929,555; Pichia]; [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75;1929; Ito et al. (1983) J. Bacteriol. 153:163 Saccharomyces]; [Beach and Nurse (1981) Nature 300:706; Schizosaccharomyces]; [Davidow et al. (1985) Curr. Genet. 10:39; Gaillardin et al.
(1985) Curr. Genet. 10:49; Yarrowia].

Antibodies

20

As used herein, the term "antibody" refers to a polypeptide or group of polypeptides composed of at least one antibody combining site. An "antibody combining site" is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows a binding of the antibody with the antigen. "Antibody" includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanised antibodies, altered antibodies, univalent antibodies, Fab proteins, and single domain antibodies.

Antibodies against the proteins of the invention are useful for affinity chromatography, immunoassays, and distinguishing/identifying Neisserial proteins.

Antibodies to the proteins of the invention, both polyclonal and monoclonal, may be prepared by conventional methods. In general, the protein is first used to immunize a suitable animal, preferably a mouse, rat, rabbit or goat. Rabbits and goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of labeled anti-rabbit and anti-goat antibodies. Immunization is generally performed by mixing or emulsifying the protein in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 μg/injection is typically sufficient. Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline, preferably using

Freund's incomplete adjuvant. One may alternatively generate antibodies by in vitro immunization using methods known in the art, which for the purposes of this invention is considered equivalent to in vivo immunization. Polyclonal antisera is obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25°C for one hour, followed by incubating at 4°C for 2-18 hours. The serum is recovered by centrifugation (eg. 1,000g for 10 minutes). About 20-50 ml per bleed may be obtained from rabbits.

Monoclonal antibodies are prepared using the standard method of Kohler & Milstein [Nature (1975) 256:495-96], or a modification thereof. Typically, a mouse or rat is immunized as described above. However, rather than bleeding the animal to extract serum, the spleen (and optionally several large lymph nodes) is removed and dissociated into single cells. If desired, the spleen cells may be screened (after removal of nonspecifically adherent cells) by applying a cell suspension to a plate or well coated with the protein antigen. B-cells expressing membrane-bound immunoglobulin specific for the antigen bind to the plate, and are not rinsed away with the rest of the suspension. Resulting B-cells, or all dissociated spleen cells, are then induced to fuse with myeloma cells to form hybridomas, and are cultured in a selective medium (eg. hypoxanthine, aminopterin, thymidine medium, "HAT"). The resulting hybridomas are plated by limiting dilution, and are assayed for the production of antibodies which bind specifically to the immunizing antigen (and which do not bind to unrelated antigens). The selected MAb-secreting hybridomas are then cultured either in vitro (eg. in tissue culture bottles or hollow fiber reactors), or in vivo (as ascites in mice).

If desired, the antibodies (whether polyclonal or monoclonal) may be labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly ³²P and ¹²⁵I), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3',5,5'-tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. "Specific binding partner" refers to a protein capable of binding a ligand molecule with high specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor. Other specific binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. It should be understood that the above description is not meant to categorize the various labels into distinct classes, as the same label may serve in several different modes. For example, ¹²⁵I may serve as a radioactive label or as an electron-dense reagent. HRP may serve as enzyme or as antigen for a MAb. Further, one may combine various labels for desired effect. For example, MAbs and avidin also require labels in the practice of this invention: thus, one might label a MAb with biotin, and detect its presence with avidin labeled with ¹²⁵I, or with an anti-biotin MAb labeled with HRP. Other permutations

()

10

20

and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.

Pharmaceutical Compositions

Pharmaceutical compositions can comprise either polypeptides, antibodies, or nucleic acid of the invention.

The pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides, antibodies, or polynucleotides of the claimed invention.

The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given

For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

situation can be determined by routine experimentation and is within the judgement of the clinician.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions

are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

Delivery Methods

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (eg. see WO98/20734), needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

Vaccines

Vaccines according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie. to treat disease after infection).

Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with "pharmaceutically acceptable carriers," which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, etc. pathogens.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59TM (WO 90/14837; Chapter 10 in *Vaccine design: the subunit and adjuvant approach*, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer

such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RibiTM adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DetoxTM); (3) saponin adjuvants, such as StimulonTM (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (eg. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (eg. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59TM are preferred.

As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.

The immunogenic compositions (eg. the immunising antigen/immunogen/polypeptide/protein/ nucleic acid, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.

Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (eg. nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating

15

doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

The immunogenic compositions are conventionally administered parenterally, eg. by injection, either subcutaneously, intramuscularly, or transdermally/transcutaneously (eg. WO98/20734). Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

As an alternative to protein-based vaccines, DNA vaccination may be employed [eg. Robinson & Torres (1997) Seminars in Immunology 9:271-283; Donnelly et al. (1997) Annu Rev Immunol 15:617-648; see later herein].

Gene Delivery Vehicles

Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention, to be delivered to the mammal for expression in the mammal, can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches in *in vivo* or *ex vivo* modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence in vivo can be either constitutive or regulated.

The invention includes gene delivery vehicles capable of expressing the contemplated nucleic acid sequences. The gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vector. The viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, or togavirus viral vector. See generally, Jolly (1994) Cancer Gene Therapy 1:51-64; Kimura (1994) Human Gene Therapy 5:845-852; Connelly (1995) Human Gene Therapy 6:185-193; and Kaplitt (1994) Nature Genetics 6:148-153.

Retroviral vectors are well known in the art and we contemplate that any retroviral gene therapy vector is employable in the invention, including B, C and D type retroviruses, xenotropic retroviruses (for example, NZB-X1, NZB-X2 and NZB9-1 (see O'Neill (1985) *J. Virol.* 53:160) polytropic retroviruses *eg.* MCF and MCF-MLV (see Kelly (1983) *J. Virol.* 45:291), spumaviruses and lentiviruses. See RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985.

Portions of the retroviral gene therapy vector may be derived from different retroviruses. For example, retrovector LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma

()

Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.

These recombinant retroviral vectors may be used to generate transduction competent retroviral vector particles by introducing them into appropriate packaging cell lines (see US patent 5,591,624). Retrovirus vectors can be constructed for site-specific integration into host cell DNA by incorporation of a chimeric integrase enzyme into the retroviral particle (see WO96/37626). It is preferable that the recombinant viral vector is a replication defective recombinant virus.

Packaging cell lines suitable for use with the above-described retrovirus vectors are well known in the art, are readily prepared (see WO95/30763 and WO92/05266), and can be used to create producer cell lines (also termed vector cell lines or "VCLs") for the production of recombinant vector particles. Preferably, the packaging cell lines are made from human parent cells (eg. HT1080 cells) or mink parent cell lines, which eliminates inactivation in human serum.

Preferred retroviruses for the construction of retroviral gene therapy vectors include Avian Leukosis Virus, Bovine Leukemia, Virus, Murine Leukemia Virus, Mink-Cell Focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis Virus and Rous Sarcoma Virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley and Rowe (1976) *J Virol* 19:19-25), Abelson (ATCC No. VR-999), Friend (ATCC No. VR-245), Graffi, Gross (ATCC Nol VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No. VR-998) and Moloney Murine Leukemia Virus (ATCC No. VR-190). Such retroviruses may be obtained from depositories or collections such as the American Type Culture Collection ("ATCC") in Rockville, Maryland or isolated from known sources using commonly available techniques.

Exemplary known retroviral gene therapy vectors employable in this invention include those described if patent applications GB2200651, EP0415731, EP0345242, EP0334301, WO89/02468; WO89/05349, WO89/09271, WO90/02806, WO90/07936, WO94/03622, WO93/25698, WO93/25234, WO93/11230, WO93/10218, WO91/02805, WO91/02825, WO95/07994, US 5,219,740, US 4,405,712, US 4,861,719, US 4,980,289, US 4,777,127, US 5,591,624. See also Vile (1993) Cancer Res 53:3860-3864; Vile (1993) Cancer Res 53:962-967; Ram (1993) Cancer Res 53 (1993) 83-88; Takamiya (1992) J Neurosci Res 33:493-503; Baba (1993) J Neurosurg 79:729-735; Mann (1983) Cell 33:153; Cane (1984) Proc Natl Acad Sci 81:6349; and Miller (1990) Human Gene Therapy 1.

Human adenoviral gene therapy vectors are also known in the art and employable in this invention. See, for example, Berkner (1988) *Biotechniques* 6:616 and Rosenfeld (1991) *Science* 252:431, and WO93/07283, WO93/06223, and WO93/07282. Exemplary known adenoviral gene therapy vectors employable in this

invention include those described in the above referenced documents and in WO94/12649, WO93/03769, WO93/19191, WO94/28938, WO95/11984, WO95/00655, WO95/27071, WO95/29993, WO95/34671, WO96/05320, WO94/08026, WO94/11506, WO93/06223, WO94/24299, WO95/14102, WO95/24297, WO95/02697, WO94/28152, WO94/24299, WO95/09241, WO95/25807, WO95/05835, WO94/18922 and WO95/09654. Alternatively, administration of DNA linked to killed adenovirus as described in Curiel (1992) Hum. Gene Ther. 3:147-154 may be employed. The gene delivery vehicles of the invention also include adenovirus associated virus (AAV) vectors. Leading and preferred examples of such vectors for use in this invention are the AAV-2 based vectors disclosed in Srivastava, WO93/09239. Most preferred AAV vectors comprise the two AAV inverted terminal repeats in which the native D-sequences are modified by substitution of nucleotides, such that at least 5 native nucleotides and up to 18 native nucleotides, preferably at least 10 native nucleotides up to 18 native nucleotides, most preferably 10 native nucleotides are retained and the remaining nucleotides of the D-sequence are deleted or replaced with non-native nucleotides. The native D-sequences of the AAV inverted terminal repeats are sequences of 20 consecutive nucleotides in each AAV inverted terminal repeat (ie. there is one sequence at each end) which are not involved in HP formation. The non-native replacement nucleotide may be any nucleotide other than the nucleotide found in the native D-sequence in the same position. Other employable exemplary AAV vectors are pWP-19, pWN-1, both of which are disclosed in Nahreini (1993) Gene 124:257-262. Another example of such an AAV vector is psub201 (see Samulski (1987) J. Virol. 61:3096). Another exemplary AAV vector is the Double-D ITR vector. Construction of the Double-D ITR vector is disclosed in US Patent 5,478,745. Still other vectors are those disclosed in Carter US Patent 4,797,368 and Muzyczka US Patent 5,139,941, Chartejee US Patent 5,474,935, and Kotin WO94/288157. Yet a further example of an AAV vector employable in this invention is SSV9AFABTKneo, which contains the AFP enhancer and albumin promoter and directs expression predominantly in the liver. Its structure and construction are disclosed in Su (1996) Human Gene Therapy 7:463-470. Additional AAV gene therapy vectors are described in US 5,354,678, US 5,173,414, US 5,139,941, and US 5,252,479.

The gene therapy vectors of the invention also include herpes vectors. Leading and preferred examples are herpes simplex virus vectors containing a sequence encoding a thymidine kinase polypeptide such as those disclosed in US 5,288,641 and EP0176170 (Roizman). Additional exemplary herpes simplex virus vectors include HFEM/ICP6-LacZ disclosed in WO95/04139 (Wistar Institute), pHSVlac described in Geller (1988) Science 241:1667-1669 and in WO90/09441 and WO92/07945, HSV Us3::pgC-lacZ described in Fink (1992) Human Gene Therapy 3:11-19 and HSV 7134, 2 RH 105 and GAL4 described in EP 0453242 (Breakefield), and those deposited with the ATCC as accession numbers ATCC VR-977 and ATCC VR-260.

()

WO 00/66741 32

Also contemplated are alpha virus gene therapy vectors that can be employed in this invention. Preferred alpha virus vectors are Sindbis viruses vectors. Togaviruses, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Middleberg virus (ATCC VR-370), Ross River virus (ATCC VR-373; ATCC VR-1246), . Venezuelan equine encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC VR-532), and those described in US patents 5,091,309, 5,217,879, and WO92/10578. More particularly, those alpha virus vectors described in US Serial No. 08/405,627, filed March 15, 1995,WO94/21792, WO92/10578, WO95/07994, US 5,091,309 and US 5,217,879 are employable. Such alpha viruses may be obtained from depositories or collections such as the ATCC in Rockville, Maryland or isolated from known sources using commonly available techniques. Preferably, alphavirus vectors with reduced cytotoxicity are used (see USSN 08/679640).

PCT/IB00/00642

DNA vector systems such as eukaryotic layered expression systems are also useful for expressing the nucleic acids of the invention. See WO95/07994 for a detailed description of eukaryotic layered expression systems. Preferably, the eukaryotic layered expression systems of the invention are derived from alphavirus vectors and most preferably from Sindbis viral vectors.

Other viral vectors suitable for use in the present invention include those derived from poliovirus, for example ATCC VR-58 and those described in Evans, Nature 339 (1989) 385 and Sabin (1973) J. Biol. Standardization 1:115; rhinovirus, for example ATCC VR-1110 and those described in Arnold (1990) J Cell Biochem L401; pox viruses such as canary pox virus or vaccinia virus, for example ATCC VR-111 and ATCC VR-2010 and those described in Fisher-Hoch (1989) Proc Natl Acad Sci 86:317; Flexner (1989) Ann NY Acad Sci 569:86, Flexner (1990) Vaccine 8:17; in US 4,603,112 and US 4,769,330 and WO89/01973; SV40 virus, for example ATCC VR-305 and those described in Mulligan (1979) Nature 277:108 and Madzak (1992) J Gen Virol 73:1533; influenza virus, for example ATCC VR-797 and recombinant influenza viruses made employing reverse genetics techniques as described in US 5,166,057 and in Enami (1990) Proc Natl Acad Sci 87:3802-3805; Enami & Palese (1991) J Virol 65:2711-2713 and Luytjes (1989) Cell 59:110, (see also McMichael (1983) NEJ Med 309:13, and Yap (1978) Nature 273:238 and Nature (1979) 277:108); human immunodeficiency virus as described in EP-0386882 and in Buchschacher (1992) J. Virol. 66:2731; measles virus, for example ATCC VR-67 and VR-1247 and those described in EP-0440219; Aura virus, for example ATCC VR-368; Bebaru virus, for example ATCC VR-600 and ATCC VR-1240; Cabassou virus, for example ATCC VR-922; Chikungunya virus, for example ATCC VR-64 and ATCC VR-1241; Fort Morgan Virus, for example ATCC VR-924; Getah virus, for example ATCC VR-369 and ATCC VR-1243; Kyzylagach virus, for example ATCC VR-927; Mayaro virus, for example ATCC VR-66; Mucambo virus, for example ATCC VR-580 and ATCC VR-1244; Ndumu virus, for example

ATCC VR-371; Pixuna virus, for example ATCC VR-372 and ATCC VR-1245; Tonate virus, for example

ATCC VR-925; Triniti virus, for example ATCC VR-469; Una virus, for example ATCC VR-374; Whataroa virus, for example ATCC VR-926; Y-62-33 virus, for example ATCC VR-375; O'Nyong virus, Eastern encephalitis virus, for example ATCC VR-65 and ATCC VR-1242; Western encephalitis virus, for example ATCC VR-70, ATCC VR-1251, ATCC VR-622 and ATCC VR-1252; and coronavirus, for example ATCC VR-740 and those described in Hamre (1966) *Proc Soc Exp Biol Med* 121:190.

Delivery of the compositions of this invention into cells is not limited to the above mentioned viral vectors. Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see US Serial No. 08/366,787, filed December 30, 1994 and Curiel (1992) *Hum Gene Ther* 3:147-154 ligand linked DNA, for example see Wu (1989) *J Biol Chem* 264:16985-16987, eucaryotic cell delivery vehicles cells, for example see US Serial No.08/240,030, filed May 9, 1994, and US Serial No. 08/404,796, deposition of photopolymerized hydrogel materials, hand-held gene transfer particle gun, as described in US Patent 5,149,655, ionizing radiation as described in US5,206,152 and in WO92/11033, nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip (1994) *Mol Cell Biol* 14:2411-2418 and in Woffendin (1994) *Proc Natl Acad Sci* 91:1581-1585.

Particle mediated gene transfer may be employed, for example see US Serial No. 60/023,867. Briefly, the sequence can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described in Wu & Wu (1987) J. Biol. Chem. 262:4429-4432, insulin as described in Hucked (1990) Biochem Pharmacol 40:253-263, galactose as described in Plank (1992) Bioconjugate Chem 3:533-539, lactose or transferrin.

Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and US 5,580,859. Uptake efficiency may be improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.

Liposomes that can act as gene delivery vehicles are described in US 5,422,120, WO95/13796, WO94/23697, WO91/14445 and EP-524,968. As described in USSN. 60/023,867, on non-viral delivery, the nucleic acid sequences encoding a polypeptide can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell

15

()

targeting ligands such as asialoorosomucoid, insulin, galactose, lactose, or transferrin. Other delivery systems include the use of liposomes to encapsulate DNA comprising the gene under the control of a variety of tissue-specific or ubiquitously-active promoters. Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin *et al* (1994) *Proc. Natl. Acad. Sci. USA* 91(24):11581-11585. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials. Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in US 5,149,655; use of ionizing radiation for activating transferred gene, as described in US 5,206,152 and WO92/11033

- Exemplary liposome and polycationic gene delivery vehicles are those described in US 5,422,120 and 4,762,915; in WO 95/13796; WO94/23697; and WO91/14445; in EP-0524968; and in Stryer, Biochemistry, pages 236-240 (1975) W.H. Freeman, San Francisco; Szoka (1980) Biochem Biophys Acta 600:1; Bayer (1979) Biochem Biophys Acta 550:464; Rivnay (1987) Meth Enzymol 149:119; Wang (1987) Proc Natl Acad Sci 84:7851; Plant (1989) Anal Biochem 176:420.
- A polynucleotide composition can comprises therapeutically effective amount of a gene therapy vehicle, as the term is defined above. For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

Delivery Methods

Once formulated, the polynucleotide compositions of the invention can be administered (1) directly to the subject; (2) delivered ex vivo, to cells derived from the subject; or (3) in vitro for expression of recombinant proteins. The subjects to be treated can be mammals or birds. Also, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal or transcutaneous applications (eg. see WO98/20734), needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

Methods for the *ex vivo* delivery and reimplantation of transformed cells into a subject are known in the art and described in *eg*. WO93/14778. Examples of cells useful in ex vivo applications include, for example, stem cells, particularly hematopoetic, lymph cells, macrophages, dendritic cells, or tumor cells.

Generally, delivery of nucleic acids for both ex vivo and in vitro applications can be accomplished by the following procedures, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.

5 Polynucleotide and polypeptide pharmaceutical compositions

In addition to the pharmaceutically acceptable carriers and salts described above, the following additional agents can be used with polynucleotide and/or polypeptide compositions.

A.Polypeptides

One example are polypeptides which include, without limitation: asioloorosomucoid (ASOR); transferrin; asialoglycoproteins; antibodies; antibody fragments; ferritin; interleukins; interferons, granulocyte, macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), stem cell factor and erythropoietin. Viral antigens, such as envelope proteins, can also be used. Also, proteins from other invasive organisms, such as the 17 amino acid peptide from the circumsporozoite protein of plasmodium falciparum known as RII.

15 B. Hormones, Vitamins, etc.

Other groups that can be included are, for example: hormones, steroids, androgens, estrogens, thyroid hormone, or vitamins, folic acid.

C.Polyalkylenes, Polysaccharides, etc.

Also, polyalkylene glycol can be included with the desired polynucleotides/polypeptides. In a preferred embodiment, the polyalkylene glycol is polyethlylene glycol. In addition, mono-, di-, or polysaccharides can be included. In a preferred embodiment of this aspect, the polysaccharide is dextran or DEAE-dextran. Also, chitosan and poly(lactide-co-glycolide)

D.Lipids, and Liposomes

The desired polynucleotide/polypeptide can also be encapsulated in lipids or packaged in liposomes prior to delivery to the subject or to cells derived therefrom. 25

Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid. The ratio of condensed polynucleotide to lipid preparation can vary but will generally be around 1:1 (mg DNA:micromoles lipid), or more of lipid. For a review of the use of liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight (1991) Biochim. Biophys. Acta. 1097:1-17; Straubinger (1983) Meth. Enzymol. 101:512-527.

Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner (1987) *Proc. Natl. Acad. Sci. USA* 84:7413-7416); mRNA (Malone (1989) *Proc. Natl. Acad. Sci. USA* 86:6077-6081); and purified transcription factors (Debs (1990) *J. Biol. Chem.* 265:10189-10192), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleyloxy)propyl]-N,N,Ntriethylammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL. Grand Island, NY. (See, also, Felgner supra). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boerhinger). Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, eg. Szoka (1978) Proc. Natl. Acad. Sci. USA 75:4194-4198; WO90/11092 of for description the synthesis DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

The liposomes can comprise multilammelar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs). The various liposome-nucleic acid complexes are prepared using methods known in the art. See eg. Straubinger (1983) Meth. Immunol. 101:512-527; Szoka (1978) Proc. Natl. Acad. Sci. USA 75:4194-4198; Papahadjopoulos (1975) Biochim. Biophys. Acta 394:483; Wilson (1979) Cen. 17:77); Deamer & Bangham (1976) Biochim. Biophys. Acta 443:629; Ostro (1977) Biochem. Biophys. Res. Commun. 76:836; Fraley (1979) Proc. Natl. Acad. Sci. USA 76:3348); Enoch & Strittmatter (1979) Proc. Natl. Acad. Sci. USA 76:145; Fraley (1980) J. Biol. Chem. (1980) 255:10431; Szoka & Papahadjopoulos (1978) Proc. Natl. Acad. Sci. USA 75:145; and Schaefer-Ridder (1982) Science 215:166.

E.Lipoproteins

In addition, lipoproteins can be included with the polynucleotide/polypeptide to be delivered. Examples of lipoproteins to be utilized include: chylomicrons, HDL, IDL, LDL, and VLDL. Mutants, fragments, or fusions of these proteins can also be used. Also, modifications of naturally occurring lipoproteins can be used, such as acetylated LDL. These lipoproteins can target the delivery of polynucleotides to cells

expressing lipoprotein receptors. Preferably, if lipoproteins are including with the polynucleotide to be delivered, no other targeting ligand is included in the composition.

Naturally occurring lipoproteins comprise a lipid and a protein portion. The protein portion are known as apoproteins. At the present, apoproteins A, B, C, D, and E have been isolated and identified. At least two of these contain several proteins, designated by Roman numerals, AI, AII, AIV; CI, CII, CIII.

A lipoprotein can comprise more than one apoprotein. For example, naturally occurring chylomicrons comprises of A, B, C, and E, over time these lipoproteins lose A and acquire C and E apoproteins. VLDL comprises A, B, C, and E apoproteins, LDL comprises apoprotein B; and HDL comprises apoproteins A, C, and E.

The amino acid of these apoproteins are known and are described in, for example, Breslow (1985) Annu Rev. Biochem 54:699; Law (1986) Adv. Exp Med. Biol. 151:162; Chen (1986) J Biol Chem 261:12918; Kane (1980) Proc Natl Acad Sci USA 77:2465; and Utermann (1984) Hum Genet 65:232.

Lipoproteins contain a variety of lipids including, triglycerides, cholesterol (free and esters), and phospholipids. The composition of the lipids varies in naturally occurring lipoproteins. For example, chylomicrons comprise mainly triglycerides. A more detailed description of the lipid content of naturally occurring lipoproteins can be found, for example, in *Meth. Enzymol.* 128 (1986). The composition of the lipids are chosen to aid in conformation of the apoprotein for receptor binding activity. The composition of lipids can also be chosen to facilitate hydrophobic interaction and association with the polynucleotide binding molecule.

Naturally occurring lipoproteins can be isolated from serum by ultracentrifugation, for instance. Such methods are described in *Meth. Enzymol.* (supra); Pitas (1980) J. Biochem. 255:5454-5460 and Mahey (1979) J Clin. Invest 64:743-750. Lipoproteins can also be produced by in vitro or recombinant methods by expression of the apoprotein genes in a desired host cell. See, for example, Atkinson (1986) Annu Rev Biophys Chem 15:403 and Radding (1958) Biochim Biophys Acta 30: 443. Lipoproteins can also be purchased from commercial suppliers, such as Biomedical Techniologies, Inc., Stoughton, Massachusetts, USA. Further description of lipoproteins can be found in WO98/06437.

F.Polycationic Agents

Polycationic agents can be included, with or without lipoprotein, in a composition with the desired polynucleotide/polypeptide to be delivered.

30 Polycationic agents, typically, exhibit a net positive charge at physiological relevant pH and are capable of neutralizing the electrical charge of nucleic acids to facilitate delivery to a desired location. These agents

15

()

PCT/IB00/00642

have both in vitro, ex vivo, and in vivo applications. Polycationic agents can be used to deliver nucleic acids to a living subject either intramuscularly, subcutaneously, etc.

The following are examples of useful polypeptides as polycationic agents: polylysine, polyarginine, polyornithine, and protamine. Other examples include histones, protamines, human serum albumin, DNA binding proteins, non-histone chromosomal proteins, coat proteins from DNA viruses, such as (X174, transcriptional factors also contain domains that bind DNA and therefore may be useful as nucleic aid condensing agents. Briefly, transcriptional factors such as C/CEBP, c-jun, c-fos, AP-1, AP-2, AP-3, CPF, Prot-1, Sp-1, Oct-1, Oct-2, CREP, and TFIID contain basic domains that bind DNA sequences.

Organic polycationic agents include: spermine, spermidine, and purtrescine.

The dimensions and of the physical properties of a polycationic agent can be extrapolated from the list above, to construct other polypeptide polycationic agents or to produce synthetic polycationic agents.

Synthetic polycationic agents which are useful include, for example, DEAE-dextran, polybrene. LipofectinTM, and lipofectAMINETM are monomers that form polycationic complexes when combined with polynucleotides/polypeptides.

15 Immunodiagnostic Assays

Neisserial antigens of the invention can be used in immunoassays to detect antibody levels (or, conversely, anti-Neisserial antibodies can be used to detect antigen levels). Immunoassays based on well defined, recombinant antigens can be developed to replace invasive diagnostics methods. Antibodies to Neisserial proteins within biological samples, including for example, blood or serum samples, can be detected. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. Protocols for the immunoassay may be based, for example, upon competition, or direct reaction, of sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzymelabeled and mediated immunoassays, such as ELISA assays.

Kits suitable for immunodiagnosis and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the compositions of the invention, in suitable containers, along with the remaining reagents and materials (for example, suitable buffers, salt solutions, etc.) required for the conduct of the assay, as well as suitable set of assay instructions.

25

Nucleic Acid Hybridisation

"Hybridization" refers to the association of two nucleic acid sequences to one another by hydrogen bonding. Typically, one sequence will be fixed to a solid support and the other will be free in solution. Then, the two sequences will be placed in contact with one another under conditions that favor hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase sequence to the solid support (Denhardt's reagent or BLOTTO); concentration of the sequences; use of compounds to increase the rate of association of sequences (dextran sulfate or polyethylene glycol); and the stringency of the washing conditions following hybridization. See Sambrook *et al.* [supra] Volume 2, chapter 9, pages 9.47 to 9.57.

"Stringency" refers to conditions in a hybridization reaction that favor association of very similar sequences over sequences that differ. For example, the combination of temperature and salt concentration should be chosen that is approximately 120 to 200°C below the calculated Tm of the hybrid under study. The temperature and salt conditions can often be determined empirically in preliminary experiments in which samples of genomic DNA immobilized on filters are hybridized to the sequence of interest and then washed under conditions of different stringencies. See Sambrook *et al.* at page 9.50.

Variables to consider when performing, for example, a Southern blot are (1) the complexity of the DNA being blotted and (2) the homology between the probe and the sequences being detected. The total amount of the fragment(s) to be studied can vary a magnitude of 10, from 0.1 to 1μg for a plasmid or phage digest to 10⁻⁹ to 10⁻⁸ g for a single copy gene in a highly complex eukaryotic genome. For lower complexity polynucleotides, substantially shorter blotting, hybridization, and exposure times, a smaller amount of starting polynucleotides, and lower specific activity of probes can be used. For example, a single-copy yeast gene can be detected with an exposure time of only 1 hour starting with 1 μg of yeast DNA, blotting for two hours, and hybridizing for 4-8 hours with a probe of 10⁸ cpm/μg. For a single-copy mammalian gene a conservative approach would start with 10 μg of DNA, blot overnight, and hybridize overnight in the presence of 10% dextran sulfate using a probe of greater than 10⁸ cpm/μg, resulting in an exposure time of ~24 hours.

Several factors can affect the melting temperature (Tm) of a DNA-DNA hybrid between the probe and the fragment of interest, and consequently, the appropriate conditions for hybridization and washing. In many cases the probe is not 100% homologous to the fragment. Other commonly encountered variables include the length and total G+C content of the hybridizing sequences and the ionic strength and formamide content of the hybridization buffer. The effects of all of these factors can be approximated by a single equation:

Tm=
$$81 + 16.6(\log_{10}\text{Ci}) + 0.4[\%(G + C)] - 0.6(\%\text{formamide}) - 600/n - 1.5(\%\text{mismatch}).$$

(

where Ci is the salt concentration (monovalent ions) and n is the length of the hybrid in base pairs (slightly modified from Meinkoth & Wahl (1984) Anal. Biochem. 138: 267-284).

In designing a hybridization experiment, some factors affecting nucleic acid hybridization can be conveniently altered. The temperature of the hybridization and washes and the salt concentration during the washes are the simplest to adjust. As the temperature of the hybridization increases (*ie.* stringency), it becomes less likely for hybridization to occur between strands that are nonhomologous, and as a result, background decreases. If the radiolabeled probe is not completely homologous with the immobilized fragment (as is frequently the case in gene family and interspecies hybridization experiments), the hybridization temperature must be reduced, and background will increase. The temperature of the washes affects the intensity of the hybridizing band and the degree of background in a similar manner. The stringency of the washes is also increased with decreasing salt concentrations.

In general, convenient hybridization temperatures in the presence of 50% formamide are 42°C for a probe with is 95% to 100% homologous to the target fragment, 37°C for 90% to 95% homology, and 32°C for 85% to 90% homology. For lower homologies, formamide content should be lowered and temperature adjusted accordingly, using the equation above. If the homology between the probe and the target fragment are not known, the simplest approach is to start with both hybridization and wash conditions which are nonstringent. If non-specific bands or high background are observed after autoradiography, the filter can be washed at high stringency and reexposed. If the time required for exposure makes this approach impractical, several hybridization and/or washing stringencies should be tested in parallel.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1 to 7 show BOXSHADE-rendered alignments of (1) ORF40 (2) ORF4 (3) 225 (4) 23(5) 287 (6) 519 (7) 919. Conserved amino acids have a solid background.

Figure 8 shows a phylogenetic tree.

Figure 9A illustrates amino acid sequence variability within *N. meningitidis* for ORF4, ORF40, 225, 235, 287, 519, and 919. These sequences were used to construct the phylogenetic tree shown in Figure 9B.

Figures 10 to 19 show BOXSHADE-rendered alignments of (10) ORF4 (11) ORF40 (12) ORF46 (13) 225 (14) 235 (15) 287 (16) 519 (17) 726 (18) 919 (19) 953.

Figure 20 shows Western blots for ORF4, 225, 235, 519 and 919.

EXAMPLES

Example 1

Example 1 of WO99/36544 discloses the cloning and expression of a Neisserial protein referred to as "ORF40". Protein and DNA sequences from serogroup A and B *N.meningitidis* are disclosed, and the complete protein sequences show 83.7% identity over 601 aa overlap.

ORF40 was sequenced for a reference population of 21 strains of N. meningitidis:

Identification number	Strain	Reference	
Group B			
zn02_1	BZ198	Seiler et al.(1996)	
zn03_1	NG3/88	Seiler et al.(1996)	
zn04_1	297-0	Seiler et al.(1996)	
zn06_1	BZ147	Seiler et al.(1996)	
zn07_1	BZ169	Seiler et al.(1996)	
zn08_1	528	Seiler et al.(1996)	
zn10_1	BZ133	Seiler et al.(1996)	
zn11_1ass	NGE31	Seiler et al.(1996)	
zn14_1	NGH38	Seiler et al.(1996)	
zn16_1	NGH15	Seiler et al.(1996)	
zn18_1	BZ232	Seiler et al.(1996)	
zn19_1	BZ83	Seiler et al.(1996)	
zn20_1	44/76	Seiler et al.(1996)	
zn21_1	MC58	Virji et al. (1992)	
Group A			
zn22_1	205900	Chiron SpA	
zn23_1	F6124	Chiron SpA	
z2491_1	Z2491	Maiden et al. (1998)	
Group C			
zn24_1	90/18311	Chiron SpA	
zn25_lass	93/4286	Chiron SpA	
Others	Others		
zn28_lass	860800 (group Y)	Maiden et al. (1998)	
zn29_lass	E32 (group Z)	Maiden et al.(1998)	

An alignment of these 21 sequences is shown in Figure 1. Stretches of conserved amino acids are evident. The first 17 amino acids, for instance, are conserved (MNKIYRIIWNSALNAWV), although

BNSDOCID: <WO_____0066741A2_l_>

the serine at residue 11 is not present in 100% of *Neisseria*. This is followed by an amino acid which is not conserved, which is in turn followed by a stretch of 16 conserved amino acids (VSELTRNHTKRASATV). The C-terminal of the protein consists of 116 conserved amino acids.

The conserved regions identified in this example confirm that fragments of the full-length ORF40 protein are suitable as multi-specific vaccines or diagnostic reagents.

ORF40 was re-sequenced for 31 strains in total, and the sequences were aligned. The results are shown in Figure 11.

Conserved regions of particular interest are:

- MNKIYRIIWNSALNAWV
- 10 VSELTRNHTKRASATV
 - TAVLATLL
 - TLKAGDNLKIKO
 - FTYSLKKDLTDLTSV
 - TEKLSFGANG
- 15 KVNITSDTKGLNFAKETAGTNGD
 - TVHLNGIGSTLTDTL
 - RAAS (V/I) KDVLNAGWNIKGVK
 - NVDFVRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGK
 - KGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGT
- 20 GTTATVSKDDOGNITV
 - YDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETVNINAGNNIEITRNGKNIDIATSM
 - PQFSSVSLGAGADAPTLSVD
 - NKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKSMMA\(\) GGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW.

25 Example 2

Example 26 of WO99/24578 discloses the cloning and expression of a Neisserial protein referred to as "ORF4". Protein and DNA sequences from serogroup A and B *N.meningitidis* are disclosed, along with sequences from *N.gonorrhoeae*. The identity between the sequences at an amino acid level are:

	N.meningitidis A	N.gonorrhoeae
N.meningitidis B	99.7% over 287 aa	97.6% over 288 aa

30 ORF4 was sequenced for a reference population of 32 strains of Neisseria:

Identification number	Strain	Reference
Group B		
zv01_4	NG6/88	Seiler et al. (1996)
zv02_4	BZ198	Seiler et al. (1996)
zv03_4ass	NG3/88	Seiler et al. (1996)
zv04_4	297-0	Seiler et al. (1996)
zv05_4	1000	Seiler et al. (1996)
zv06_4	BZ147	Seiler et al. (1996)
zv07_4	BZ169	Seiler et al. (1996)
zv08_4	528	Seiler et al. (1996)
zv09_4	NGP165	Seiler et al. (1996)
zv10_4	BZ133	Seiler et al. (1996)
zv11_4	NGE31	Seiler et al. (1996)
zv12_4ass	NGF26	Seiler et al. (1996)
zv13_4	NGE28	Seiler et al. (1996)
zv15_4	SWZ107	Seiler et al. (1996)
zv16_4	NGH15	Seiler et al. (1996)
zv17_4	NGH36	Seiler et al. (1996)
zv18_4	BZ232	Seiler et al. (1996)
zv19_4	BZ83	Seiler et al. (1996)
zv20_4	44/76	Seiler et al. (1996)
zv21_4	MC58	Virji et al. (1992)
zv96_4	2996	Chiron SpA
Group A		
zv22_4	205900	Chiron SpA
z2491_4	Z2491	Maiden et al., 1998
Group C		
zv24_4	90/18311	Chiron SpA
zv25_4	93/4286	Chiron SpA
Others		
zv26_4ass	A22 (group W)	Maiden et al. (1998)
zv27_4	E26 (group X)	Maiden et al. (1998)
zv28_4	860800(group Y)	Maiden et al. (1998)
zv29_4	E32 (group Z)	Maiden et al. (1998)
N.gonorrhoeae		
zv32_4	Ng F62	Maiden et al. (1998)
zv33_4	Ng SN4	R. Moxon

44

fa1090_4	FA1090	Dempsey et al. (1991)

An alignment of the sequences generated using PILEUP is shown in Figure 2. Stretches of conserved amino acids are evident. The first 34 amino acids, for instance, are conserved, although the serine at residue 26 is not present in 100% of Neisseria. The C-terminal of the protein consists of 228 conserved amino acids.

The conserved regions identified in this example confirm that fragments of the full-length ORF4 protein are suitable as multi-specific vaccines or diagnostic reagents.

ORF4 was re-sequenced for 35 strains in total, and the sequences were aligned. The results are shown in Figure 10.

Conserved regions of particular interest are:

- 10 MKTFFKTLSAAALALILAACGGQKDSAPAASASAAADNGA
 - KKEIVFGTTVGDFGDMVKE
 - ELEKKGYTVKLVEFTDYVRPNLALAEGELDINVFOHKPYLDDFKKEHNLDITEVFOVPTAPLGLYPGK LKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWIKLKDGINPLTASKADIAENLKNIKIVELEAAQL PRSRADVDFAVVNGNYAISSGMKLTEALFQEPSFAYVNWSAVKTADKDSQWLKDVTEAYNSDAFKAYA HKRFEGYKSPAAWNEGAAK

Example 3

15

Example 16 of WO99/57280 discloses the cloning and expression of a Neisserial protein referred to as "225". Protein and DNA sequences from serogroup A and B N. meningitidis are disclosed, along with sequences from *N.gonorrhoeae*.

20 225 has now been sequenced for a reference population of 34 strains of Neisseria:

Identification	Strain	Source reference
number		
C P	_1	<u> </u>
Group B		
zo01_225	NG6/88	Seiler <i>et al.</i> , 1996
zo02_225	BZ198	Seiler et al., 1996
zo03_225	NG3/88	Seiler et al., 1996
zo04_225	297-0	Seiler et al., 1996
zo05_225	1000	Seiler et al., 1996
zo06_225	BZ147	Seiler et al., 1996
zo07_225	BZ169	Seiler et al., 1996
zo08_225	528	Seiler et al., 1996

zo09_225	NGP165	Seiler et al., 1996	
zo10_225	BZ133	Seiler et al., 1996	
zo11_225	NGE31	Seiler et al., 1996	
zo12_225	NGF26	Seiler et al., 1996	
zo13_225	NGE28	Seiler et al., 1996	
zo14_225	NGH38	Seiler et al., 1996	
zo15_225	SWZ107	Seiler et al., 1996	
zo16_225	NGH15	Seiler et al., 1996	
zo17_225	NGH36	Seiler et al., 1996	
zo18_225	BZ232	Seiler et al., 1996	
zo19_225	BZ83	Seiler <i>et al.</i> , 1996	
zo20_225	44/76	Seiler et al., 1996	
zo21_225	MC58	Chiron SpA	
zo96_225	2996	Chiron SpA	
Group A			
zo22_225	205900	Chiron SpA	
zo23_225	F6124	Chiron SpA	
z2491	Z2491	Maiden <i>et al.</i> , 1998	
Group C			
zo24_225	90/18311	Chiron SpA	
zo25_225	93/4286	Chiron SpA	
Others			
zo26_225	A22 (group W)	Maiden et al., 1998	
zo27_225	E26 (group X)	Maiden et al., 1998	
zo28_225	860800(group Y)	Maiden <i>et al.</i> , 1998	
zo29_225	E32 (group Z)	Maiden et al., 1998	
Gonococcus			
zo32_225	Ng F62	Maiden et al., 1998	
zo33_225	Ng SN4	Chiron SpA	
fa1090	FA1090	Chiron SpA	
- · · · · · · · · · · · · · · · · · · ·			

An alignment of the sequences generated using PILEUP is shown in Figure 3. Stretches of conserved amino acids are evident. The first 74 amino acids, for instance, are conserved, although the isoleucine at residue 51 is not present in 100% of *Neisseria*. The C-terminal of the protein consists of 148 conserved amino acids. A similar alignment is shown in Figure 13.

5 The conserved regions identified in this example confirm that fragments of the full-length 225 protein are suitable as multi-specific vaccines or diagnostic reagents.

Example 4

Example 16 of WO99/57280 discloses the cloning and expression of a Neisserial protein referred to as "235". Protein and DNA sequences from serogroup A and B *N.meningitidis* are disclosed, along with sequences from *N.gonorrhoeae*.

5 235 has now been sequenced for a reference population of 31 strains of Neisseria:

Identification number	Strain	Reference
Group B		
gnmzq01	NG6/88	Seiler et al., 1996
gnmzq02	BZ198	Seiler et al., 1996
gnmzq03	NG3/88	Seiler et al., 1996
gnmzq04	1000	Seiler et al., 1996
gnmzq05	1000	Seiler et al., 1996
gnmzq07	BZ169	Seiler et al., 1996
gnmzq08	528	Seiler et al., 1996
gnmzq09	NGP165	Seiler et al., 1996
gnmzq10	BZ133	Seiler et al., 1996
gnmzq11	NGE31	Seiler et al., 1996
gnmzq13	NGE28	Seiler et al., 1996
gnmzq14	NGH38	Seiler et al., 1996
gnmzq15	SWZ107	Seiler et al., 1996
gnmzq16	NGH15	Seiler et al., 1996
gnmzq17	NGH36	Seiler et al., 1996
gnmzq18	BZ232	Seiler et al., 1996
gnmzq19	BZ83	Seiler et al., 1996
gnmzq21	MC58	Virji et al., 1992
Group A		
gnmzq22	205900	Chiron SpA
gnmzq23	F6124	Chiron SpA
z2491	Z2491	Maiden et al., 1998
Group C		
gnmzq24	90/18311	Chiron SpA
gnmzq25	93/4286	Chiron SpA
Others		
gnmzq26	A22 (group W)	Maiden et al., 1998
gnmzq27	E26 (group X)	Maiden et al., 1998

BNSDOCID: <WO_____0066741A2_1_>

gnmzq28	860800 (group Y)	Maiden et al., 1998
gnmzq29	E32 (group Z)	Maiden et al., 1998
gnmzq31	N. lactamica	Chiron SpA
Gonococcus		
gnmzq32	Ng F62	Maiden et al., 1998
gnmzq33	Ng SN4	Chiron SpA
fa1090	FA1090	Dempsey et al. 1991

An alignment of the sequences generated using PILEUP is shown in Figure 4. Stretches of conserved amino acids are evident. The protein is wholly conserved, although the serine at residue 168 shows some variance.

The conserved regions identified in this example confirm that fragments of the full-length 235 protein are suitable as multi-specific vaccines or diagnostic reagents.

235 was re-sequenced for 35 strains in total, and the sequences were aligned. The results are shown in Figure 14.

Example 5

Example 16 of WO99/57280 discloses the cloning and expression of a Neisserial protein referred to as "287". Protein and DNA sequences from serogroup A and B *N. meningitidis* are disclosed, along with sequences from *N. gonorrhoeae*.

287 has now been sequenced for a reference population of 6 strains of Neisseria:

Identification number	Strain	Reference
Group B		
287_2	BZ198	Seiler et al.(1996)
287_9	NGP165	Seiler et al.(1996)
287_14	NGH38	Seiler et al.(1996)
287_21	MC58	Virji et al. (1992)
Group A		
z2491	Z2491	Maiden et al.(1998)
Gonococcus		
fa1090	FA1090	Dempsey et al. (1991)

An alignment of the sequences generated using PILEUP is shown in Figure 5. Stretches of conserved amino acids are evident. The first 42 amino acids, for instance, are well conserved and a long conserved region can be seen at the C-terminus.

The conserved regions identified in this example confirm that fragments of the full-length 287 protein are suitable as multi-specific vaccines or diagnostic reagents.

287 was re-sequenced for 35 strains in total (including C11, a serogroup C N.meningitidis strain), and the sequences were aligned. The results are shown in Figure 15.

Conserved regions of particular interest are:

- MFKRSVIAMACI
- 10 ALSACGGGGGSPDVKSADT
 - SKPAAPVV
 - QDMAAVS
 - ENTGNGGAATTD
 - QNDMPQ
- 15 DGPSQNITLTHCK
 - KSEFE
 - RRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEGNYRYLTYGAEKL
 - GGSYAL
 - VQGEPAKGEMLAGTAVYNGEVLHFH
- 20 GRFAAKVDFGSKSVDGIIDSGDDLHMG
 - QKFKAAIDGNGFKGTWTENGGGDVSG(R/K)FYGPAGEEVAGKYSYRPTDAEKGGFGVFAGKKDRD

Example 6

Example 16 of WO99/57280 discloses the cloning and expression of a Neisserial protein referred to as "519". Protein and DNA sequences from serogroup A and B *N.meningitidis* are disclosed, along with sequences from *N.gonorrhoeae*.

519 has now been sequenced for a reference population of 22 strains of Neisseria:

Identification number	Strain	Source
Group B		
zv01_519	NG6/88	Seiler et al., 1996
zv02_519	BZ198	Seiler et al., 1996
zv03_519ass	NG3/88	Seiler et al., 1996
zv04_519	297-0	Seiler et al., 1996
zv05_519	1000	Seiler et al., 1996

zv06_519ass	BZ147	Seiler et al., 1996
zv07_519	BZ169	Seiler et al., 1996
zv11_519	NGE31	Seiler et al., 1996
zv12_519	NGF26	Seiler et al., 1996
zv18_519	BZ232	Seiler et al., 1996
zv19_519	BZ83	Seiler et al., 1996
zv20_519ass	44/76	Seiler et al., 1996
zv21_519ass	MC58	Chiron SpA
zv96_519	2996	Chiron SpA
Group A		
zv22_519ass	205900	Chiron SpA
z2491_519	Z2491	Maiden <i>et al.</i> , 1998
Others		
zv26_519	A22 (group W)	Maiden <i>et al.</i> , 1998
zv27_519	E26 (group X)	Maiden et al., 1998
zv28_519	860800 (group Y)	Maiden et al., 1998
zv29_519ass	E32 (group Z)	Maiden et al., 1998
Gonococcus		
zv32_519	Ng F62	Maiden et al., 1998
fa1090_519	FA1090	Chiron SpA

An alignment of the sequences generated using PILEUP is shown in Figure 6. Stretches of conserved amino acids are evident, and the protein shows conservation along its complete length.

The conserved regions identified in this example confirm that fragments of the full-length 519 protein are suitable as multi-specific vaccines or diagnostic reagents.

5 519 was re-sequenced for 33 strains in total, and the sequences were aligned. The results are shown in Figure 16.

Conserved regions of particular interest are:

- MEFFIILL
- AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSLKEIPLDVPSQVCITRDN TQLTVDGIIYFQVTDPKLASYGSSNYIMAITQLAQTTLRSVIGRMELDKTFEERDEINSTVV
- ALDEAAGAWGVKVLRYEIKDLVPPQEILRSMQAQITAEREKRARIAESEGRKIEQINLASGQREAEIQ QSEGEAQAAVNASNAEKIARINRAKGEAESLRLVAEANAEANRQIAAALQTQSGADAVNLKIAGQYVT AFKNLAKEDNTRIKPAKVAEIGNPNFRRHEKFSPEAKTAK

10

Example 7

Example 16 of WO99/57280 discloses the cloning and expression of a Neisserial protein referred to as "919". Protein and DNA sequences from serogroup A and B *N.meningitidis* are disclosed, along with sequences from *N.gonorrhoeae*.

5 919 has now been sequenced for a reference population of 35 strains of Neisseria:

Identification number	Strains	Source
Group B		
zm01	NG6/88	Seiler et al., 1996
zm02	BZ198	Seiler et al., 1996
zm03	NG3/88	Seiler et al., 1996
zm04	297-0	Seiler et al., 1996
zm05	1000	Seiler et al., 1996
zm06	BZ147	Seiler et al., 1996
zm07	BZ169	Seiler et al., 1996
zm08n	528	Seiler et al., 1996
zm09	NGP165	Seiler et al., 1996
zm10	BZ133	Seiler et al., 1996
zm11asbc	NGE31	Seiler et al., 1996
zm12	NGF26	Seiler et al., 1996
zm13	NGE28	Seiler et al., 1996
zm14	NGH38	Seiler et al., 1996
zm15	SWZ107	Seiler et al., 1996
zm 16	NGH15	Seiler et al., 1996
zm 17	NGH36	Seiler et al., 1996
zm 18	BZ232	Seiler et al., 1996
zm19	BZ83	Seiler et al., 1996
zm20	44/76	Seiler et al., 1996
zm21	MC58	Chiron SpA
zm96	2996	Chiron SpA
Group A		
zm22	205900	Chiron SpA
zm23asbc	F6124	Chiron SpA
z2491	Z2491	Maiden et al., 1998
Group C		
zm24	90/18311	Chiron SpA
zm25	93/4286	Chiron SpA

Others		
zm26	A22 (group W)	Maiden et al., 1998
zm27bc	E26 (group X)	Maiden et al., 1998
zm28	860800 (group Y)	Maiden et al., 1998
zm29asbc	E32 (group Z)	Maiden et al., 1998
zm31asbc	N. lactamica	Chiron SpA
Gonococcus		
zm32asbc	Ng F62	Maiden et al., 1998
zm33asbc	Ng SN4	Chiron SpA
fa1090	FA1090	Chiron SpA

An alignment of the sequences generated using PILEUP is shown in Figure 7. Another alignment is shown in Figure 18. Stretches of conserved amino acids are evident. The protein shows almost complete conservation.

The conserved regions identified in this example confirm that fragments of the full-length 919 protein are suitable as multi-specific vaccines or diagnostic reagents.

Conserved regions of particular interest are:

- MKKYLFRAAL
- GIAAAILAACQSKSIQTFPQPDTSVINGPDRPVGIPDPAGTTV(G/A)GGGAVYTVVPHLSLPHWAAQ DFAKSLQSFRLGCANLKNRQGWQDVCAQAFQTPVHSFQAKQFFERYFTPWQVAGNGSLAGTVTGYYEP
- 10 VLKGDDRRTAQARFPIYGIPDDFISVPLPAGLRSGKALVRIRQTGKNSGTIDN
 - GGTHTADLS
 - FPITARTTAIKGRFEGSRFLPYHTRNQINGGALDGKAPILGYAEDPVELFFMHIQGSGRLKTPSGKYI RIGYADKNEHPYVSIG(R/K)YMADKGYLKLGQTSMQGIK
 - YMRQNPQRLAEVLGQNPSYIFFREL
- 15 NDGPVGALGTPLMGEYAGAVDRHYITLGAPLFVATAHPVTRKALNRLIMAQDTGSAIKGAVRVDYFWG YGDEAGELAGKQKTTGYVWQLLPNGMKPEYRP

Example 8

Example 55 of WO99/23578 discloses the cloning and expression of a Neisserial protein referred to as "ORF46". Protein and DNA sequences from serogroups A and B N.meningitidis are disclosed, along with sequences from N.gonorrhoeae.

Full-length ORF46 has been sequenced for a reference population of 6 strains of serogroup B. An alignment of these sequences is shown in Figure 12, from which stretches of conserved amino acids are evident.

Conserved regions of particular interest are:

- RKISLILSILAVCLPMHAHASDLANDSFIRQVLDRQHFEPDGKYHLFGSRGELAERSGHIGLG
- IQSHQLGNLMIQQAAIKGNIGYIVRFSDHGHEVHSPFDNHASHSDSDEAGSPVDGFSLYRIHWDGYEH
 HPADGYDGPQGGGYPAPKGARDIYSYDIKGVAQNIRLNLTDNRSTGQRLADRFHNAG
- 5 MLTQGVGDGFKRATRYSPELDRSGNAAEAFNGTADIVKNIIGAAGEIVGAGDAVQGISEGSNIAVMHG LGLLSTENKMARINDLADMAQLKDYAAAAIRDWAVONPNAAOGIEAVSNIF
 - IPIKGIGAVRGKYGLGGITAHP(V/I)KRSQMGEIALPKGKSAVS
 - NFADAAYAKYPSPYHSRNIRSNLEQRYGKENITSSTVPPSNGKNVKLANKRHPKTKVPFDGKGFPNFE
 KDVKY
- 10 The conserved regions in ORF46 confirm that fragments of this protein are suitable as multi-specific vaccines or diagnostic reagents.

Example 9

WO99/57280 discloses the cloning and expression of a Neisserial protein referred to as "726". Protein and DNA sequences from serogroups A and B N. meningitidis are disclosed.

15 726 has been sequenced for a reference population of 7 N. meningitidis strains in serogroups A, B and C. An alignment of these sequences is shown in Figure 17, from which stretches of conserved amino acids are evident.

Conserved regions of particular interest are:

- IYFKNGFYDDTLG
- 20 IPEGAVAVRAEEYAALLAGQAQGGQIAADSDGRPVLTPPRPS (D/E) YHEWDGKKW
 - AAAAARFAEQKTATAFRLA
 - KADELKNSLLAGYPQVEIDSFYRQEKEALARQADNNAPTPMLAQIAAARGVELDVLIEKV(I/V)EKS
 - IETAPGLDALEKEIEEWT
- The conserved regions in 726 confirm that fragments of this protein are suitable as multi-specific vaccines or diagnostic reagents.

Example 10

WO99/57280 discloses the cloning and expression of a Neisserial protein referred to as "953". Protein and DNA sequences from serogroups A and B *N.meningitidis* are disclosed, along with sequences from *N.gonorrhoeae*.

BNSDOCID: <WO 0066741A2 1 >

953 has been sequenced for a reference population of 8 strains of *N. meningitidis* serogroups A, B and C. An alignment of these sequences is shown in Figure 19, from which stretches of conserved amino acids are evident. The protein is well-conserved.

Conserved regions of particular interest are:

- 5 MKKIIFAALAAAAVGTASAATYKVDEYHANARFAIDHFNTSTNVGGFYGLTGSVEFDQAKRDGKIDIT IP(I/V)ANLQSGSQHFTDHLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVDGNLTMHGKTAPVKLK AEKFNCYQSPM
 - ATYKVDEYHANARFAIDHFNTSTNVGGFYGLTGSVEFDQAKRDGKIDITIP(I/V)ANLQSGSQHFTD HLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVDGNLTMHGKTAPVKLKAEKFNCYQSPM
- 10 KTEVCGGDFSTTIDRTKWG(M/V)DYLVNVGMTKSVRIDIQIEAAKQ

The conserved regions in 953 confirm that fragments of this protein are suitable as multi-specific vaccines or diagnostic reagents.

Phylogenetic tree

()

Figure 8 is a dendrogram showing the genetic relationship among 107 N.meningitidis strains, based on MLST analysis of six gene fragments [adapted from Maiden et al. (1998) PNAS USA 95:3140]. The dendrogram can be used to select strains representative of meningococcus serogroup B (arrows). Five additional strains, for which genetic assignment to hypervirulent lineages has been independently determined by Wang et al. [J.Infect.Dis (1993) 167:1320], Seiler et al. [Mol.Microbiol. (1996) 19:841], and Virji et al. [Mol.Microbiol. (1992) 6:1271] are superimposed on the dendrogram and indicated by asterisks. In addition to the 22 strains of MenB, three strains of MenA, two strains of MenC, and one strain each of Men Y, X, Z and W135 were used. These are indicated by bold letters before the name. Where phylogenetic data were not available, the strains are shown outside the tree. The hypervirulent strains ET-5, ET-37 and IV-1 are indicated.

25 Sequence variability

Figure 9a is a schematic representation of amino acid sequence variability with *N.meningitidis* for proteins 225, 235, 287, 519, 919, ORF4 and ORF40. The horizontal axis represents the sequence of MC58. Amino acid differences within MenB strains are indicated by vertical lines above the horizontal axis; differences within serogroups A, C, Y, X, Z and W135 are indicated by lines below the axis. The height of the vertical lines represents the number of strains with amino acid differences. Peaks thus show variable regions. The bard below 225 and 287 represent sequence segments that are missing from some strains.

Figure 9b is a dendrogram of *N.meningitidis* strains obtained using the same 7 proteins. The phylogenetic analysis based on these genes provided a dendrogram which clusters the hypervirulent strains in agreement with Figure 8. Bars indicate strains which cluster with 100% bootstrap support in agreement with MLST analysis. Numbers at the base of each node are bootstrap scores (only those >80% are reported). Gene sequences from different strains were aligned with the program PILEUP from the GCG package. The phylogenetic analysis was performed using the neighbour-joining algorithm [Saitou & Nei (1987) *Mol.Biol.Evol.* 4:406] as implemented in the NEIGHBOR program of the PHYLIP package. Pairwise distances were calculated using the Kimura-two parameter [Kimura (1980) *J.Mol.Evol.* 16:111] on the 31 *N.meningitidis* strains. The N-terminal region of ORF40, the entire 287, and the tandem repeats of 225 were excluded from the analysis. A total of 1000 bootstrap replicates were allowed to evaluate the level of support. The clustering of the hypervirulent strains was confirmed by maximum parsimony analysis.

Western blots

Antigens ORF4, 225, 235, 519 and 919 were analysed by Western blot for various strains. The results are shown in Figure 20. In the case of 225, the blot shows fragments of different sizes in the different strains, with arrows indicating the band of correct size. 225 contains regions of deletion and insertion of a defined repeat and the size of the fragments on the blots matches the gene variability data.

20 The strains used for Figure 20 are as follows:

N. meningitidis serogroup B:

N. meningitidis serogroup A:

$$22 = 205900$$
 $23 = F6124$

N. meningitidis serogroup C:

$$30 24 = 90/18311 25 = 93/4286$$

Other N. meningitidis

26 = A22 (serogroup W)

27 = E26 (serogroup X)

28 = 860800 (serogroup Y)

29 = E32 (serogroup Z)

Other Neisseria

30 = N. cinerea

L17 = N.lactamica

L19 = N.lactamica

31 = N. gonorrhoeae F62

32 = N.gonorrhoeae SN4

It will be appreciated that the invention has been described by means of example only, and that modifications may be made whilst remaining within the spirit and scope of the invention.

15

CLAIMS

- 1. A protein comprising a fragment of a Neisserial protein, wherein said fragment consists of 7 or more consecutive conserved amino acids, provided that said protein is not a full-length Neisserial protein.
- 5 2. The protein of claim 1, wherein said fragment consists of 20 or more consecutive conserved amino acids.
 - 3. The protein of claim 1 or claim 2, wherein the conserved amino acids are found in at least 50% or more of a *Neisseria* reference population.
- 4. The protein of claim 3, wherein the reference population includes a plurality of different

 Neisseria species, preferably N. meningitidis and N. gonorrhoeae.
 - 5. The protein of claim 4, wherein the reference population includes a plurality of different serogroups of N. meningitidis.
 - 6. The protein of claim 3 or claim 4, wherein the reference population comprises: N.meningitidis A, strain Z2491; N.meningitidis B, strain NG6/88; N.meningitidis W, strain A22; and N.gonorrhoeae, strain Ng F62.
 - 7. The protein of claim 5, wherein the reference population comprises: N. meningitidis A, strain Z2491; N. meningitidis B, strain NG6/88; and N. meningitidis W, strain A22.
 - 8. The protein of any preceding claim, comprising a fragment of a protein disclosed in WO99/24578, WO99/36544, WO99/57280 or WO00/22430.
- 20 9. The protein of claim 8, comprising a fragment of one or more of ORF4, ORF40, ORF46, protein 225, protein 235, protein 287, protein 519, protein 726, protein 919 and protein 953.
 - 10. The protein of any one of claims 1 to 7, comprising a fragment of a protein disclosed in Tettelin et al. [Science (2000) 287:1809-1815].
 - 11. Nucleic acid encoding a protein according to any preceding claim.
- 25 12. A protein according to any one of claims 1 to 10, or nucleic acid according to claim 11, for use as a medicament.

BNSDOCID: <WO____0066741A2_I_>

- 13. The use a protein according to any one of claims 1 to 10, or nucleic acid according to claim 11, in the manufacture of a medicament for treating or preventing infection due to Neisserial bacteria.
- 14. The use a protein according to any one of claims 1 to 10, or nucleic acid according to claim
 11, in the manufacture of a multi-specific diagnostic reagent.
 - 15. A protein according to claim 1, comprising one or more of the following amino acid sequences:

MNKIYRIIWNSALNAWV;

VSELTRNHTKRASATV;

10 TAVLATLL:

()

()

TLKAGDNLKIKO;

FTYSLKKDLTDLTSV;

TEKLSFGANG;

KVNITSDTKGLNFAKETAGTNGD;

15 TVHLNGIGSTLTDTL;

RAAS (V/I) KDVLNAGWNIKGVK;

NVDFVRTYDTVEFLSADTKTTTVNVESKDNGKKTEVKIGAKTSVIKEKDGKLVTGK;

KGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGT;

-GTTATVSKDDQGNITV;

20 YDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGNVSPSKGKMDETVNINAGNNIEITRNGKNIDIATSM; PQFSSVSLGAGADAPTLSVD:

NKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIATAGLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW.;

MKTFFKTLSAAALALILAACGGQKDSAPAASASAAADNGA;

25 KKEIVFGTTVGDFGDMVKE:

ELEKKGYTVKLVEFTDYVRPNLALAEGELDINVFQHKPYLDDFKKEHNLDITEVFQVPTAPLGLYPGKLKSLE EVKDGSTVSAPNDPSNFARVLVMLDELGWIKLKDGINPLTASKADIAENLKNIKIVELEAAQLPRSRADVDFA VVNGNYAISSGMKLTEALFQEPSFAYVNWSAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNE GAAK;

30 MFKRSVIAMACI;

ALSACGGGGGGSPDVKSADT;

SKPAAPVV;

QDMAAVS;

ENTGNGGAATTD:

35 DGPSONITLTHCK:

RRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEGNYRYLTYGAEKL;

VQGEPAKGEMLAGTAVYNGEVLHFH;

GRFAAKVDFGSKSVDGIIDSGDDLHMG:

QKFKAAIDGNGFKGTWTENGGGDVSG(R/K)FYGPAGEEVAGKYSYRPTDAEKGGFGVFAGKKDRD;

40 MEFFIILL;

AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSLKEIPLDVPSQVCITRDNTQLTVDGIIYFQVTDPKLASYGSSNYIMAITQLAQTTLRSVIGRMELDKTFEERDEINSTVV;

ALDEAAGAWGVKVLRYEIKDLVPPQEILRSMQAQITAEREKRARIAESEGRKIEQINLASGQREAEIQQSEGE AQAAVNASNAEKIARINRAKGEAESLRLVAEANAEANRQIAAALQTQSGADAVNLKIAGQYVTAFKNLAKEDN TRIKPAKVAEIGNPNFRRHEKFSPEAKTAK;

MKKYLFRAAL;

5 GIAAAILAACQSKSIQTFPQPDTSVINGPDRPVGIPDPAGTTV(G/A)GGGAVYTVVPHLSLPHWAAQDFAKS LQSFRLGCANLKNRQGWQDVCAQAFQTPVHSFQAKQFFERYFTPWQVAGNGSLAGTVTGYYEPVLKGDDRRTA QARFPIYGIPDDFISVPLPAGLRSGKALVRIRQTGKNSGTIDN;

GGTHTADLS;

10

FPITARTTAIKGRFEGSRFLPYHTRNQINGGALDGKAPILGYAEDPVELFFMHIQGSGRLKTPSGKYIRIGYA
DKNEHPYVSIG(R/K)YMADKGYLKLGQTSMQGIK;

YMRQNPQRLAEVLGQNPSYIFFREL;

NDGPVGALGTPLMGEYAGAVDRHYITLGAPLFVATAHPVTRKALNRLIMAQDTGSAIKGAVRVDYFWGYGDEA GELAGKQKTTGYVWQLLPNGMKPEYRP;

RKISLILSILAVCLPMHAHASDLANDSFIROVLDROHFEPDGKYHLFGSRGELAERSGHIGLG;

15 IQSHQLGNLMIQQAAIKGNIGYIVRFSDHGHEVHSPFDNHASHSDSDEAGSPVDGFSLYRIHWDGYEHHPADG YDGPQGGGYPAPKGARDIYSYDIKGVAQNIRLNLTDNRSTGQRLADRFHNAG;

MLTQGVGDGFKRATRYSPELDRSGNAAEAFNGTADIVKNIIGAAGEIVGAGDAVQGISEGSNIAVMHGLGLLS TENKMARINDLADMAQLKDYAAAAIRDWAVQNPNAAQGIEAVSNIF;

IPIKGIGAVRGKYGLGGITAHP(V/I)KRSQMGEIALPKGKSAVS;

NFADAAYAKYPSPYHSRNIRSNLEQRYGKENITSSTVPPSNGKNVKLANKRHPKTKVPFDGKGFPNFEKDVKY;
IYFKNGFYDDTLG:

IPEGAVAVRAEEYAALLAGQAQGGQIAADSDGRPVLTPPRPS (D/E) YHEWDGKKW;

AAAAARFAEOKTATAFRLA;

KADELKNSLLAGYPQVEIDSFYRQEKEALARQADNNAPTPMLAQIAAARGVELDVLIEKV(I/V)EKSARLAV

25 AAGAIIGKRQQLEDKLN;

IETAPGLDALEKEIEEWT;

 $\label{thm:mkkiifaalaaavgtasaatykvdeyhanarfaidhfntstnvggfygltgsvefdqakrdgkiditip(1/V) anlqsgsqhftdhlksadifdaaqypdirfvstkfnfngkklvsvdgnltmhgktapvklkaekfncyqspm; atykvdeyhanarfaidhfntstnvggfygltgsvefdqakrdgkiditip(1/V) anlqsgsqhftdhlksa$

DIFDAAQYPDIRFVSTKFNFNGKKLVSVDGNLTMHGKTAPVKLKAEKFNCYQSPM; and KTEVCGGDFSTTIDRTKWG (M/V) DYLVNVGMTKSVRIDIOIEAAKO.

Ø

S

๙

đ

z n 2 n 2 n 0 n z

1/97

VETAVLATLIEATVQASANNEEQEEDI
VETAVLATLIEATVQASANNEEQEEDI
VETAVLATLIEATVQASANNEEQEEDI
VETAVLATLIEATVQASANNEEQEEDI
VETAVLATLIEATVQASTT
VATAVLATLIEATVQASTT
VATAVLATLIEATVQASTT
VATAVLATLIEATVQASTT
VATAVLATLIEATVQANAT
VATAVLATLIEATVQANAT
VATAVLATLIEATVQANAT
VETAVLATLIEATVQANAT
VETAVLATLIEATVQANAT
VETAVLATLIEATVQANATOEDEEEE
VETAVLATLIEATVQANATOEDEEEE
VETAVLATLIEATVQANATOEDEEEE
VETAVLATLIEATVQANATOEDEEEE
VETAVLATLIEATVQANATOEDEEEE
VETAVLATLIEATVQANATOEDEEEE
VETAVLATLIEATVQANATOEDEEEE
VATAVLATLIEATVQANATOEDEEEE
VATAVLATLIEATVQANATOEDEEEEE
VATAVLATLIEATVQANATOTDEEEE VVSELTRNHTKRASATVKT VVSELTRNHTKRASATVKT VVSELTRNHTKRASATVET VVSELTRNHTKRASATVKT vseltrnhtkrasatv<mark>a</mark> /Seltrnhtkrasatva /Seltrnhtkrasatva VSELTRNHTKRASATV VSELTRNHTKRASATV VSELTRNHTKRASATV VSELTRNHTKRASATV SELTRNHTKRASATV SELTRNHTKRASATV SELTRNHTKRASATV SELTRNHTKRASATV SELTRNHTKRASATV nkiyriimnsalnawu<mark>a</mark> nkiyriimnsalnawu<mark>a</mark> KIYRIIWNSALNAWV KIYRIIWNSALNAWVA KIYRIIWNSALNAWV Kiyriimnsalnawv **KIYRIIWNSALNAWV** Kiyriiwnsalnawd Kiyriimnsainawva Kiyriimnsalnawa KIYRIIWNSALNAWV KIYRIIWNSALNAW KIYRIIMNSALNAW

F16. 1

SUBSTITUTE SHEET (RULE 26)

1111

4

zn1 z24

zn16_

zn04

z249.

2000

S

တ

đ

zn11_ zn02_

zn18

zn21, zn06

zn2

zn19 zn03

2/0/	
DPVORTVAVLIVNSDKEGRGERENVEENSDWAVYENERGVLTEREFTIKAGDNIKTKO DPVORTVAVLIVNSDKEGRGERENVEENSDWAVYENERGVLTEREFTIKAGDNIKTKO DPVORTVAVLIVNSDKEGRGERENVEENSDWAVYENERGVLTEREFTIKAGDNIKTKO DPVORTVAVLIVNSDKEGRGERENVEENSDWAVYENERGVLTEREFTIKAGDNIKTKO DPVORTVAVLIVNSDKEGRGERENVEENSDWAVYENERGVLTEREFTIKAGDNIKTKO DPVORTVAVLIVNSDKEGRGEREN VTEDSNWGVYENERGVLTEREFTIKAGDNIKTKO DPVORTVAVLIVNSDKEGRGEREN VTEDSNWGVYENDKKGVLTAGTTIKAGDNIKTKO DPVORTVAVLSFRADSEGRGERE VTEDSNWGVYENDKKGVLTAGTTIKAGDNIKTKO DPVORTVAVLSFRADSEGRGERE VTEDSNWGVYENDKKGVLTAGTTIKAGDNIKTKO DPVORTVAVLSFRADSEGRGERE GTEDSNWAVYENDERRVLKAGDNIKTKO DPVORTVAVLSFRADKEGRGERE GTEDSNWAVYENDERRVLKAGDNIKTKO DPVORTVAVLSFRADKEGRGERE GTEDSNWAVYENDERRVLKAGDNIKTKO DPVORTVAVLOFMINKEGNGELETISLSMTNDSKEFVUDPYIVVTKRAGDNIKTKO DSVORS .VVGSIQASMEGSGELETISLSMTNDSKEFVUDPYIVVTKRAGDNIKTKO DSVORS .VVGSIQASMEGSGELETISLSTAT DIGMSTYRDDHTHEGATVTHIKAGDNIKTKO DSVORS .VVGSIQASMEGSGELETISLSTAT DIGMSTYRDDHTHEGATVTHIKAGDNIKTKO DSVORS .VVGSIQASMEGSGELETISLSTAT DIGMSTYRDDHTHEGATVTHIKAGDNIKTKO DSVORS .VVGSIQASMEGSGELETISLSTAT DIGMSTYRDDHTHEGATVTHIKAGDNIKTKO	TSPWVKWAPWESFHSDKISGWGSKISEVGASSNLTWKWDKNKWGTWFFKKKGDNFKFKQ
The state of the s	. Z y _ a s s

FIG. 1A(CONTD.)

										-										
NEWNETYSTKKDLTDLTSV@TEKLSFSANGNKVNITSDTKGLNFAKETAG	2	TENE EN ET	2	•	ENT	ENT	Z E	Z 回	Z 臼	Z 回	ENT	ENT	enting spaystakkologi invegentse	ENTINASSETYSLKKD	Entinesisetystkkdingidinwembkise	ENTE	· · · SGKDETAY	SGKDETYSTKKETKDT	PLZE	Z 回
•		•	•	•	NHOHN.	DEN	NTDEN	NHNEN	NTNEN	NENTNEN	TNKNTNEN	NTNEN	NINEN.	NINEN	TNEN	TNEN	•	•	NHOHN	NEN
2	2	2	7	0	Н	Н	Н	Н	Н	Н	Н	Н	115	Н	Н	Н	Н	Н	Н	Н
07	n20_	n21_	_ 0 0	n19_	03_	n18_	$n11_{-}$	n02_	n04_	16	n14_	2491	zn10_1	22	23_	္စ	n24_	n25_	 	n29_

F1G. 1A(CONTD.)

FIG. 1B

									•	, _	,									
DEKKRAASWKDVLNAGWNIKGVK	DEKKRAAS KKOVINAGANIKGVKP	ODEKKRAAS WKDVINAGWIKGVKP	ODEKKRAASWKDVLNAGWNIKGVK P	DEKKRAASWKDVLNAGWNIKGVKP	$\geqslant_{\!$	KKRAASW	DDEKKRAASWKDVLNAGWNTKGVKP	EKKRAASV	EKKRAASVI	SDKKKRAAS WKDVLNAGWNIKGVKP	hyt <mark>raas</mark> iikdvinagwnikgvk	HYTRAAST	. HYTRAASEKDVLNAGWNIKGVKT	. HYTRAASMKDVLNAGWNIKGVKT	DEKKRAAS WKDVLNAGWIKGVK	AAS KDVLNAGWIKGVK	. HYTRAASTKDVLNAGWNIKGVKT	AAS KDVLNAGWNIKGVK	. HYTRAASTKDVLNAGWNIKGVKF	•
LNEGA	LUNG GATTNVTND NVED	JINHGA THINTHONVED	LINEGRETINATIONATED	ILNEGO DENVENDNVED	Z	LINGGATINATIONALD	LINEGATINATION VED	LINEGATINATION VED	TINDERTHNATURATED	JINEGATINVINDNVEDD	AGESESHVDAGNOSM.	AGSSESHVDAGNOSM.	PAGSSES HVDAGNOSE	=1		HAGSSESHVDAGNOSE.	SHVDAGNOSF	SHVDAGN	HAGSSMSHVDAGNOSM.	
IGS	TIGETT CHTUCTES TRUETE	TNGDTTVHLNGIGSTLTDT	TNGDTTVHINGIGSTLTDT	TNGDTTVHLNGIGSTLTDT	TNGDITVHINGIGSTLTDT	TNGDTTVHLNGIGSTLTDT	TNGDP TVHINGIGSTLTDT	tingde tveingigs titdt	Tingd Pavelingi GS Tlade	TNGDTTVHLNGIGSTLTDT	TNGDTTVHINGIGSTLTDT	TNGDTTVHLNGIGSTLTDT	TNGDTTVHLNGIGSTLTDT	TNGDTTVHLNGIGSTLTDT	TNGD TTVHINGIGS THUD	TNGDPTVHINGIGSTLTDT	TNGDP TVHLNGIGSTLTDT	TNGDTTVHINGIGSTLTDT	TNGDP TVHINGIGSTLTDT	
C 1	1/1	7	~	~	~	~	~	~	~	~	~	~	~	~	~	9	9	~	7	•
n07_	zn20_1 zn21_1	n06_	n19_	n03_	n18_	n11_	$n02_{-}$	n04_	n16_	n14_	2491	n10_	n22_	n23	n28_	n24_	n25_	n 08	9	

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
---------------------------------------	--

F1G. 1B(CONTD.)

FIG. 1B(CONTD.)

6/97

VTGKDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGOTGQADKFETVTSGTNV VTGKDKGENGSSTDEGEGLVTAKEVIDAVNKAGHPMYTTTANGOTGQADKFETVTSGTNV	VTGKDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGOTGOADK FETVTSGTNV	VTGKDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGOTGOADKFETVTSGTNV	VTGKDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGOTGOADKFETVTSGTNV	VTGKDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKV	VTGKDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKV	VTGKDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKV	V Y CK CK DENGSS TD EGE GLV TAKEVIDAVNKA GWRMKT TTANGO TGOAD KFETVTS GTNV	V T GKGKDENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNV	VTGKGKDENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKV	V T G K G K G E N G S S T D E G E G L V T A K E V I D A V N K A G W R M K T T T A N G Q T G Q A D K F E T V T S G T N V	V-PGKGKGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKT-TTANGQTGQADKFETVTSGTNV	V-CKGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGOTGOADKFETVTSGTNV	V. CKGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGOTGOADKFETVTSGTNV	VTGKGKGENGSSTDEGEGLVTAKEVIDAVNKAGHRMKTTTANGQTGQADKFETVTSGTNV	VTGKGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNV	VTCKGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKV	VTGKGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKV	VTGKGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTNV	VTGKGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTKV
2 8 8 9	ω	∞	φ (o o	n (n (א ע	7 (א עכ	5 (C	∞	ω (∞	∞	ω (00	∞	5 0	2
zn07_1 zn20_1	zn21_1	zn06_1	u G	r .	7	d 1	700	10.4 1	ָר ה	7 T C			7			zn24_1	n N	T 8 0 u	znzy_ass

VMYDVNVGDALNVNHLQNSGWDLDSKAVAGSSGKVISGN VKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGN VKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGN VKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGN VKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGN VKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGN VKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGN VKYDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGN Y DVN V GDALN V NOLONS GWNLDSKAVAGSSGKVISGN YDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGN YDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGN Y DVIN V GDALIN V NO LONS GWNLDSKAVAGSSGKVISGN YDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGI YDVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISGI Y D V N V G D A L N V N Q L Q N S G W N L D S K A V A G S G K V I S G DVNVGDALNVNQLQNSGWNLDSKAVAGSSGKVISG SGWNLDSKAVAGSSGKV AYDVINGDALINVIOLO GTTATVSKDDQGNITV GTTATVSKDDQGNITV GTTATVSKDDQGNITV GTTATVSKDDQGNITV **GTTATVSKDDQGNITV GTTATVSKDD**QGNITV **GTTATVSKDDQGNITV GTTATVSKDDQGNITV Sttatusk**ddogenitu **GTTATVSKDDQGNITV TTATVSKDDQGNITV GTTATVSKDDQGNITV GTTATVSKDDQGNITV GTTATVSKDDQGNITV** TTATVSKDDQGNIT TFASGKO TFASGKO TFASGKO TFASGKO TFASGNOTE TFASGNOTE TFASGNOTE TEASGNOTE TEASGN FASGK FASGK FASGN $\sigma\sigma\sigma\sigma\sigma\sigma$ 444400000000444444400 S S S Ø Ø Ø đ 444 ಥ -90uz zn21, zn19 zn03 zn18 znll zn22 zn23 4 S zn2 zn2 zn2 zn0 Z

F1G. 1

()

	3
KMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGGGGABKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGGGGABKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGGGGABKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGGGGABKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDGGGGABKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGGKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGGKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGKKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGAKMDETVNINAGNNIEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGAKMDETVNINAGNIETRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVDDGGAKMDETVNINAGNIETRAGANTATSMTPQFSSVSLGAGADAPTLSVDGGA	
EITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD EITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVD IEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVD IEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVD IEISRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMAPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD IEITRNGKNIDIATSMTPQFSSVSLGAGADAPTLSVD	
	ă
	£
	7
	2
	2 2 2
	2
K K K K K K K K K K K K K K K K K K K	
	3
ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI ETVNINAGNNI	
	2
	2
100000000000000000000000000000000000000	
000000000000000000000000000000000000000	
	۱ ۱
8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	۱ ۱
44444444444444444444444444444444444444	לד ממ
	1

FIG. 1C(contd.)

7	9	LNVGSKKDINKPVRTTNVAPGVKEGDVTNVAOT KGVAONTNINPT IN WITCHA BACTACATA E
o	9	LNVGSKKDINKPVRITINVAPGVKEGDVTNVAOIKGVAONINNRITINVICNAPAGTAOATAT
ا ښا	9	LNVGSKKD NKPVRITNVAPGVKEGDVTNVAOIKGVAONINNRIDNVDGNARAGTA OATA T
وا	9	LNVGSKKDINKPVRITNVAPGVKEGDVTNVAOIKGVAONINNRIDNVDGNAPAGTAOATAT
م	9	LNVGSKKD NKPVRI TNVAPGVKEGDV TNVAOLKGVAONINNRI DNVDGNARAGTAOATAT
03	<u>-</u>	LNVGSKDANKPVRI TNVAPGVKEGDVTNVAQ1KGVAONINNHI DNVDGNARAGTA OATA TA
n18_1	<u>- 1</u>	LNVGSKDANKPVRI TNVAPGVKEGDVTNVAQLKGVAQNLNNHIDNVDGNARAGTAQATAT
	471	LNVGSKDANKPVRI TNVAPGVKEGDVTNVAQLKGVAQNLNNHIDNVDGNARAGIAQAIAT
70 u	~ [LNVGSKDFINKPVRI TNVAP GVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAQAIAF
n 0 4	- 1	
197u	_	enveskoankpvri tnvapevkegdvtnvaqikgvaqninnridnvdenaragiaoaia
n14_	_	LNVGSKDANKPVRI TNVAPGVKEGDVTNVAQLKGVAQNLNNRI DNVDGNARAGTAQATAT
491	Q	LNVGSKDANKPVRITNVAPGVKEGDVTNVAOLKGVAONINNRIDNVDGNARAGTA OATA T
0	9	LNVGSKDANKPVRITNVAPGVKEGDVTNVAOIKGVAONINNRIDNVDGNAPAGTAOATAT
7	9	LNVGSKDANKPVRITNVAPGVKEGDVTNVAOLKGVAONINNRIDNVDGNARAGIA OATAT
က	9	LNVGSKDANKPVRITNVAPGVKEGDVTNVAOIKGVAONINNRIDNVDGNARAGIAOAIA
ر ص	9	LNVGSKDANKPVRI TNVAPGVKEGDV TNVAOTKGVAONINNRTDNVDGNA RAGTA OATA T
zn24_1	9	LNVGSKDANKPVRITNVAPGVKEGDVTNVAQ1KGVAONINNRIDNVDGNARAGTAQATAT
2	9	LNVGSKDANKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGIAOAIAT
ا ھ		LNVGSKDANKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNFIDNVDGNARAGTAOATAT
Ť	~	LNVGSKDANKPVRITNVAPGVKEGDVTNVAQLKGVAQNLNNRIDNVDGNARAGTAOATAT

F/G. 1C(contd.)

AGLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	AGLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSKGHFGASASV	AGLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWITKGTASGNSRGHFGASASV	1GLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	IGLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	IGLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	SILVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	<u> aglvoaylpcksmmaiggd</u> tyrgeagyaigyssisdggnwiikgtasgnsrghfgasasv	<u> NGLVQAYLPGKSMMAIGGD</u> TYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	<u> iglaqaylpgksmmaigggtyrgeagyaigyssisd</u> ignw <u>w</u> ikgtasgnsrghfgasasv	 GLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	 Glvqaylpgksmmaigggtyrgeagyaigyssisdggnwiikgtasgnsrghfgasa sv	IGLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	<u> Iglvoaylpgksmmaigggtyrgeagyaigyssisdggnwiikgtasgnsrghfgasasv</u>	<u> Gevoaylpgksmmaigggtyrgeagyaigyssisdggnwiikgtasgnsrghfgasasv</u>	IGLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	iglacaylegksmmaigggtyrgeagyaigyssisdegnm@ikgtasgnsrghfgessy	igladayldgksmmaigggtyrgeagyaigyssisdtgnwwikgtasgnsrghfgtsysv	GLVQAYLPGKSMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASV	<u> nglvoaylpgksmmaigggtyrgeagyaigyssisdggnwiikgtasgnsrghfgasasv</u>
522	10	\sim	8	m	က	m (m	m	m	m	2	2	7	N	N	N	N	m	m
zn07_1	12	zn06_1		zn03_1	- 1	C	0.2	n04_	1.6	14	9	0	zn22_1	m M	ω ω	_1	1		zn29_ass

FIG. 1D(CONTD.)

```
znn07_1
znn20_1
znn20_1
znn21_1
znn21_1
znn06_1
znn06_1
znn19_1
znn08_1
znn18_1
znn04_1
znn04_1
znn14_1
znn14_1
znn23_1
znn23_1
znn28_ass
znn28_ass
592
6440064
znn28_ass
znn28_ass
592
6440064
znn28_ass
znn28_ass
592
6440064
G440064
Znn28_ass
znn28_ass
592
6440064
G440064
Znn28_ass
Znn2
```

FIG. 2A

DNGAAKKEIVFGTTV DNGAAKKEIVFGTTV DNGAAKKEIVFGTTV DNGAEKKEIVFGTTV DNGAEKKEIVFGTTV	AADNGA EKKETV FGTTVG AADNGA EKKETV FGTTVG AADNGA EKKETV FGTTVG AADNGA EKKETV FGTTVG AADNGA EKKETV FGTTVG	DNGAEKKEIVFGT DNGAEKKEIVFGT DNGAEKKEIVFGT DNGAEKKEIVFGT DNGAEKKEIVFGT DNGAEKKEIVFGT	AADNGA A KKE I V FGTTVG	. AADNGA EKKET V FGTTVG
GQKDSAPAASAAA GQKDSAPAASAAA GQKDSAPAASAAA GQKDSAPAASASA GQKDSAPAASASA	FKT LSAAA LALILAACGGQKDSAPAASA FKT LSAAA LALILAACGGQKDSAPAASA FKT LSAAA LALILAACGGQKDSAPAASA FKT LSAAA LALILAACGGQKDSAPAASA FKT LSAAA LALILAACGGQKDSAPAASA FKT LSAAA LALILAACGGQKDSAPAASA	FKT LSAA A LAL I LAACGGOKDSAPAASAS, FKT LSAA A LAL I LAACGGOKDSAPAASAS,	MKTFFKTLSAAALALILAACGGQKDSAPAASASA MKTFFKTLSAAALALILAACGGQKDSAPAASASA MKTFFKTLSAAALALILAACGGQKDSAPAASASA MKTFFKTLSAAALALILAACGGQKDSAPAASASA MKTFFKTLSAAALALILAACGGQKDSAPAASASA MKTFFKTLSAAALALILAACGGQKDSAPAASASA MKTFFKTLSAAALALILAACGGQKDSAPAASASA MKTFFKTLSAAALALILAACGGQKDSAPAASASA MKTFFKTLSAAALALILAACGGQKDSAPAASASA MKTFFKTLSAAALALILAACGGQKDSAPAASASA	MKTFFKTLSAAALALILAACGGOKDSAPAASASA

FIG. 2A(contd.)

EOIOAEL EKKGY TVKI VEFTDYVRPNI AL AFGEL DINVEOH V BYL'DD EVZEHN	שני ו שני	GELDINVEOUK PYLDD	ELDINVFOHKPYLDD	EHIOPELEKKGYTVKLVEFTDYVRPNLALAEGELDINVFOHK PYLDD FKKFHN	EHIOPELEKKGYTVKLVEFTDYVRPNLALAEGELDINVFOHK PYLDD FKKEHN	Y TVKLVEFTDYVRPNLALAEGELDINVFOHK PYLDD	EHI OPELEKKGYTVKLVEFTDYVRPNLALAEGELDINVFOHK PYLDD FKKEHN	YTVKLVEFTDYVRPNLALAEGELDINVFOHK PYLDD	EHI OPELEKKGY TVKLVEFTDYVRPNLALAEGELDINVFOHK PYLDD FKKEHN	Y.TVKLVEFTDYVRPNLALAEGELDINVFOHK PYLDD	TVKLVEFTDYVRPNLALAEG	ELEKKGY TVKLVEFTDYVRPNLALAEGELDINVFOHK PYLDD	EHIQPELEKKGYTVELVEFTDYVRPNLALAEGELDINVFOHK PYLDD FKKEHN	ELEKKGYTVKLVEFTDYVRPNLALAEGELDINVFOHKPYLD		ELDINVFOHK PYLDD	GELD INVFOHK PYLDD	OHK PYLDD	EQIQAELEKKGYTVELVEFTDYVRPNLALAEGELDINVFOHK PYLDD FKKEHN	IOABLEKK	I QPELEKKGY TVKLV	EQIQPELEKKGYTVKLVEFTDYVRPNLALAEGELDINVFQH K PYLDD FKKEHN	EQIQPELEKKGY TVKLVEFTDYVRPNLALAEGELDINVFQH K PYLDD FKKEHN	EQIQAELEKKGY TVKLVEFTDYVRPNLALAEGELDINVFQHK PYLDDFKKEHN	EQIQAELEKKGY TVKLVEFTDYVRPNLALAEGELDINVFQH K PYLDD FKKEHN	EQIQAELEKKGYIVKLVEFTDYVRPNLALAEGELDINVFQHK PYLDD FKKEHN
						09																				
fa1090_4	2v32_4	2v33_4	zv02_4	zv15_4	zv03_4ass	zv04_4	zv05_4	2009_4	zv16_4	zv18_4	2v26_4	2v28_4	2008_4	zv10_4	2v25_4	2/17_4	2v96_4	zv06_4	zv19_4	zv20_4	22491_4	zv13_4	2027_4	2001_4	zv07_4	zv21_4

zv11_4 60 zv29_4 60 zv22_4 60 zv12_4ass 60 zv24_4ass 60

FIG. 2B(contd.)

GKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWIKLKDG GKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWIKLKDG GKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWIKLKDG PTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWIR PTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWIR PTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWIR PTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWIR PTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWIR QVPTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWII QVPTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWII QVPTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWII OVPTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVM L DELGWIH QVPTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVM L DELGWIH QVPTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVM L DELGWIH QVPTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARALVM L DELGWIH QVPTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWI QVPTAPLGLYPGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWI PGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWI PGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWI PGKLKSLEEVKDGSTVSAPNDPSNFARVLVMLDELGWI 120 120 120 120 2v13_4 2v27_4 2v01_4 2v07_4 2v21_4 2v11_4 2v29_4 2v22_4 2v12_4ass 1 zv24_4ass zv02_4 zv15_4 z2491_4 2V26_4 2V28_4 2V08_4 2V10_4 2V25_4 2V17_4 2V17_4 2V96_4 2V19_4 2V19_4 zv09_4 zv16_4 zv05_4 zv18_4

FIG. 2B(contd.)

OEP.	OEP	OEP	ŎEP.	ÕEP	OEP.	ÕEP	OEP	OEP	OEP	OEP.	OEP	OEP.	OEP	OEP.	OEP	OEP	OEP	QEP.	QEP.	QEP	QEP
LTEALE	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF	LTEALF
SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK	SSGMK
NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI	NGNYAI
VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDFAVV	VDEAVV
PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD	PRSRAD
LEAAQL	LEAAQLI	LEAAQL	LEAAÕLI	LEAAQLI	LEAAQLI	LEAAQL	LEAAQL	LEAAQLI	LEAAQL	LEAAQL	LEAAQL	LEAAQL	LEAAQL	LEAAQL	LEAAQL	LEAAQL	LEAAQL	LEAAQL	LEAAQL	LEAAQL	LEAAQL
IKIVE	IIKIVE	II K IVE	II K IVE	II K I VE	IIKIVE	II K I VE	II K IVE	JIKIVE	ITKIVE	IKIVE	II K IVE	II K IVE	II K IVE	I K IVE	IIKIVE	II K IVE	II K IVE				
AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKI	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKN	AENLKI	AENLK
(ADI	(AD I	(ADI	KADI	KADI	(ADI	KADI	(ADI	KADI	KADI	KADI	KADI	KADI	KADI	KADI	KADI	KADI	KADI	KADI	KADI	KADI	KADI
181	181	181	180	180		180	180	180	180	180	180	180	180	180	180	180	180	180	180	180	180
fa1090_4	zv32_4	zv33_4	zv02_4	zv15_4	zv03_4ass	zv04_4	zv05_4	zv09_4	zv16_4	zv18_4	zv26_4	zv28_4	zv08_4	zv10_4	2v25_4	zv17_4	zv96_4	zv06_4	zv19_4	zv20_4	22491_4

FIG. 2C

180 180 180 180 180 180 180 zv13_4 zv27_4 zv01_4 zv07_4 zv21_4 zv11_4 zv29_4 zv22_4 zv12_4ass 1 zv24_4ass 1

SUBSTITUTE SHEET (RULE 26)

()

F/G. 2C(contd.)

SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKYPAAWNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKYPAAWNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAGNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAMNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK*
SAVKTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK* KTA<mark>H</mark>KDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK KTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK KTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK KTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK KTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK KTADKDSÓWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK KTADKDSQWLKDVTEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK /TEAYNSDAFKAYAHKRFEGYKSPAAWNEGAAK SAVE 241 241 240 2v32_4
zv33_4
zv02_4
zv15_4
zv15_4
zv03_4ass
zv03_4
zv28_4
zv18_4
zv28_4
zv8_6
zv8 fa1090

9	
n (WEST STREET
77 80	ह्यान्त्र स्टाइन्डिक स्टाइन्डिक्ट्रिक
691	#WEIGHTSTRUM WINDSTON STORE ST
11_22	MOSPRES
20_22	WO SPYRANDA WANTANIAN SANTANIAN WAS AND SANTANIAN SANTANI
01_22	WOSEPERSONWENDERWERNTREAMERSTONE PROPERTY OF THE WAS A PROPERTY OF THE PROPERT
009_225	8
12_22	WOSFFIXFIVWEVEWEWEWERVERFEVEREREFERVERFERFERFERFERFERFERFERFFE
22_22	WOSFFFARM WOON FOR PARTY TO THE TO THE PROPERTY OF THE PROPERT
23_22	WOSETFERENCE VERWINDER DE LE
24_22	WOSIFFICE WWW. WEWFANTER SANTER SOFT WAS THE WOOD OF THE WOOD WAS THE WAS THE WOOD WAS THE WOOD WAS THE WOOD WAS THE WOOD WAS THE WAS THE WOOD WAS T
25_22	MOSTATION OF THE PARTY OF THE P
26_22	MOSFFERE TO
96_22	WOSEFFIXE WWW. VEWFAWE WITH LAND THE WEEKEN SELECTION OF THE TOTAL OF THE PROPERTY OF THE PROP
02_22	WOSIFIFED WAS WEST FOR THE WAS SELECT OF THE WAS SELECT OF THE SELECT OF
04_22	WOSIFFIXFINWENTENDERINFENTENDERINFENDERENDERINFERISSIEFENTOFFIFFE
06_22	WO GET PLANT TO THE WEST OF THE PROPERTY OF TH
07_22	WO SPINARY WAS VERWING WINDS WAS A PART OF SHARE
10_22	WOSFFERENCOM VROW LANDS VILLE LAND BEFERENCE SENSE REPROPERTY OF THE PROPERTY
14_22	WOBERTHOSP WORD VROW PROPERVISE PROPERTY PROPERTY OF THE CONTRACT OF THE CONTR
16_22	<u>क्टिंग्रान्स्</u> रिक्ट
17_22	WOSFIFE WOOD VERWINGS WITH PARTIES OF THE SELECT SELECTION OF THE SELECT SELECTION OF THE SELECT SELECTION OF THE SELECT SELECTION OF THE SELECT SELE
18_22	WO SPRING
19_22	WOSFFERS WIND WENT AND WIND AND SELECT SERVED SELECT OF THE SERVED SERVE
21_22	MOGFFTA
27_22	Wostatian was very property and the contraction of
28_22	MOSFE STATE
29_22	MOSFFEED IN
13_22	MOSPINA
03_22	Wostatishumandamananilahipanganangangangangangangangangangangangan
15_22	MOGFAX
060	WINDSPARSE TO THE PARTY OF THE
2	WOODFFEED WAS
3_22	VIOSIPATATA

AND ASSISTED THE WORLD TO THE PROPERTY OF THE	ν ειννήση να σο	OPVLPVNRVPARRAGNADELIGNAMGLNEOPYMOWRY	OPVLPVNRVPARRAGNADELIGNAMGLNEOPW	OPVLPINRAPARRAGNADELIGSAMGLNEOPVIPVNR	TWGO.	VLPVNRVPAR	VIGEVN	VLPVNRV	VEPVNRV	VLPVNRVPA	VLPVNRVPA	VLPVNRVP	THE PARTY OF THE P	$\Delta \Gamma$	VE	VLPVNRVP	VLPVNRVPA	VLPVNRVP	VLPVNRVPARRA	VLPVNRVPAR	· · · · · · · · · · · · · · · · · · ·	• • • • • • • • • • • • • • • • • • •	· · · · · · · · · · · · · · · · · · ·	• • • • • • • • • • • • • • • • • • •	VLPVNRVP	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	**************************************					
NADELIGSAMGENE	NAD	NA	NAD	NADELIG	NADEL	NAD	NADEL	NADEL	NADEL	NADE	NADE	NADEL	NADELIG	NADEL	NADEL	NADEL	NADEL	NADELIG	NADELIG	NADELIGS	NADELIGS	NADELIGSA	NADELIGSA	NADELIGSA	NADELIGSA	NADEL GSA	NADELIGSA	NADELIGSA	NADELIG	NADELIG	NADELIG	NADELIGSA	NADBLIGSAWGIN	19/
005_225 6	~	2491 6	011_225 6	020_225 6	001_225 6	009_225 6	012_225 6	022_225 6	023_225 6	024_225 6	025_225 6	026_225 6	096_225 6	002_225 6	004_225 6	006_225 6	007_225 6	010_225 6	014_225 6	016_225 6	017_225 6	018_225 6	019_225 6	021_225 6	0 577 / 70	0 077 970	029_225	013_225 6	003_225 6	015_225 6	a1090 6	032_225 6	033_225 6	
															•																			

STGFDCSG STGFDCSG STGFDCSG STGFDCSG STGEDCS GED CED(GED(DELIGSAMGINEDPVLPVNRAPARRAGNADELIGNAMGLIGINYRYGGTSSTG
DELIGGAMGINEDPVLPVNRAPARRAGNADELIGNAMGLIGINYRYGGTSSTG
DELIGNAMGINEDPVLPVNRAPARRAGNADELIGNAMGLIGINYRYGGTSSTG
DELIGNAMGINEDPVLPVNRAPARRAGNADELIGNAMGLIGINYRYRGGTSSTG
DELIGNAMGINEDPVLPVNRAPARRAGNADELIGNAMGLIGINYRYRGGTSSTG
DELIGNAMGINEDPVLPVNRAPARRAGNADELIGNAMGLIGINYRYRGGTSSTG
DELIGNAMGINEDPVLPVNRAPARRAGNADELIGNAMGLIGINYRYRYGGTSSTG
DELIGNAMGINEDPVLPVNRAPARRAGNADELIGNAMGLIGTNYRYRGGTSSTG
DELIGNAMGINEDPVLPVNRAPARRAGNADELIGNAMGLIGTNYRYRGGTSSTG
DELIGNAMGLINEDPVLRAFARRAGNADELIGNAMGLIGTNYRYRGGTSSTG 0വ пинанинининининининининининин വവ NN NN 1 1

FIG. 31

152 WORTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
181 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
182 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
183 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
184 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
185 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
185 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
186 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
187 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
188 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
189 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNER
180 WOHTERRANGTHIERTSANDARMOTEVARSELOPGONVERTIGGSRISHVOLVIGNNE VON 610 U 0 516 **FFRTLGGSRIS** MULTIPLE CO 3 (A) (VV 9 30 PRTSAEQARMGTEVARSEL RSI)îte) htekramginiprtsaeoai ਰਹਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰਰ S S S S

FIG.3B(contd.)

иниии

N

и и и и и и и

и и и

FIG. 3C

*23|9*7

1HAPRTGKNIEITSLSHKYWSGKYAFARRYKKNDPSRFLN 1HAPRTGKNIEITSLSHKYNSKYNDPSRFLN 1HAPRTGKNIEITSLSHKYNSKNDPSRFLN Su Sur los (NXI) de la ខាស

SUBSTITUTE SHEET (RULE 26)

ISPLE LICELAN WINGS BLOOM OF THE PROPERTY SERVING TO BE THE WAY PRINTED IN THE PROPERTY OF THE KOPLEEGGAAN WAXABERGQVQKAYPOPPOKTEBFKOFKORSEKSEKSEKYVYPPEKKKESFOKKESFOKK ISPLETICELAS WILLES CO ON OIT TO THE TOTAL SECOND TO THE SECOND S IXPLEITEDDAY WÂLGING ON OKLIP DE DE TEST SKEIN BEKELSE KELKEL ON ÎP PEKKE ÎP DÎN NOFIN CEM CÎP Î KPLELIGOLLANTELERGOVOKELPDFOTESFKEFKEKPLERGEKTERFKETEN FOFERESEPEKTERF WINGSPINE IN THE KASIBEEREMAN VAN KISA GOVOKASIBEEREERIASISTASIA KASIBAA SAAN VERENISEEDA MAARAA KASIBAA KASIBA KASIB MASTELECTION OF THE CONSTRUCTION OF SOME OF SOME INTERIOR OF THE CONTROL OF THE CONTROL OF THE WINGSTOWN OF THE CONTROL OF THE WINGSTOWN OF THE CONTROL OF T **ġvivo**ppamasipavnermev <u>Viperwasipoivnernev</u> IXPERITEMENTANDENEENEENEENOOMENTEENEENEENEENKEENEENEENEENEEN VAN PERMINISTERINGEN *ANNEED MASSIPPINAMENTO PROPERTIES PROPERTI* <u>Vernasiendonnermen</u> SEWEGE ৽ঽঢ়৾৽৽৽৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸৸ zzieranavinikarenenvonanaranarenen erakarananananan ISPERINGERAN WELLSTON SON STATE STATE STATES OF THE STATES

SUBSTITUTE SHEET (RULE 26)

gnmzq19

gnmzq21

gnmzq17

gnmzq1 gnmzq1 gnmzg22

gnmzg2 gnmzg2 gnmzg2

gnmzq27

gnmzq2 gnmzq2 gnmzq1 gnmzq1 gnmzq2

gnmzq10 gnmzq11 gnmzq13

gnmzq07

gnmzq05 gnmzq08

gnmzq32 gnmzq33 gnmzq01

gnmzq31

fa1090

gnmzg03 gnmzg04

gnmzq02

FIG. 4A(contd.)

AAPLSEAGYYVFPAAVVEETFKQNGLTNAADIHAVRPEKLHQ
AAPLSEAGYY AAPLSEAGYY AAPLSEAGYY AAPLSEAGYY AAPLSEAGYY AAPLSEAGYY AAPLSEAGYY AAPLSEAGYY AAPLSEAGYY

SAVUNCIANSLT SAVUNCIANNILT SAVUNCIANNILT SAVUNCIANSLT SAVUNCIANSLT SAVUNCIANSLT SAVUNCIANSLT SAVUNCIANSLT SAVUNCIANSLT SAVUNCIANSLT avvnoianslt Avvnoianslt AVVNQIANSLT AVVNQIANSLT AVVNQIANSLT AVVNOIANSL AVVNOIAN YOLLDSVITYSARARLYDSRNGRYLMSGSASIREGSNNSNSGLLGALVGANY

YOLLDSVITYSARARLYDSRNGRYLMSGSASIREGSNNSNSGLLGALVGANY

YOLLDSVITYSARARLYDSRNGRELMSGSASIREGSNNSNSGLLGALVGANY

YOLLDSVITYSARARLYDSRNGRELMSGSASIREGSNNSNSGLLGALVGANY

YOLLDSVITYSARARLYDSRNGRELMSGSASIREGSNNSNSGLLGALVGANY

YOLLDSVITYSARARLYDSRNGRELMSGSASIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSASIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSASIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSASIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSASIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSASIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSASIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSSSIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSSSIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSSSIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSSSIREGSNNSNSGLLGALVSANY

YOLLDSVITVSARARRLYDSRNGRELMSGSSSIREGSN α 489 DARABARAHHHHHOOOOOOOMMOMO שמש שמש שמש

FIG. 4E

F/G.4B(contd.)

```
GYQVSKTAAYNLLSPYSHNGILKGPRFVEEQPR
GYQVSKTAAYNLLSPYSHNGILKGPRFVEEQPR
GYQVSKTAAYNLLSPYSHNGILKGPRFVEEQPR
GYQVSKTAAYNLLSPYSHNGILKGPRFVEEQPR
                                            GYQVSKTAAYNLLSPYSHNGILKGPREVEEG
GYQVSKTAAYNLLSPYSHNGILKGPREVEEG
GYQVSKTAAYNLLSPYSHNGILKGPREVEEG
GYQVSKTAAYNLLSPYSHNGILKGPREVEEG
                                                               gyovsktarynllspyshngilkgprfvee(gyovsktaryle)
SPYSHNGI LKGPREV
GBHUBGBHACOHBUGC9HGB4GC89
                             4 & 6
                                                                   omommoo
                                                                                              gnmz q28
                                                                                                          นี้ผู
                                                                                                                 25
                  grancg
grancg
                          )bzwub
שים יט
          ש
               מ
                                                                                                  gnmz q2
z2491
   gnmz
fal0
           gnmz
nmz.
                                                                                                                 gnmz (
                                                                                                          gnmz
```

MFKRSVIAMACIFALSACGGGGGSPDVKSADTLSKPAAPVVSEKETEA MFKRSVIAMACIFALSACGGGGGSPDVKSADTLSKPAAPVVSEKETEA MFKRSVIAMACIFALSACGGGGGSPDVKSADTLSKPAAPVVSEKETEA MFKRSVIAMACIFALSACGGGGGSPDVKSADTLSKPAAPVVSEKETEA MFKRSVIAMACIVALSACGGGGGSPDVKSADTLSKPAAPVVSEDVGEEVLPKEKKEEA MFKRSVIAMACIFPLSACGGGGGSPDVKSADTESKPAAPVVSEDVGEGVLPKEKKEEA	Kedapoa geoggapsaoggodmaavseentgnggaaatdkpknedegaondmponaadt Kedapoa geoggapsaoggodmaavseentgnggaaatdkpknedegaondmponaagt Kedapoa geoggapsaogsodmaavseentgnggavtadnpknedevagen Kedapoa geoggapsaogsodmaavseentgnggavtadnpknedevagen Vegapoadtodatagkggodmaavsaentgnggaattdnpegkdegondmadt Aggapoadtodatagkggodmaavsaentgnggaattdnpknedegondmadt	DSLTPNHTPASNWPAGNWENQAPDAGESEQPANQPDWANTADGWQGDDPSAGGENAGNTA DSLTPNHTPASNWPAGNWENQAPDAGESEQPANQPDWANTADGWQGDDPSAGGENAGNTA DSSTPNHTPDPNWLAGNWENQATDAGESSQPANQPDWANAADGWQGDDPSAGGONAGNTA DSSTPNHTPDPNWLAGNWENQATDAGESSQPANQPDWANAADGWQGDDPSAGGONAGNTA DSSTPNHTPAPNWLAGNWENQATDAGESSQPANQPDWANAADGWQGDDPSAGGONAGNTA
ਜਿਜਜਜ		111111
287 1287 287 287 287 287 287 287 29 1887 29 1887 29 1887 29 1887 29 29 29 29 29 29 29 29 29 29 29 29 29	287_14 287_2 287_2 22491 287_9 £a1090	287 14 287 2 287 21 287 21 587 91 falo90

F/G.5

FIG. 5(contd.

()

O AOĞTNOAENNOTAGSONPASSÜNPSATNSGGDFGRTNYĞNSVYTDGPSONITLTHCKGDS O AOĞTNOAENNOTAGSONPASSTNSATNSGGDFGRTNYĞNSVYTDGPSONITLTHCKGDS O AOĞANOAGNNOAAGSSDPIPASNPAPANGGSNFGRVDYANGVÜIDGPSONITLTHCKGDS O AOĞANOAGNNOAAGSSDPIPASNPAPANGGSNFGRVDYANGVÜIDGPSONITLTHCKGDS 8 DQAANOAENNOVĞGSONPASSTNPNATNGGSDFGRINVANGENĞNGTÜTLTHCKGDS 7 . ESANOTGNNOPAGSSDSAPAŞNPAPANGGSDFGRINVANGENSVYTDGPSONITLTHCKGDS	O CSGNNEIDEEVQLKSEEEKISDADKISNYKKDGKNDGKNÖKEVGIVADSVQMKGINQYIII O CSGNNEIDEEVQLKSEEEKISDADKHSNYKKDGKNDGKNÖKEVGIVADSVQMKGINQYIII O CSGNNEIDEEVQLKSEEEKISDADKKSNYKKDGKNÖKEVGIVADSVQMKGINQYIII O CSGNNEIDEEVQLKSEEEKISDADKISNYKKDGKNÖKEVGIVADSVQMKGINQYIII 8 CDRD. EIDEEAPPKSEEEKISDEEKINKYKKDEQRENEVGIVADRVEKNGTNKYKIII 6 CNGDNILIDEEAPSKSEEEKISDEEKI	6 EYKPKP. ESFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEG 6 EYKPKP. ESFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEG 6 EYKPKP. ESFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEG 6 EYKPKP. ESFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEG 3 IYKDKSASSSARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEG 2 EYTDKPPT RSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEG
1170011	122222 12222 12222	0000000
287_14 287_1 287_2 287_21 22491 287_9 fal090	287 14 287 12 287 12 287 21 287 9 581 9	287 14 287 14 287 2 287 2 287 2 1 0 9 0

FIG. 5(contd.)

Nyryltyggæklpggsyalrvogepskgemlagtavyngevlhfhtengrpspspskgrfaa Nyryltygaeklpggsyalrvogepskgemlagtavyngevlhfhtengrpspspskgrfaa Nyryltygaeklpggsyalrvogepakgemlagaavyngevlhfhtengrpypmrgrfaa Nyryltygaeklgggsyalrvogepakgemlagtavyngevlhfhtengrpypsgggrfaa Nyryltygaeklgggsyalsvogepakgemlagtavyngevlhfhmengrpspsggrfaa	KVDFGSKSVDGIIDSGDGLHMGTQKFKAAIDGNGFKGTWTENGGGDVSGMFYGPAGEEVA KVDFGSKSVDGIIDSGDGLHMGTQKFKAAIDGNGFKGTWTENGGDVSGMFYGPAGEEVA KVDFGSKSVDGIIDSGDDLHMGTQKFKAAIDGNGFKGTWTENGSGDVSGMFYGPAGEEVA KVDFGSKSVDGIIDSGDDLHMGTQKFKAAIDGNGFKGTWTENGSGDVSGMFYGPAGEEVA KVDFGSKSVDGIIDSGDDLHMGTQKFKAWIDGNGFKGTWTENGGGDVSGMFYGPAGEEVA	GKYSYRPTDAEKGGFGVFAGKKEQD*GKYSYRPTDAEKGGFGVFAGKKEQD*GKYSYRPTDAEKGGFGVFAGKKEQD*GKYSYRPTDAEKGGFGVFAGKKEQD*GKYSYRPTDAEKGGFGVFAGKKEQD*GKYSYRPTDAEKGGFGVFAGKKEQD*GKYSYRPTDAEKGGFGVFAGKKEQD*GKYSYRPTDAEKGGFGVFAGKKEQD*GKYSYRPTDAEKGGFGVFAGKKERD*
ычычыд 444450 884460	44444 000044 884467	44444 000000 884480
287_14 287_2 287_2 287_2 287_9 587_9 681_9	287 14 287 2 287 2 287 9 6 1 0 9 0	287 287 287 224 21 21 21 21 21 21 21 21 21 21

AVAVEGEKSEVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSL AVAVEGEKSEVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSL AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSL **Vavegeksfuvipqqevhvverlgrfhraltaginilipfidrvayrhs**l <u>Avavegeksfuvipqqevhvverlgrfhraltaglnilipfidrvayrhsl</u> AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILI PFIDRVAYRHSL AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSL AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSL AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSL FGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSL **VFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSL** AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSL avavegeksfuvipqqevhvverlgrfhraltaginilipfidrvayrhsl avavegeksevvipqqevhvverlgrfhraltagenilipfidrvayrhsi AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSI AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSI AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSI **NAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSI** VFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHS! AVAVFGFKSFVVIPQQEVHVVERLGRFHRALTAGLNILIPFIDRVAYRHSI WEFFILLVA WEFFILLVA MEFFILLLA MEFFILLLA Kanana adalah deleter en de <u>Mederateria</u>a <u>Meses en en a</u> <u>Merentara</u>A Variated V Variation V A Property of the Authority A**ৰিক্ৰা**ৰ্ডান্ত Version en en en en en Λ Variation интана

z2491_519
zv26_519
zv26_519
zv22_519ass
zv28_519
zv28_519
zv02_519
zv02_519
zv01_519
zv01_519
zv01_519
zv12_519
zv12_519
zv27_519
zv27_519
zv20_519ass
zv20_519ass

러 러 러 러 러 러 러 러 리 리 리 리 리 리 리 리 리 금

SUBSTITUTE SHEET (RULE 26)

BNSDOCID: <WO____0066741A2_1_>

FIG. 6A(contd.)

z2491_519	121	RMELDKUPEERDETNSTVVSAIDEAAGAMGVKVIBVETVBITTEDISTI
51		RMELDKAPERENT TO THE TRANSPORT OF THE TR
17.2 5.10 p.g	C	DWGT TERMINES TO THE TRANSMINES OF THE TRANSMINE
T (1	KMELDKTFEERDEINSTVVSALDEAAGAWGVKVLRYEIKDLVPPOEILRSWOAOITAERE
a1090_51	~	RMELDKTFEERDEINSTVVSALDEAAGAMGVKVLRYEIKDIVPPOETTRAMOAOTTAEPE
_51	~	RWELDKTFEERDEINSTVVSALDEAAGAWGVKVLRYETKDLVPPORTTRAMOAOTTAEPE
_51		RMELDKTFEERDEINSTVVAALDEAAGAMGVKVLRYETKDLVPPOETTESMOAOTTAFPE
zv28_519	~	RMELDKTFEERDEINSTVVAALDEAAGAWGVKVLRYETKDLVPPOETTBEWOATTAEPE
zv96_519	N	RMELDKTFEERDEINSTVVAALDEAAGAWGVKVLRYETKDLVDDOETLDCWOAGTEAER
zv02_519	~	RMELDKTFEERDEINSTVVSALDEAAGAWGVKVI.RVFTKDIVERDFTF DEWOADTERSE
zv03_519	~	RMELDKAPEERDEINSTVVSALDEARGAWGVVVI. PVETZDITUEDGETE BENGA GIERA
zv04_519	121	RWEIDKTERFRERNSTAVORALIBERARIONAVIANTEVALIBATIONALIBERA
ZV05 519	~	RWELLY AND THE TANK THE TANK OF THE TANK THE TAN
1101	1 6	THE PARTY OF THE PROPERTY OF T
101		KWELDKYFEERDE INSTVVAALDEAAGAWGVKVLRYEIKDLVPPQEILRSWQAQITAERE
TG-/0A	N	RMELDKTFEERDEINSTVVAALDEAAGAWGVKVLRYEIKDLVPPOEIIRSWOAOITAERE
_51		RMELDKTFEERDEINSTVVAALDEAAGAWGVKVLRYETKDLVPPOETTRSMOAOTTARE
51		RMELDKTFEERDEINSTVVAALDEAAGAWGVKVLRYETKDLVPPORTIRSMOAOTHAFRE
zv19_519		RMELDKTFEERDEINSTVVAALDEAAGAWGVKVLRYETKDLVPPOETT PEWOADTAREPE
zv21_519ass	N	RMEIDKUPBERDEINSTVVAALDEAAGAWGVKVLRVETKITVIOTOTT TEMOACTERE
zv27_519	121	RWEIDKTFEERDEINSTVVANTEACAMGVKVIPVTATTVILVERGEINSTVANTATT
5	-	AND TOWNS THE TREE TREE TREE TREE TREE TREE TREE
	1 +	NEGLONIE EERDEINSIVYAALDEAAGAWGVKVLKYEIKDLVPPQEILRSWQAQITAERE
	T 7 T	KWEITDKIVEBERDEIMSTVIFSAIDEAAGAWGVKVERYEIKDLVPPOEILRSWOAGITAERK
zv29_519ass	121	RMELDKTFEERDEINSTVVSALDEAAGAWGVKVLRYEIKDLVPPQEILRSWOAGITAERE

F/G. 6A(contd.)

LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA LESEGRKIEQINLASGOREA	AESEGRKIEQINLASGQREAEIQQSEGEAQAAVNASNAEKIARINRAKGEAESLR IESEGRKIEQINLASGQREAEIQQSEGEAQAAVNASNAEKIARINRAKGEAESLR
والماما والماما والماما والماما والماما والماما	ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI ELOCSEGEACAAVNASNI

SUBSTITUTE SHEET (RULE 26)

8 0

LVAEANAEAIRQIAAALOTOGGADAVNLKIAEOXVAAFNNIAKESNTI TWBANVANTGST	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEOXVAAFNNLAKESNTI TWPANVADT GST	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEOXVAAFNNLAKESNTLIMPANVADTGST	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEOYVAAFNNLAKESNTLIMPANVADTGST	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLTWPANVADTGST.	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEOYVAAFNNLAKESNTLIMPANVADTGST	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLTMPANVADTGST.	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLTMPANVADTGST	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSI.	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSI.	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADTGSL	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNFLTMPANVADTGST	LVAEANAEATRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNFLTWPANVADTGST	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNHAKESNFLTWPANVADTGST	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNIAKESNTLTMPANVADT CS	LVAEANAEAIRQIAAALQTOGGADAVNLKIAEOYVAAFNNIAKESNTI TWBANVANT CST	LVAEANAEAIRQIAAALQTQGGADAVNLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL	
4	4	4	4	4	4	4	4	4	4	4	241	4	4	4	4	4	4	4	4	4	4	
z2491_519	6_51	v22_51	090_51	2_51	1_51	8_51	51	2_51	3_51	57		V01_51	 	v12_51	v18_51	-1	zv21_519ass	zv27_519	zv20_519ass	zv06_519ass	zv29_519ass	

FIG.6B(contd.)

()

()

FIG. 6B(contd.)

SAGMKIIDSSKTAK*	SAGMKIIDSSKTAK*	SAGMKIIDSSKTAK*	SAGMKIIDSSKTAK *	SAGMKIIDSSKTAK*	SAGMKIIDSSKTAK*	SAGMKIIDSSKTAK*	SAGMKIIDSSKTAK*	SAGWKIIDSSKTAK*	SAGMKIIDSSKTAK*	SAGMKIIDSNKTAK*											
0	301	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	O	0
91_5	51	v22_519a	90	_51	1_51	8_51	6_51	2_51	3_51	4_51	zv05_519	_51	_51	ન	51	Н	-	Н	51	6_51	19as

nunderdolendeningeeer

fa1090	1 10.71 TO THE REPORT OF THE PROPERTY OF THE
33agb	Wisania is significant for the contraction of the c
32as	WOOMHELES PA
23asb	WIXINDERING OF THE STANDS OF THE PROPERTY OF T
	अत्रक्ष्यं <mark>र अर्थेड</mark> ाक्ष्
0	ऑस्ट्रस्टिट चेन्ट्रिक्टर्स्टर्स्ट चिट्टर्स्टर्स्स
	W. W
2m24	WXXXXAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
	रहा देखानुहरू इस्त्रे
zm14	<u>ज्यस्त्रकर</u> ्यक्र
zm04	ক্রেক্তিয়ের
zm1	W. S.
zm0	रहा दिन्द्रिश्यक्षात्र । जन्म
2 H 2	* 1-4-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-
Zm0	जराईन्डिन्टर ्डा
Zm0	X PROTOS ENVISORS IN
zm0	* Procession of the second
Zm0	<u>ज्यस्</u> रक्राराज्यम्
zm1	<u>ज्यस्तररर</u> ्भार
Z	MIXINDEFERE
zml	ज्यां स्टब्स्टरिक्टरिक्टरिक्टरिक्टरिक्टरिक्टरिक्टरिक
zm2	<u>ज्यस्थ्र</u>
Zm21	जारवरारायका जिल्ला
zm0	<u>भारतरहरम्बन्ध</u> ार
zm17	<u>जराईन्ट्रिन्टर</u> इंड्र
zm13	MISTORING
90	WITH THE PROPERTY OF THE PARTY
	ज्यां कार्यक्रा कार्या
-	MXXXXAAAAXXXXAAACGXXXXXXXAAXXXGGBXXQXXQGXXXQQXQQXQQXQXQQQQQXXQAXQQXQQQ
N	WITE STREET STREET A GREET
	र्करराज्ञ ज्ञानिक क्रिक्ट क्रिक्ट ज्ञानिक ज्ञा
	राराहाल जनसङ्ख्या । सर्वे प्रतिस्थान
	र्षाराराज्ञ जन्मेराराज्ञां जन्म
zm15	जार्चन्युरं र ्डा
zm31asbc	1 WXXXHEDFUXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

*38|9*7

fa109	0 61	Vary Visite and Wisite Strate Control of the Control of Strate Con
zm33a	sbc 61	VENTAL SECTION SEED SECTION SE
ಡ	r Q	ASMITTANIAN WELLEN WELE
2.3 a	bc 6	FORTH THE TRANSPORT OF THE PROPERTY OF THE PRO
27b	9	Sirjatiniyy, Obbayya Gara Marketaniya Karanganiya Karanganiya Karanganiya Karanganiya Karanganiya Karanganiya K
Smc 9	61	Schillings of the contraction of
zm10	61	
zm24	61	Suptemplations of the contraction
zm25		0121200F0F121213
zm14	61	3.47.0472V75(S)7
M Z		KWWPithesuttummodostasses ostandesing ostandes ostandes on see ostandes ostandes ostandes ostandes ostandes os
zm11a		KWWOREGEBERMANGODFRAKER OSFIAFICAN WARANTON ON TO THE CONTRACT OF THE CONTRACT
zm0		VEVVOPITA SEPTEMBAN OPPRINTED OF SEPTEMBER OF SEPTEMBER OF SEPTEMBER SEPTEMB
96mz -		KWWPIIPESIPEIMANQIDIPANSERQSPINKIEGANIENAMIQENIQUENIQUENIQUENIQUENIQUENIQUENIQUENI
zm01		VEVVOSITE SE
2m0		VEVVVPIEDESEPERMENS (SIEDESENS SERVISER OSTERITÄRESEN VARATIONEMOIDEN ESTE SES VALSER SERVISER SERVI
zm03		PEWWolithesalisman. Objeting Sale ostation of the conversation of the constraint of the constraint of the conversation of the
Zmo7		PENVIDITURE PRINTER (PROPERTY SERVICE) PROPERTY (PROPERTY PROPERTY
2m12		KEWVIPITE STAPTINGS (SOUTH STATES OF
zm18		NEW VISITE GRAPH MANAGER AND A CONTRACT OF THE WAY OF T
2m19		PEVVIDITE GREETING AND PROPERTY SINGLES OF STREETING STREET SINGLES OF STREET SINGLES OF STREETING STREET SINGLES OF STREETING STREET SINGLES OF STREETING S
zm20		PEVVIDITE GREET THE PROPERTY SERVESTA STATES OF THE PROPERTY O
2 zm21		PERVIDITE SELECTION OF THE PROPERTY SELECTIO
2m06		VEVVVERIORS CAPTION RANGE OF STRUCK S
zm17		VEVVORITE SEPTEMBLA QUE LA SERVIS SERVIS SERVIS SERVIS SE
zm13		VEVVO PIE LEGIED PEN SEL PEN SEL PEN
0		VEVVORIBESED SENDENCE SENDENCE SERVICE
z2491		KWWDIII LIPIIM LOOPIN L
zm22	61	PHYVVPIII BEBEELE BEELE
zm26	61	KEWWEITELSE PERMENS OF THE PROPERTY OF THE PRO
zm28	61	PERVISE LEGISLA SELECTION OF THE PROPERTY OF T
zm29as	sbc 61	krevvozite sovetenske
zm16	61	VEVVIDE CHIPE CONTROL
zm15	61	POPPENSER OF THE GENNER OF THE CONTRACT OF THE
zm31as	spc 61	

SUBSTITUTE SHEET (RULE 26)

FIG. 7A(CONTD.)

21 YETPHOVAGNIGSLAGYVETEPVLKEDDERFERTETTEDDETSVPLPAGLRGGKN
22 YETPHOVAGNIGSLAGYVETEPVLKEDDERFERTETTEDDETSVPLPAGLRGGKN
23 YETPHOVAGNIGSLAGYVETEPVLKEDGRAFFETYCTEDDDETSVPLPAGLRGGKN
24 YETPHOVAGNIGSLAGYVETYTEPVLKEDGRAFFETYCTEDDDETSVPLPAGLRSGKN
25 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFETYCTEDDDETSVPLPAGLRSGKN
26 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFETYCTEDDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFETYCTEDDDETSVPLPAGLRSGKN
28 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
29 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
20 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
21 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
21 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
21 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
22 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
23 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
24 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
25 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
26 YETPHOVAGNIGSLAGYVETYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGYVEGYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGYVEGYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARFETYCTEDDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARREFYCTEDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARREFYCTEDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARREFYCTEDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARREFYCTEDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARREFYCTEDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARREFYCTEDDETSVPLPAGLRSGKN
27 YETPHOVAGNIGSLAGTVYCGYTEPVLKEDDRAFFARREFYCTEDDETSVPL 000 U O O Ω A တ ഗ Ø on a đ Ø Д Ø đ 2 m 0 4

FIG. 7Ł

LVRIROTGKNSGTIDNAGGTHTADLSREPITARTTAIKGRFEGSRFLPYHTRNQINGGAL	LVRIRLEGENIS GYLDNAGGYBYADLSKEPLYAKYYALKGKE EGSKELEY KHYKNOLNGGAL	LYNTRECONSOCIEDING CONTRACTOR CON	EVALACIONE DE L'UNE GOVERNOUS PROPRIES DE L'ARRACTE E CORTE E	LVKI KUTGKNSGTI DNAGGTHVADLSKEPI TAKTTATI KGKE EGSKELPYHTKNOI NGGAL	Lvrikovsknisstoni ggreppijsobe praktiva i korbeskriptipa preminojnggal	Lvrikotsknsstidn <mark>e</mark> gspepadlsofplitarttarksesskelpyhtrnoinggal	Lvrikotgknsgtidntggthpadlsofdtraptatkgreegsrelpyhtrojnggal	LVRIRQTGKNSGTIDNFGGTHTADLSOFPITARTTAIKGRFEGSRFLPYHTRNQINGGAL	evrirotgknsgtidnaggthpadis <mark>repitarttaikgreegsreleyhtrno</mark> inggal	Lvrirotgknsgtidnaggretadls <mark>r</mark> epitarptikgreegsrelpyhtrnoinggal	<u>troperropageteradisa</u> e	Kotcknscrtdng ggereradlsre	SPECKINSGRIDINTGGRIFFADISRE	LVREROTGKINSGTIDINTGGTHTADLSRFPITARTTAIKGREEGSRELPYHTRINQINGGAL	Lvrtropgensgyidnyggzbyadls <mark>r</mark> fpitarpytaikgrfegsrfupyhtrnoinggal	Lvrtrotsknsgtidn _t ggthtalls <mark>r</mark> fpitarptaikgrfegsrflpyhtrnoinggal	Lvrtrotsknsstidntstradls <mark>reptparttratksreessredpyhtrnoingsal</mark>	<u>Lvrirotsknsstidntsctetadlsrfplitarpttatkgrfessrfipyhtrnotnggal</u>	<u>Lvrirotgknsgtidnfggtetadlsrfpttarptatkgrfegsrflpyhtrnotnggal</u>	<u>Otgansgyldn<mark>a</mark>ggtbtadls<mark>r</mark>pplartyatkgreegsrelpyhtrnoing</u>		Lvrirotskinsgtidintggtetadisrppitarppitksrfegsrfipyhtriotinggal	irotgknsgtidntgethadis <mark>repitarptaikgrebesreleyhtrno</mark> ing	-	Irotcknsgtidnfggthtadlsrepttrrttaikgrfegsrfleyhtrnging	. Irotcknsctidntggthtadismedtyfettarkereegsrelpyhtrnoing	LVRIROTGKNSGT-IDNTGGTHFFADLSOEP TARTTR IKGREEGSRE 19 YHTRNOINGGAL	LVRIROTGKNSGTIDNTGGTHVADISOFPITARTTA IKGREEGSRFIPYHTRNQINGGAL	Lvrtropgeknschidnfggtbpadlsofpltrrypatkgreegsrelpyhtrnoinggal	LVRIROTGKNSGT-IDNTGGT-HTADLSOFP-TARTTALKGRFEGSRF-1PYHTRNOINGGAL	TGKNSGT DNTGGTETADLSOFP TARTTA KGREEGSRED	Wokness Idnagrapisoed warmankgreesred	INVENTION OF THE PROPERTY OF T	TANKANY LANGO COMPANY DE LA CO
다 r 80 c 다 r	\mathbf{x}	OC	0 0	α	∞	∞	œ	∞	ω	ω	∞	œ	∞	∞	ω	ω	∞	∞	∞	∞	$\boldsymbol{\omega}$	œ	∞	∞	∞	ထ	ω	∞	ω	ω	ω	∞	∞ o	0
1090	国358	#32asD	mzsasp.	m27D	E 0	m1	E 5	S	딥	0	m11	0	9 6	ě	0 E	9	0	E	E E	E	E 2	E 2	00	TE	E	OE	24	2 E	2 E	ZE	F 2	덭	ار ا	S

FIG. 7B(contd.)

DGKAP FLGYAEDPVELFEMHIOGSGRLKTPSGKY IRIGYADKNEHPYVSIGNYMADKGYL DGKAP FLGYAEDPVELFFMHIOGSGRLKTPSGKY FRIGYADKNEHPYVSIGNYMADKGYL DGKAP FLGYAEDPVELFFMHIOGSGRLKTPSGKY FRIGYADKNEHPYVSIGNYMADKGYL DGKAP FLGYAEDPVELFFMHIOGSGRLKTPSGKY FRIGYADKNEHPYVSIGNYMADKGYL DGKAP FLGYAEDPVELFFMHIOGSGRLKTPSGKY FRIGYADKNEHPYVSIGNYMADKGYL	DGKAP ILGYAEDPVELFFMHIDGSGRIKTPSGKYIRIGYADKNEHPYVSIGKYMADK(DGKAP ILGYAEDPVELFFMHIDGSGRIKTPSGKYIRIGYADKNEHPYVSIGKYMADK(DGKAP ILGYAEDPVELFFMHIDGSGRIKTPSGKYIRIGYADKNEHPYVSIGKYMADK(DGKAP ILGYAEDPVELFFMHIDGSGRIKTPSGKYIRIGYADKNEHPYVSIGKYMADK(DGKAP ILGYAEDPVELFFMHIDGSGRIKTPSGKYIRIGYADKNEHPYVSIGKYMADK(DGKAPILGYAEDPVELFEMHIQGSGRLKTPSGKYIRIGYADKNEHPYVSIG YMADK DGKAPILGYAEDPVELFFMHIQGSGRLKTPSGKYIRIGYADKNEHPYVSIG YMADK DGKAPILGYAEDPVELFFMHIQGSGRLKTPSGKYIRIGYADKNEHPYVSIG YMADK DGKAPILGYAEDPVELFFMHIQGSGRLKTPSGKYIRIGYADKNEHPYVSIG YMADK DGKAPILGYAEDPVELFFMHIQGSGRLKTPSGKYIRIGYADKNEHPYVSIG YMADK	DGKAPILGYAEDPVELFFMHIQGSGRLKTPBGGKYIRIGYADKNEHPYVSIGRY DGKAPILGYAEDPVELFFMHIQGSGRLKTPBGKYIRIGYADKNEHPYVSIGRY DGKAPILGYAEDPVELFFMHIQGSGRLKTPBGKYIRIGYADKNEHPYVSIGRY DGKAPILGYAEDPVELFFMHIQGSGRLKTPSGKYIRIGYADKNEHPYVSIGRY DGKAPILGYAEDPVELFFMHIQGSGRLKTPSGKYIRIGYADKNEHPYVSIGRY
य य य य य य य	य य य य य य य य ।	<i>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</i>	4 C C C C C C C C C C C C C C C C C C C	'
	0101010	90000444 90000444	и и и и и и и и и и и и и и и и и и и	

1
666666666666666666666666666666666666666
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
O C E E E E E E E E E E E E E E E E E E
ANANNNUNANAANNNUNNNUNNNUNAAAAAANNNA XXXXXXXXXX
355555555555555555555555555555555555555
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0


F/G. 7C(CONTD.)

361 SDRHYTTGAPLEVATABBYTRKALARLITANDDTGSALKGAVRVDYFWGYGDEAGELAGK
361 SDRHYTTGAPLEVATABBYTRKALARLITANDDTGSALKGAVRVDYFWGYGDEAGELAGK
361 SDRHYTTGAPLEVATABBYTRKALARLITANDDTGSALKGAVRVDYFWGYGDEAGELAGK
361 VDRHYTTGAPLEVATABBYTRKALARLITANDDTGSALKGAVRVDYFWGYGDEAGELAGK
361 VDRHYTTGAPLEVATABBYTRKALARLITANDTGSALKGAVRVDYFWGYGDEAGELAGK
361 VDRHYTTGAPLEVATABBYTRKALARLITANDDTGSALKGAVRVDYFWGYGDEAGELAGK
361 VDRHYTTGAPLEVATABBYTRKALARLINADATGAN $\tilde{\mathbf{n}}$ 000 s b c s b s ည် gs Д 0 8 iv O Ø σ ื่ D, to Ø Ħ 0 0 0 0 0 0 0 0 4 0 4 Н 1040404 1040404 zml zml

FIG. 71

G2276G27049NGH4(0)7747979747970	OKTORYWROLDING MICHORYPORTS	OKUMEXVWOLFIPNGWKPPVKP	MKEP CYVROLLDNGMKPSVRD	\mathbf{E}	EYR	MKPBYR	EYR	YVW QLLPNGMKPEYR	NGMKPEYR	NGMKPEY	TGYVWOLLPNGMKPEYR	GYVWOLLPNGMKPEYR	TGYVWQLLPNGMKPEYR	<u> Tgyvnollpngmkpey</u>	YVW QLEPNGMKPEYR	TGYVNOLLPNGMKPEYR	tgyvwollpngmkpeyr	GYVW OLLPNGMKPEYR	Vumollp ngmkpeyr	tgyvwollepngmkpeyr	Syvnolipiongmkpey r	LLPNGMKPBYR	ngmkpeyr	NGMKPEYR	NGMKPEYR	EYR	NGMKPEYR	OKTWGYVWQLLPNGMKPEYRP*	Oktockumodadadkeeyre*	OKTTGYVWOLLPNGMKPEYRP*	okatentarenerene	okatcavacledokpeyrp*	okawcyvmollengmkpeyrp*		•
421	421	. 4	. 4	14	1	11	1.1	CA	c_A	421	CA.	a	$\boldsymbol{\alpha}$	421	421	421	421	421	421	421	421	421	7	421	2	3	3	3	421	421	421	421	421	421	
9	133asb	2 a s	23asb	m27			zm24	zm25	zm14	zm04	zm11asbc		2m96	zm01	zm02	zm0.3	zm07	zm12	z m 1 8					zm17		zm05		zm22		zm28	E	zm16	zm15	zm3lasbc	

F/G. 7D(contd.)



SUBSTITUTE SHEET (RULE 26)

0

FIG. 9a





FIG. 9b



SUBSTITUTE SHEET (RULE 26)

(

()

_lacta FA1090

48/97

ABLEKKGYTVKLVEFT
ABLEKKGYTVKLVEFT
ABLEKKGYTVKLVEFT
ABLEKKGYTVKLVEFT
ABLEKKGYTVKLVEFT
ABLEKKGYTVKLVEFT
VELEKKGYTVKLVEFT
VELEKK EKKEIVFGTTVGDFGDMVKEOI AKKEIVFGTTVGDFGDMVKEOI KKEIVEGTTVGDEGDWVKEH KKEIVEGTVGDEGDWVKEH KKEIVEGTTVGDEGDMVKEH KKEIVFGTTVGDFGDMVKE KKEIVFGTTVGDFGDMVKE KEIVFGTTVGDFGDMVKE KEIVEGTTVGDFGDMVKE KELVEGTTVGDFGDMVKE KEIVFGTTVGDFGDMVKE KEIVFGTTVGDFGDMVKE AADNGA MKTFFKTLSAALALILAACGGGKDSAPAASASA
MKTFFKTLSAALALILAACGGGKDSAPAASASA
MKTFFKTLSAALALILAACGGGKDSAPAASASA
MKTFFKTLSAALALILAACGGGKDSAPASASA
MKTFFKTLSAANLALILAACGGGKDSAPASASA
MKTFFKTLSAANLALILAACGGGKDSAPASASA
MKTFFKTLSAANLALILAACGGGKDSAPASASA
MKTFFKTLSAANLALILAACGGGKDSAPASASA
MKTFFKTLSAANLALILAACGGGKDSAPASASA
MKTFFKTLSAANLALILAACGGGKDSAPASASA
MKTFFKTLSAANLALILAACGGGKDSAPASASA
MKTFFKTLSAANLALILAACGGOKDSAPASASA
MKTFFKTLSAANLALILAACGGOKDSAPASASA BZ147 NGH36 2996 2996 BZ83 44-76 NG6-88 BZ169 NGF26 NGF28 NGF29 NGF29 NGF29 NGF28 NGF2 19-SN4

0 YYRRIALLARGELDINNY CHRYLDDEKKEHNID TEWP CVETARICHY FERKUSEE WIGGSTVARNIDERNARLY

0 DYYRRIALLARGELDINNY CHRYLDDEKKEHNID TEWP CVETARICHY FERKUSEE WIGGSTVARNIDERNARLY

0 DYRRIALLARGELDINNY CHRYLDDEKKEHNID TEWP CVETARICHY FERKUSEE WIGGSTVARNID FRIRANLY

0 DYRRIALLARGELDINNY CHRYLDDEKKEHNID TEWP CVETARICHY FERKUSEE WIGGSTVARNID FRIRANLY

0 DYRRIALLARGELDINNY CHRYLDDEKKEHNID TEWP CVETARICHY FERKUSEE WIGGSTVARNID FRIRANLY

0 DYRRIALLARGELDINNY CHRYLLDDEKKEHNID TEWP CVETARICHY FERKUSEE WIGGSTVARNID FRIRANLY

0 DYRRIALLARGELDINNY CHRYLLDD NGP165 NGH38-SWZ107 NGH15-BZ232-90-18311-A22-860800-BZ133-93-4286-NG-F62-NG-F62-NG-SN4-FA1090-_lactam BZ1147
BZ1447
BZ996
BZ83
A44-76
NG6-88
RG726
NG726
RG726
RG728
RG728
RG728
RG728
RG728

FIG. 10A(соитр.)

()

60 MIDELGWIKIKDGINPLTASKADIANNINIKYYELEAAQLPRSRADYDFAVVNONYI SSGGKKLTFALFOERSFAYNW 61 MIDELGWIKIKDGINPLTASKADIANNIKNIKYYELEAAQLPRSRADYDFAVVNONYI SSGGKKLTFALFOERSFAYNW 62 MIDELGWIKIKDGINPLTASKADIANNIKNIKYYELEAAQLPRSRADYDFAVVNONYI SSGGKKLTFALFOERSFAYNW 63 MIDELGWIKIKDGINPLTASKADIANNIKNIKYELEAAQLPRSRADYDFAVVNONYI SSGGKKLTFALFOERSFAYNW 64 MIDELGWIKIKDGINPLTASKADIANNIKNIKYELEAAQLPRSRADYDFAVVNONYI SSGGKKLTFALFOERSFAYNW 65 MIDELGWIKIKDGINPLTASKADIANNIKNIKYELEAAQLPRSRADYDFAVVNONYI SSGGKKLTFALFOERSFAYNW 66 MIDELGWIKIKDGINPLTASKADIANNIKNIKYELEAAQLPRSRADYDFAVVNONYI SSGGKKLTFALFOERSFRAYNW 66 WIDELGWIKIKDGINPLTASKADIANNIKNIKYELEAAQLPRSRADYDFAVVNONYI SSGGKKLTFALFOERSFRAYNW 66 WIDELGWIKIKDGINPLTASKADIANNIKNIKYELEAAQLPRSRADYDFAVNONYI SSGGKKLTFALFOERSFRAYNW 66 WIDELGWIKIKDGIN 09 9 9 009009 60 9 9 9 60 61 61 8311 N_lactam

FIG. 10B


SUBSTITUTE SHEET (RULE 26)

29996 NG6-883 NG7169 NG7169 NG726 NG726 NG726 NG726 NG726 NG728 NG728 NG728 205900 F61124 NG3-88 NG3-88

NGP165 NGH38 SWZ107 NGH15 BZ232 90-1831 AZ2 860800 BZ133 93-4286

NG-SN4 FA1090

FIG. 10B(contd.)



SUBSTITUTE SHEET (RULE 26)

FIG. 11A

52/97

	02/3/
ORTUANTIONS ORTUANTIONS ORTUANTIONS ORTUANTIONS ORTUANTIONS	V V V V V V V V V V V V V V V V V V V
NEEQEEDLYHDPW NEEQEEDLYHDPW NEEQEEDLYHDPW NEEQEEDLYHDPW NEEGEEDLYHDPW DEEDEEDHDPW	? H · · · · · · · · · · · · · · · · · ·
ATVOASAN ATVOASAN ATVOASAN ATVOASAN ATVOASAN	ATVOANA
TUKTAVIATILE TUKTAVIATILE TUKTAVIATILE TUKTAVIATILE TUETAVIATILE	TAVIDATII TAVIDATIII
SELTRNHTKRASATVK SELTRNHTKRASATVK SELTRNHTKRASATVK SELTRNHTKRASATVK SELTRNHTKRASATVE SELTRNHTKRASATVE	SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK SELTRNHTKRASATUK
YRIIWNSALNAWUVU YRIIWNSALNAWUVU YRIIWNSALNAWUVU YRIIWNSALNAWUVU YRIIWNSALNAWUVU	KIYRIIWNSALNAWVAV KIYRIIWNSALNAWVAV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVAV KIYRIIWNSALNAWVAV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV KIYRIIWNSALNAWVVV
MNKIYR MNKIYR MNKIYR MNKIYR WNKIYR	MNKIYRI MNK
2 2 4 2 2 2 2 2 2 3 3 4 4 4 4 4 4 4 4 4	# 1

SUBSTITUTE SHEET (RULE 26)

NGT	SVGE	1 E		i	5 E	G		6	E 10 2	E E					1 6	1 5		3 G									(A (A (A (A (A (A (A (A (A (A	TEAS	iV E
TDLT	H	T T T T	TTT.	TOTA	TOTA	ሞከተሞ	TO LET		TO DE	THE PERSON	פייישטעים		TTT.	TULT	TDT TO	TTT.						THE COLUMN	TOT.	Ant mo	ХDT	ŀ	TOL	មា (៤៣	Hell 1
LKKDL	CKKD	בי אינו בי אינו	LKKDI	SINKKDI	SINKKDI	TOKKIDT	LKKDE	YSLKKDL	SIKKDE	DKKDT	ΚK	INKKIDI	TKKDT	SLKKDL	OKKDI	STKKET	STKKDT	TKKDT	KKDT	TKKDT	STAKEDL	SLKKDY	rkknr	T. K. K. IDIT	T K U	Z. K. K.	LKKDT	LKKDL	TEKKDE
NFTYS	NETYS	1 A E	A III III	FTY	ETEV	FFE	FTY	1	5	ADVO	БRV	F.T.V	FIFTY	Y UL	FTV	Pint V	F T	4 th th	7	<u> </u>	FTY	FTY	<u>т</u>	SALE OF	Port	F.T.Y	FTY	SFTYSI	FTYS
NG.		(F	E	E C	တ	INDS:					CNIDS				SON	A P	A A		Ų	Ø	PINAS	V)	× 4	SCX	ğ	SGK	S	MASS	MASS
•	•	•			. NTNEN	ENTNE	NTNE	Ę	Ð	NTDEN	ENTNEN:	ENTN	NTNE	NTNE	TNE	NTDE	NTN	HATA	NTNE	NTNE	NTNE	E C	NTDE				ENTDEN	ENTDENT	ENTNEN
					TNK.	NKNT	×.	•	•	•		•	•		MIN							•	•			•	NTD	TD	NE
KIKO	T KO	Y K	KIKO	KIKO	CIKO	KIKO	KIKO	CIKO	CIKO	KIKO	KIKO	KTKO	CIKO	CERO	STKO	CTKO	1 0 0 0 1	6 8 8	() ()	0 % 0	CIKO	CHKO	S S	CH KO	ST KO	CHKO.	CLIKO D	STKO E	HKQ M
GDML		S CONTRACTOR	GDNE	GDNLE	GDNL	GDNL	GDNL	GDNL	GDINLE	GDNL	GDNE	GDNIE	GD NAM	GDNLE	GDNL	GDNIA	G DATE:	GDNIN	GDNIE	GD)NIO	GDNLE	GDNLE	GDND	GDML	GDNLE	GDMLE	GDNER	CDNL	GDNLF
TLKA	T. LOK.		TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TICKE	(A) (2 (A)		Jun K	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA	TLKA
ж. В	X X E	X E	. RE	G	.AT	. AT	.AT	.GT	G.	G.	G.	. GA	. GA	. GA	. GA	GT.	H	X	XI	H	H	. AT	۲	4	4	AT	G.		 G
		E P	VET	VET	TUHC	THE	THE	VITA	VET	VET	VEK	VEX	VEK	VEX	VEK	VIK	FVDP	FVD	FVDP	FVDP	FVDP	THE	THE	THE	THE	THE	VEK	VEX.	N N N
K	N E K G	K	NEKG	NEKG	DNHN	NHNO	NHN	DKKG	DKKG	OKKG	DEKR	DEKR	DEKR	DEKR	DEKR	EKNG	SKE	×	SKE	OSKE	SKE	DHN	NHO	DHN	NHO	DHN	EKR	EKG	KNR
AVVI	A VACE	AVE	AVE	AVVE	$\mathbf{S}\mathbf{I}\mathbf{M}\mathbf{X}$	SIV	$\mathbf{S}\mathbf{I}\mathbf{M}$	GWZE	GVLF	377	AVEF	AVE	AVEE	AVZE	AVEE	GIVE	SMTN	Σ	SMTN	SMTN	SMTN	SIEK	SIVY	S I I I X	SILV	SILY	GIVE	E A	TVE
MOS	N C S	SDW	SDW	SDW	HGW	IGW	I GW	SNW	NNS	S	SNW	SNW	SNW	SNW	NNS	TNW	SL	ISL	ISL	ISL	SL	ΩX	Ωž	IGW	IGW	35		NHS	SNL
N CE	KVEEN	Θ	N E	四 >	H	Ħ	STG.	H	Ħ	H	₽	H	H	GTE.	H	Ϋ́	•		I			TG.	ĦG.	JG.	0	HG.	HG.	ы	V G A
O K	2 0 X 5 0	S V	J.K.D	15	Z	9	e Ne s	오	13	전	전	ᄧ	OX OX	~	O X O	33	9	<u> </u>	OLE B	<u> </u>	S	(A)	4.5	1,3	E H	CO.	S X S	o X o	ন
	36T	эGТ	3GT	3GT	3GN	SGN	N S S	3GT	H	Ţ	H	H	H	H	H	T	E S	S	S	S	S	Z	Z	Z	N	Z	E	E	<u> </u>
77		7	7	N E	Ω.	9 8	S)	4	4	4	4	4	4	4	4	ᆵ	4	4	4	4	4	R E	N E	N E	S	2			N T
	-											-	-	-	-					-	-	-	-	-	-1		- '		-
10	3 4	ς 2	214	g e 2	g 6 -	g£2	gh38	g3-	N	ge3	gh1	9	219	σ	gh3	2	213	059	£6124	249	6 08	00	2	gp16	0-1831	3-428	w z 10	~	m

FIG. 11A(CONTD.)

RAPASSES SENSON DTTVHINGGGSTIFFDTILNTGART TTVHINGGGSTIFFDTILNTGART TTVHINGGGSTIFFDTILNTGARS TTVHINGGGSTIFFTILDTILNTGARS TTVHINGTAR TTVHINGGGSTIFFTILDTILNTGARS TTVHINGGGSTIFFTILDTILNTGARS TT NKVNITSDTKGLNFAKETAGTNGDTTV ERLISEGANGN eklegangk eklegangk eklegangk eklegangk elsegangk KLSEGANGN KLSEGANGN KLSEGANGN SFGA KLSE(111111 44444 702222 3 3 1 3 6 7 bz169 bz83 44-76 mc58

FIG. 11B

TEVRIGARTSVIKERDGRLVTGRDKG KATEVRIGARTSVIKERDGRLVTGRDKG KATEVRIGARTSVIKERDGRLVTGRDKG KATEVRIGARTSVIKERDGRLVTGRGKG KATEVRIGARTSVIKERDGRUGTGRGK KATEVRIGARTSVIKERDGRUGTGRGK KATEVRIGARTSVIKERDGRUGTGRGK KATEVRIGARTSVIKERDGRG SONVDEVRIYDIVEELSADIKITIVNVESKONGK SONVDEVRIYDIVEELSADIKITIVNVESKONGK SONVDEVRIYDIVEELSADIKITIVNVESKONGK SONVDEVRIYDIVEELSADIKITIVNVESKONGK SONVDEVELYDIVEELSADIKITIVNVESKONGK SONVDEVRIYDIVEELSADIKITIVNVESKONGK SONVDEVRIYNDIVEELSADIKITIVNVESKONGK SONVENTATOVEELSADIKITIVNVESKONGK SONVDEVRIYNDIVEELSADIKITIVNVESKONGK SONVENTATOVEELSADIKITIVNVESKONGK SONVENTATOVER SONGK SONVENTATOVEELSADIKITIVNVENTATOVEK SONVENTATOVER SONGK SONVENTATOVER SONGK SONGK SONVENTATOVER SONGK SONGK SONGK SONVENTATOVEN SONGK SO GWNIKGVKPG GWNIKGVKPG GWNIKGVKPG GWNIKGVKPG GWNIKGVKPG GWNIKGVKPG GWNIKGVKPG GWNIKGVKPG 042165 90-18311 93-4286 842107 832

FIG. 11B(contd.)

{ }

56/97

XDVNVGDA XDVNVGDA YDVNVGDA YDVNVGDA YDVNVGDA YDVNVGDA YDVNVGDA YDVNVGDA YDVNVGDA YDVNVGDA XDVNVGDA XDVNVGDA XDVNVGDA XDVNVGDA XDVNVGDA KGTTATUSKDDGGNITUM KGTTATUSKDDGGNITUM KGTTATUSKDDGGNITUM KGTTATUSKDDGGNITUK VIEASGQ STDEGEGLVTAKEVIDAVNKAGWRWKTTTANGGIGGADKEETVISCTNVTE STDEGEGLVTAKEVIDAVNKAGWRWKTTANGGIGGADKEETVISCTNVTE STDEGEGLVTAKEVIDAVNKAGWRWKTTANGGIGGADKEETVISCTNVTE STDEGEGLVTAKEVIDAVNKAGWRWKTATANGGIGGADKEETVISCTNVTE STDEGEGLVTAKEVIDAVNKAGWRWKTATANGGI 9047 9047 907165 90718311 822107 832 000991 bz83 44-76 mc58

⁵16. 110

POESSVSLGAGADAP 10 INVOCED SCHOLD SKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
10 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
10 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
11 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
12 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
13 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
14 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
15 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
16 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
17 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNIEI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHVIDSKAVAGS SCKVI SCHVER KKREDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER KKREDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER SKCKMDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER SKCKMDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER SKCKMDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER SKCKMDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER SKCKMDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER SKCKMDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER SKCKMDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER SKCKMDET VI INACHNI EI TRNGKNI DI ATSMIPOESS
18 INVOCED SCHNILDSKAVAGS SCKVI SCHVER SKCKMDET VI INACHNI EI TRNGKNI DI ngp165 90-18311 93-4286 swz107 a22 bz169 bz83 44-76 mc58

FIG. 11C(contd.)

 $(\hat{ })$

()




FIG 1

bz169	539	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
bz83	539	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW*
44-76	539	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
mc58	539	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW*
bz147	539	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW*
nge28	538	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
ng6-88	474	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW*
ngf26	478	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW*
ngh38	547	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
ng3-88	542	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
bz232	542	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
nge31	542	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
ngh15	546	SMMAIGGGTYRGEAGYAIGYSSISDTGNWWIKGTASGNSRGHFGASASVGYQW
2996	546	SMMAIGGGTYRGEAGYAIGYSSISDTGNWWIKGTASGNSRGHFGTSASVGYQW
bz198	542	SMMAIGGDTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
297-0	542	SMMAIGGDTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
ngh36	546	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
e26	548	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
bz133	540	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
205900	540	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
f6124	540	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHEGASASVGYQW
z2491	540	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHEGASASVGYQW
860800	540	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW* SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW*
1000	543 543	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
528	537	SMMAIGGGTYRGEAGYAIGYSSISDTGNWWIKGTASGNSRGHFGTSASVGYQW
ngp165 90-18311	537	SMMAIGGGTYRGEAGYAIGYSSISDTGNWMIKGTASGNSRGHFGTSASVGYQW
93-4286	537	SMMAIGGGTYRGEAGYAIGYSSIEDTGNWUIKGTASGNSRGHFGTSASVGYQW
swz107	546	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW:
8W2107	547	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
a22 e32	548	SMMAIGGGTYRGEAGYAIGYSSISDGGNWIIKGTASGNSRGHFGASASVGYQW
e 3 4	240	

FIG. 11D(CONTD.)

5 FIG. 12A

VDGFSLYRIHWDGYEHHPADGYDGPQGGGYPAPKGARDIYSYDIKGVAQNIRLNLTDNRS	7	C S
VDGFSLYRI	121	2996
VDGFSLYRI	8	CH
VDGFSLYRI	Н	000
VDGFSLYRI	Н	223
VDGFSLYRI		Z 1
SCHIGLGKIQSHQLGNLMIQQAAIKGNIGYIVKFSDHGHEVHSPFDNHASHSDDEAGSP SGHIGLGKIQSHQLGNLMIQQAAIKGNIGYIVRFSDHGHEVHSPFDNHASHSDSDEAGSP	6 T	AC58
SGHIGLGNI		H O
SGHIGLGNI		000
зентеге <mark>к</mark> тозно		22
SGHIGLG VIQSHQLGNLMIQQAAIKGNIGYIVRFSDHGHEVHSPFDNHASHSDSDEAGSP		Z13
LGISRKISL	ᆏ	C 2
LGISKKISL	ત્ન	9
LGISKKISL	ਜ	GH
TSIN ~~~~	ન	1000
~~~~RKISL	ᆏ	<b>Z</b> 23
LGISRAGIST	<b>~</b> 1	<b>Z</b> 1

## FIG. 12A(CONTD.)

TGORLADRFHNAGAMLTOGVGDGFKRATRYSPELDRSGNAAEAFNGTADIVKNIIGAAGE TGORLADRFHNAGAMLTOGVGDGFKRATRYSPELDRSGNAAEAFNGTADIVKNIIGAAGE TGORLADRFHNAGAMLTOGVGDGFKRATRYSPELDRSGNAAEAFNGTADIVKNIIGAAGE TGORLADRFHNAGAMLTOGVGDGFKRATRYSPELDRSGNAAEAFNGTADIVKNIIGAAGE	TGORLADRFHNAGSMLTQGVGDGFKRATRYSPELDR SGNAAEAFNGTADIVKNI IGAAGE TGORLADRFHNAGSWLTQGVGDGFKRATRYSPELDR SGNAAEAFNGTADIVKNI IGAAGE	IVGAGDAVQGISEGSNIAVMHGLGLLSTENKMARINDLADMAQLKDYAAAAIRDWAVQNP IVGAGDAVQGISEGSNIAVMHGLGLLSTENKMARINDLADMAQLKDYAAAAIRDWAVQNP IVGAGDAVQGISEGSNIAVMHGLGLLSTENKMARINDLADMAQLKDYAAAAIRDWAVQNP	IVGAGDAVQGISEGSNIAVMHGLGLLSTENKMARINDLADMAQLKDYAAAAIRDWAVQNP IVGAGDAVQGISEGSNIAVMHGLGLLSTENKMARINDLADMAQLKDYAAAAIRDWAVQNP	IEAV IEAV	NAAQGIEAVSNIFMAAIPIKGIGAVRGKYGLGGITAHPÄKRSQMGAIALPKGKSAVS <mark>D</mark> NF NAAQGIEAVSNIFMAAIPIKGIGAVRGKYGLGGITAHPÄKRSOMGAIALPKGKSAVSDNF	NAAQGIEAVSNIFMAAIPIKGIGAVRGKYGLGGITAHPEKRSOMGAIALPKGKSAVSDNF NAAQGIEAVSNIFMAAIPIKGIGAVRGKYGLGGITAHPEKRSOMGAIALPKGKSAVSDNF	
181 177 176 181	ထထ	2 2 3 4 1 2 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	444	301	၈၀	00	
BZ133 BZ232 1000 NGH38	വര	BZ133 BZ232 1000 NGH38	C 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	BZ133 BZ232	000	9 9	

()

62/97

# FIG. 12A(CONTD.)

SVPFDGK SVPFDGK SVPFDGK SVPFDGK	EKNVQEI EKNVQEI EKNVQEI EKNVQEI	KENGFTN ~~~~~~~ KENGFTN KENGFTN KENGFTN
PSPYHSRNIRSNLEQRYGKENITSSTVPPSNGKNVKLADQRHPKTGVPFDGK PSPYHSRNIRSNLEQRYGKENITSSTVPPSNGKNVKLADQRHPKTGVPFDGK PSPYHSRNIRSNLEQRYGKENITSSTVPPSNGKNVKLADQRHPKTGVPFDGK PSPYHSRNIRSNLEQRYGKENITSSTVPPSNGKNVKLADQRHPKTGVPFDGK		QLEREINKLKSADEINFADGMGKFTDSMNDKAFSRLVKSVKE
ADAAYAKYPSP ADAAYAKYPSP ADAAYAKYPSP ADAAYAKYPSP ADAAYAKYPSP	GFPNFEKHVKY GFPNFEKHVKY GFPNFEKHVKY GFPNFEKHVKY	RNGNKNSNFSQHA  RNGNKNSNFNQHA RNGNKNSNFSQHA RNGNINSNFSQHA
8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	4 4 4 4 4 4 2 2 1 2 2 2 2 2 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	444444 800088 484444
BZ232 1000 NGH38 2996 MC58	BZ133 BZ232 1000 NGH38 MC58	BZ133 BZ232 1000 NGH38 Z996 AC58

### FIG. 12B

つ イ ス	Ţ	FORT TO THE CARLEY RENNE VERAL THE LATE TO THE LATE TO THE POPUL SERVICE
32232	428	2 2 2 2 2 2
000	~	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
GH	4	VVEYVE
9	4	VVEYVE
C 5	4	PVVEYVEINGKAYIVRGNNRVFAAEYLGRIHELKFKKVDFPVPNTSWKNPTDVLNESGNV
213	0	KRPRYRSK
22	N	•
000	N	******
NGH38	601	KRPRYRSK
9	0	RPRY
0.5	0	RYRS

	•	:	• •	PVLPV	OPVLPV	DOPULPI	•	•	•	•		6	4,	/9	7	•	•		•	•	•	•	•	•	• •	• •	•	•	•	•	•	
	ALADELTNILISSREQILIRQFAEDEQPVIPWNRAPARRAGNADELIGSAWGINE.	FAED	)	TNLLSSREQILRÕFAED	<u>aedeopvlpinraparragnadeligsamglne</u>	paladeltinilissreotlrofaedeqpvlptinraparragnadeltigsamgine <mark>o</mark> p	Paladeltinilissreqilkofaedeqpvlptinraparragnadeligsamglin <mark>e</mark>	PALADELTNILISSREQILRQFAEDEQPVLPINRAPARRAGNADELIGSAMGLNE	PALADELTNILSSREQILRQFAEDEQPVLPINRAPARRAGNADELIGSAMGLNE	PALADELTNILISKEOI LKOFAEDEOPVLPINKAPARRAGNADELIGSAMGLNE.	PALADELINLISSARQILLAQFARDEQFVLFINAS DARDAGNADELIGSANGLNE	BITWINGSKEOITKOPABDEOPVIPINKAPARAGNADEN GEAMGINE	PALADELTNILS SREQILROFAEDEOPVLPINRAPARRAGNADELIGSAMGINE.	eltnilssregilrofaedeopvlpinraparragnadeligsamgine.	eltnilssreqilrofaedeopvipinraparragnadeligsamgine.	eltnilssreqidrofaedeqpviptinraparragnadeligsamgine	eltniliskreqilrofaedeqpviptinraparragnadeligsamgine.	ELTNILISREQIIRQFAEDEQPVIPINRAPARRAGNADELIGSAMGLNE	PALADELTNILSSREQIIRQFAEDEQPVLPINRAPARRAGNADELIGSAMGLNE.	PALADELTNILISSREQILRQFAEDEQPVLPINRAPARRAGNADELIGSAMGINE.	paladeltinijissreotliropaedeopviptinraparragnadeligsamgine	PALADELTNILSSREQILRQFAEDEQPVLPINRAPARRAGNADELIGSAMGLNE.	paladeltnilssreqilrofaedeopvlpinraparragnadeligsamgine.	PAIJADELTUNISSKEOTISKOFAEDEOPVIPTINKAPARKAGNADEDIGSAMGINE	PALADELTNILSSREOTIROFAEDEOY, DINRAPARRAGNADELLGSAMGINE.	PALADELTNIFISSREOTICROFAEDEOPVIPTINRAPARRAGNADELTGSAMGINE	PALADELTNILISSREQILROFAEDEQPVLPINRAPARRAGNADELIGSAMGLNE.	NLLSSRE	NLLSSREQILRQFAED	ELTNLLSSREQILRQFAEDEQPVLPINRAPARRAGNADELIGSAMGLNE.	saladelivnigsskeoligraedeopygeringarragnadeligsamgine	
<b>C77</b>	1 MDSFFKPAVWAVLWLMFAVRPALAD	1 MDSFFKPAVWAVLWLMFAVRPALAD	MDSFFKPAVWAVLWLWFAVR	<b>MDSFFKPAVWAVLWLMFAVR</b>	MDSFEKPAVWAVLWLMFAVR	<b>MDSFFKPAVWAVLWLMFAVR</b> )	<b>MDSFFKPAVWAVLWLMFAVR</b>	<b>MDSFFKPAVWAVLWLMFAVR</b>	MDSFFKPAVWAVLWLMFAVR	WIDSFERPAVMAVIMIMEAVR	MDSFF NFAVMAVLWLMFAVR MDSFFXDAVWAVTWTWFAVR	WIDSPERPAVMAVIMIMPAVR	<b>MDSFFKPAVWAVLWLMFAVR</b>	<b>MDSFFKPAVWAVLWLMFAVR</b>	<b>MDSFFKPAVWAVLWLWFAVR</b>	<b>MDSFFKPAVWAVLWLMFAVR</b>	<b>MDSFFRPAVMAVLWLMFAVR</b>	<b>MDSFFKPAVWAVLWLMFAVR</b>	<b>MDSFFKPAVWAVLWLMFAVR</b>	<b>MDSFFKPAVWAVLWLMFAVR</b>	<b>MDSFFKPAVWAVLWLMFAVR</b>	<b>MDSFFKPAVWAVLWLMFAVR</b>	MDSFFKPAVWAVLWLMFAVR)	WDSFFXPAWAVDWDWFAVR	MDSFF NEW WAY LWLINE AV N. MDSFF X PAVWAVEWENT WEAVE	WDSFEKPAVWAVLWLWFAVR	<b>MDSFFKPAVWAVLWLMFAVR</b>	<b>MDSFFKPAVWAVLWLMFAVR</b>	MDSFFKPAVWAVLWLMFAVR	<b>MDSFFKPAVWAVLWLMFAVR</b>	MDSFERPAVNAVINIDMEAVR	
	1	A1090	, ,	GE31	2491	4-76	. 88	GP165	GF26	90	00900	0-18311	3-4286	22	86	97-0	2147	69	Z133	GH38	GH15	GH36	2232	m c	, co	60800	3.2	28	3-88	WZ107	Ng-SN4	

. 60/9/	
QPVLPVNRAPARRAGNADELIGSAMGLNEQPVLPVNRAPARRAGNADELIGBA OPVLPVNRAPARRAGNADELIGSAMGLNEQPVLPVNRAPARRAGNADELIGNA OPVLPVNRYPARRAGNADELIGSAMGLNEQPVLPVNRAPARRAGNADELIGNA APARRAGNADELIGNAMGLNEQPVLPVNRYPARRAGNADELIGNA APARRAGNADELIGNAMGLNEQPVLPVNRAPARRAGNADELIGNA OPVLPVNRVPARRAGNADELIGNAMGLNEQPVLPVNRAPARRAGNADELIGNA OPVLPVNRAPARRAGNADELIGNAMGLNEGRAGNADELIGNA OPVLPVNRAPARRAGNADELIGNAMGLNEGRAGNADELIGNA OPVLPVNRAPARRAGNADELIGNAMGLNEGRA	
<i>\( \)</i> \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \) \( \	0 0 0 0 3 m

SUBSTITUTE SHEET (RULE 26)

-16. 13A(contd

()

## FIG. 13B

GIAYRYGGTSWSTGFDCSGFMQHIFKRAMGINLPRTSAEQARMGAPVARSELQPGDMVFFRTLGGSRISHVGLYT	0	g-s
GIAYRYGGISWSTGFDCSGFWOHIFKRAMGINLPRISAEOARWGIPVARSELOPGDWVFFRTIGGSRISHVALY	0	W210
CIAYRYGGTSWSTGFDCSGFWOHIFKRAMGINLPRTSAECARMGTPVARSELOPGDMV	ന	63-8
GIAYRYGGISWSIGFDCSGFWOHIFKRAMGINLFKISAFOARWGTPVARSELDPGDMVFFRTLGGSRISHVGLYI	വ ന	5 E S
GIAYKKGGTSWSTGFDCSGFMQHIFKRAMGINDPRTSABQARMGTPVARSELQPGDMVFFRTLGGSRISHV	m c	9 0
GIAYRYGGTSWSTGFDCSGEMQHIFRRAMGINLPRTSAEQARMGTPVARSELQPGDMVFFRTLGGS	ന	26
GIAYRYGGTSWSTGFDCSGFMQHIFRRAMGINLPRTSAEQARMGTPVARSELQPGDMVFFRTLGGSRISHVGLYT	m	5
GIAYRYGGISWSTGFDCSGFWOHIFKRAMGINLPRTSAEQARMGTPVARSELOPGDMVFFRTLGGSRISHVGLYT	ന	28
GIAYRYGGTSWSTGFDCSGFWQHIFKRAMGINLPRTSABOARWGTPVARSBLOPGDWVFFRTLGGSRTSHVFLYT	m	22
GIAYRYGGTSWSTGFDCSGFMPHIFKRAMGINLPRISAEDARMGTPVARSELDPGDMVFFRTLGGSRTSHV6LVT	m	E U
2 GIAYRYGGISWSTGEDGSGEWOHIERRAMGINLPRISAEOARWGIPVARSELOPGDWVEFRILGGSPISHVFIVI	ന	SE
CHAYRYGGRSWSTGPDCSGPWOBYPKRAMGTWIPRTSABORRAGTPWARSICOP	m	E
CANTAL OF SEASONS FOR THE SEASON OF THE SEAS	าเ	3 6
GIAYRYGGISWSTGFDCSGFWQBIFKRAMGINLPRTSAEQARMGTPVARSELQPGD	m (	7
CIAYRYGGTSWSTGFDCSGFWQHIFKRAMGINLPRTSAEQARMGTPVARSELQPGDMVFFRTLGGSRISHVGLYI	ന	97
2 GIAYRYGGTSWSTGFDCSGFWQBIFKRAMGINLPRTSABQARMGTPVARSBLQPGDMVFFRTLGGSRISHVGLYI	ന	2.1
2 GIAYRYGGIS#SIGFDCSGFWDHIFKRAMGINLPRISABOARMGIPVARSBIOPGDMVFFRTIGGSRISHVFIV	ന	22
2 GIAYRYGGES STGED CSGEWOUTERRAMCTIVER SABOARWGTEVARSELOPGDWYFFF	H	3-4286
CATALYTICATION OF THE PROPERTY AND THE PROPERTY OF THE PROPERT	3 (1)	0-183
GIAYRYGGISHSTGFDCSGFWQHIFKRAMGINLPRISAEQARMGIPVARSELQPGDMVFFRILGGSRISHVGLYI	നസ	9 5
2 GIAYRYGGTSESTGFDCSGFWQHIFKRAMGINLPRTSAEQARMGTPVARSELOPGDMVFFRTIGGSRT	ന	966
2 GIAYRYGGISHSTGFDCSGFWDEIFKRAMGINIPRISAEOARWGTP	ന	S G
TO A PARTICLE NEW COURT COURT IN THE COURT OF THE COURT O	יו ו	ָ קרי קרי קרי
CLARK RIGGIONS FOR LONG GRADEL FKRAMOTIND RYSKAR BOARWOTP VARSELDP GOMVER	Or	0 / U
GIAYRYGGISMSTGFDCSGFMQBIFKRAMGINLPRTSAEQARMGIPVARSELQPGDMVFFRTLGGSRISHVGLYI	Ψ	2491
1 GIAYRYGGTSWSTGFDCSGFMQHIFKRAMGINLPRTSAEQARWGTPVARSELOPGDMVFFRTIGGSRTSHVFLYT	Ψ	GE31
2 GIAYRYGGTSESTGFDCSGFEGETFRRAMGINLPRTSAFORMGTPVARSELOPGDWYFFFTT CERT CH	4.3	28
OTAYRYGGTSESTGPDGSGPWOETFKRAWGTNNPRTSABOARWGTPVARSETOP	(L)	000
GIAKKKIGTSWSTGFDCSGFMOHIEKKAMGINDPRISAEQARMGAPVARSELOPGDMVFFRTLGGSRISHV	7 0 0	701-07 090-47
	C	

•		•
Ng-F62	183	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN:
FÁ1090	183	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN
1000	212	IHAPRTGRNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN
528	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN:
NGE31	241	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDESRFLN
22491	241	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN
44-76	241	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN:
NG6-88	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
NGP165	212	IHAPRTGKNIEITSISHKYWSGKYAFARRVKKNDPSRFLN*
NGF26	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRELN
2996	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN
205900	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLNL
F6124	212	IHAPRIGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN=
90-18311	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN
93-4286	212	IHAPRTGRNIEITSLSHKYWSGRYAFARRYKKNDPSRFING
A22	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLNE
BZ198	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLND
297-0	212	IHAPRTGRNIEITSLSHRYWSGRYAFARRVRKNDPSRFLNE
BZ147	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN
BZ169	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN:
BZ133	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
NGH38	212	IHAPRTGRNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN:
NGH15	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN:
исн36	212	IHAPRTGRNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
BZ232	212	IHAPRTGRNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
BZ83	212	IHAPRIGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
MC58	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
E26	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
860800	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
E32	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
NGE28	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
NG3-88	212	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
SWZ107	183	IHAPRTGKNIEITSLSHKYWSGKYAFARRVKKNDPSRFLN*
Ng-SN4	183	IHAPRTGKNIEITSLSHKYWSGKYAFARRAKKNDPSRFLN*

FIG. 13B(CONTD.)


MKPLILGIAAMAWILSACOVOKRAPDEDYTÄRKESKENSILVVPPLNESEDVNGTWGÜLASTAAPGESCENTYFPAAVUEET
MKPLILGIAAVILLSACOVOKRAPDEDYTÄRKESKENASILVVPPLNESEDVNGTWGÜLASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVORRAPDEDYTÄRKESKENASILVVPPLNESEDVNGTWGÜLASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVORRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGÜLASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGÜLASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGÜLASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGULASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGULASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGULASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGULASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGULASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILLSACOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGULASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILALSACOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGULASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILASCOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGULASTAAPGESCATVFPAAVUEET
MKPLILGIAAVILASCOVOKRAPDEDYTSKESKENASILVVPPLNESEDVNGTWGULASTAAPGESCATVFPAAVUEET
MKPLILGI

235

NGP165 NI_Bacta NI_Bacta NIG-F62 NIG-F62 NIG-F80 NIG-F FIG. 14A(CONTD.)

65	81	FKON	
ບ <b>ເ</b>		FKONGISTNAMOTE	
F		FKENGLTNAADIE	
S		FKENGLANAMOT	
60		FKENGLTNAADIH	
8		EKENCOMMUNESKE	
1000		FKENGLTNAADIH	
528		FKENGLTNAADIH	
N		FKENGLINAADIH	
8		FKONGLTNAADIH	
1		FKONGLTNAADIH	
297-0		FKONGLTNAADIH	
•		FKONGLTNAADIH	
0		FKONGLTNAADIH	
7		FKONGIOWNAAD	
2		FKONGLYNAADIH	
Ν.		FKONGLTNAADIH	
⊣.		FKONGLTNAADIH	
٠,		PKONG PYNRANO	
m		FKQNGLTNAADIH	
m I		FKONGLTNAADIH	
44-76		EKQNGL-NAADTH	
MC58		FKONGLTNAADIH	
, d		FKONGLTNAADIH	
~ 4		FKONGLTNAADIH	
F6124		FKONGLTNAADIH	
<b>.</b>		FKONGOZNAADI	
200		FKONGLENAADIH	
93-4286		FKONGLTNAADIH	
		FKONGLTNAADIH	
860800		FKQNGLTNAADIHAVRPEKLHQIFGNDAVLXITVTEXGTSYQILDSV1TVSAKARLVDSRNGKELWSGSASIREGSNN	
		FKQNGLTNAADIH	
NGH38		FKONGLTNAADIH	
~		FKQNGLTNAADIH	
A22	8	Fronglynaadihavrpekihoifgndavlyitvteygtsyqildsvitvsakarlydsrngkelmsgsasiregsnnsn	

### FIG. 14B



	3
<u> </u>	<pre></pre>
	XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
	4444444
	>>>>>
	वस्त्र स्टब्स
· · · · · · · · · · · · · · · · · · ·	4 4 4 4 4 4 4 4 4
<pre>&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;&gt;</pre>	
**************************************	ARARARA
	N N N N N N N N N N N N N N N N N N N
	AAAAAAAA
VKSS VKSS VKSS VKSS VKSS VKSS VKSS VKSS	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
	000000000
	000000000
ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο	
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0
THE TARKET ARE THE TA	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	H H H H H H H H H U U U U U U U U U U U
MA MA MA MA MA MA MA MA MA MA MA MA MA M	MA M
	4444444 Нининнн
R R R R R R R R R R R R R R R R R R R	
8000000 スススススススススススススプロススススス	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
MARTER E MERERALE MENTER E PER	ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ
- п п п п п п п п п п п п п п п п п п п	ਜਜਜਜਜਜਜ
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	311 5 tam
0 4 8 4 0 1 8 4 8 4 8 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8	0 8 9 4 4 0 6 0
の B B B B B B B B B B B B B B B B B B B	らっかなるアンコー
O O O O O O O O O O O O O O O O O O O	N O Z N F O B Z

FIG 154

133 6 49 VEEDAPOAGESCO CAPETOES CONTANYS ANYSACATURE BY EACH CONDUITO CONTANYS ANYSACATURE BY ENCHOLOGOUND BY EACH CONTANYS ANYSACATURE BY EACH CONTONIO CONTANYS ANYSACATURE BY EACH CONTONIO CONTANYS ANYSACATURE BY ANYSACATURE B	•			
49 VKEDAPOAGGGGAAPSTOGS DURANYSAENTGGGAATTURFRINEDEGP ONDER O	400.	00008980880	PSTOGS ODDERWSADNWGNGGAAAWDKPKN	PONDMP
49 VKEDAPOAGS GGGAPS TOGS OUMAAVSAENTGRGAATTDEPENED ESPONDED CONTRIBUTION (**EDAPOAG GGGAPS TOGS OUMAAVSAENTGGGAATTDEPENED ESPONDED CONTRIBUTION (**EDAPOAG GGGAPS TOGS OUMAAVSAENTGGGAATTDEPENED ESPONDED CONTRIBUTION (**EDAPOAG GGGAPS TOGS OUMAAVSAENTGGGAATTDEPENED ESPONDED CONTRIBUTION (**EDAPOAG GGGGAPS TOGS OUMAAVSEENTGGGAATTDEPENED ESPONDED CONTRIBUTION (**EDAPOAG GGGGAPS TOGS OUMAAVS	4286 4	EDW-OVEROCIO	PSTOGSODWAYSABNTGNGGA	<b>a</b> MGNOa
107 49 VKEDAPPAGGGGGGAPPAGGSOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGAPPAGGGOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGAPPAGGGOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGGAPPAGGGOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGGAPPAGGGOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGGAPPAGGGGGAPPAGGGNAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGAPPAGGGGGAPPAGGSOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGAPPAGGGGGAPPAGGSOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGAPPAGGGGGAPPAGGSOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGAPPAGGGOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGAPPAGGSOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 VKEDAPPAGGGGGAPPAGGSOUMAAVSAENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 AKEDAPPAGGGGGAPPAGGSOUMAAVSEENTGNGGAATTUNEPRENEDEGFONDUED.  4 9 AKEDAPPAGGGGGAPPAGGSOUMAAVSEENTGNGGAATTUNEPRENEDEGANNUEPONAA  4 9 AKEDAPPAGGGGGAPPAGGSOUMAAVSEENTGNGGAATTUNEPRENEDEGANNUEPONAA  4 9 AKEDAPPAGGGGGGAPPAGGSOUMAAVSEENTGNGGAATTUNEPRENEDEGANNUEPONAA  4 9 AKEDAPPAGGGGGGAPPAGGSOUMAAVSEENTGNGGAATTUNEPRENEDEGANNUEPONAA  4 9 AKEDAPPAGGGGGGAPPAGGSOUMAAVSEENTGNGGAATTUNEPRENEDEGANNUEPONAA  4 9 AKEDAPPAGGGGGGAPPAGGSOUMAAVSEENTGNGGAATTUNEPRENEDEGANNUEPONAA  4 9 AKEDAPPAGGGGGGAPPAGGGGOOGAPPAGGGGOOGAPPAGGGGAPPAGGGGGAPPAGGGGGGAPPAGGGGGGAPPAGGGGGG	33 4	EDATORGEOGOG	PSTOGSODWAYWSA SAPING GGAYAUMOKPKNE	<b>GMONO</b> G
50 VKEDAPOAGGGGAPSACGSOUMAAVSAENTGMGGAATTURP REPRESE PUNDUED.  49 VKEDAPOAGGGGAPSACGGONAAVSAENTGMGGAATTURP REPRESE PUNDUED.  49 VKEDAPOAGGGGGAPSACGGONAAVSAENTGMGGAATTURP REPRESE PUNDUED.  49 VKEDAPOAGGGGGAPSACGGONAAVSEENTGMGGAATTURP REPRESE PUNDUED.  49 VKEDAPOAGGGGGAPSACGGONAAVSEENTGMGGAATTURP REPRESE PUNDUED.  49 AKEDAPOAGGGGGAPSACGGONAAVSEENTGMGGAATTURP REPRESE PUNDUED.  49 AKEDAPOAGGGGGAPSACGGONAAVSEENTGMGAATTURP REPRESE PUNDUED.  40 AKEDAPOAGGGGGAPSACGGONAAVSEENTGMGAATTURP REPRESE PUNDUED.  40 AKEDAPOAGGGGGAPSACGGONAAVSEENTGMGAATTURP REPRESE PUNDUED.  40 AKEDAPOAGGGGGAPSACGGONAAVSAENTGMGGAATTURP REPRESE PUNDUED.  40 AKEDAPOAGGGGOONAAVSAENTGMGGAATTURP REPRESE PUNDUED.  41 AGGAPOAD.  42 AKEDAPOAGGGGOONAAVSAENTGMGGAATTURP REPRESE PUNDUED.  44 AKEDAPOAGGGOONAAVSAENTGMGGAATTURP REPRESE PUNDUED.  45 AKEDAPOAGGGOONAAVSAENTGMGGAATTURP REPRESE PUNDUED.  46 AKEDAPOAGGGOONAAVSAENTGMGGAATTURP REPRESE PUNDUED.	107 4	EDANONGE OCOG	PSTOGSODWA: WSA BNUGNIGNIGE CONTROL	PONDUT
4.9 AKEDAROAG GOGGARSTGGODMAAVSABNITGNGGAATIDKENKDEGTONDED. 4.9 VKEDAROAG GOGGARSTGGSODMAAVSABNITGNGGAATIDKENKDEGFONDED. 4.9 VKEDAROAG GOGGARSTGGSODMAAVSABNITGNGGAATIDKENKDEGFONDED. 4.9 VKEDAROAG GOGGARSTGGSODMAAVSABNITGNGGAATIDKENNEDEGFONDED. 4.9 VKEDAROAG GOGGARSTGGSODMAAVSABNITGNGGAATIDKENNEDEGRONDED. 4.9 VKEDAROAG GOGGARSTGGSODMAAVSABNITGNGGAATIDKENNEDEGRONDED. 4.9 VKEDAROAG GOGGARSTGGSODMAAVSABNITGNGGAATIDKENNEDEGRONDED. 4.9 VKEDAROAG GOGGARSTGGSODMAAVSENNTGNGGAATIDKENNEDEGRONDED. 4.9 AKEDAROAG GOGGARSTAGSODMAAVSENNTGNGGAATIDKENNEDEGRONDED. 4.0 AKEDAROAG GOGGARSTAGSODMAAVSENNTGNGGAATIDKENNEDEGRONDED. 4.0 AKEDAROAG GOGGARSTAGSODMAAVSENNTGNGGAATIDKENNEDEGRONDED. 4.0 AKEDAROAG GOGGARSTAGSODMAAVSENNTGNGGAATIDKENNEDGRONDED. 4.0 AKEDAROAG GOGGARSTAGSODMAAVSENNTGNGGAATIDKENNEDGGAONDED. 4.0 AKEDAROAG GOGGARSTAGSODMAAVSENNTGNGGAATIDKENNEDGGRONDED. 4.0 AKEDAROAG GOGGARSTAGSODMAAVSENNTGNGGAATIDKENNEDGGRONDED. 4.0 AKEDAROAG GOGGARSTAGGODMAAVSENNTGNGGAATIDKENNEDGGRONDED. 4.0 AKEDAROAG GOGGARSTAGGODMAAVSENNTGNGGAATIDKENNEDGGRONDED. 4.0 AVSGAROAD. 4.0 A	S	EDAPOAGSOGOG	PSTOGSODWAYVSA BANFIGAGA A TUTOK PKINE	PONDA
49 VKEDAPPOAGGGGAPSTGGSOUMAAVSABNTGNGGAATTDKPKNEDEGPONUMPO  40 VKEDAPPOAGGGGAPSTGGSOUMAAVSABNTGNGGAATTDKPKNEDEGPONUMPO  40 AKEDAPPOAGGGGAPSTGGSOUMAAVSABNTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGAPSTGGSOUMAAVSABNTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGAPSTAGGSOUMAAVSABNTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGAPSTAGGSOUMAAVSABNTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGGSOUMAAVSABNTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGSOUMAAVSENTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGSOUMAAVSENTGNGGAATTDKPKNEDEVAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGSOUMAAVSENTGNGGAATTDKPKNEDEVAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGSOUMAAVSENTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGSOUMAAVSENTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGSOUMAAVSENTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGSOUMAAVSENTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGGSOUMAAVSABNTGNGGAATTDKPKNEDEGAONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGGSOUMAAVSABNTGNGGAATTDKPKNEDEGPONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGGSOUMAAVSABNTGNGGAATTDKPKNEDEGPONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGGSOUMAAVSABNTGNGGAATTDKPKNEDGPONUMPONAA  40 AKEDAPPOAGGGGGAPSTAGGSOUMAAVSABNTGNGGAATTDKPKNEDGGONUMPONAA  40 AVSGAPQADTODATAAGGGOUMAAVSABNTGNGGAATTDKPKNEDGPONUMPONAA  40 AVSGAPQADTODATAAGGGOUMAAVSABNTGNGGAATTDKPKNEDGPONUMPONAA  40 AVSGAPQADTODATAAGGGOUMAAVSABNTGNGGAATTDKPKNEDGPONUMPONAA  40 AVSGAPQADTODATAAGGGOUMAAVSABNTGNGGAATTDNPENKDEGPONUMPONAA  40 AVSGAPQADTODATAAGGGOUMAAVSABNTGNGGAATTDNPENKDGGOUMAAVSABNTGNGGAATTDNPENKDGGOUMAAVSABNTGNGGAATTDNPENKDGGOUMAAVSABNTGNGGAATTDNPENKDGGOU	4	KEDAPOAGSOGOG	PSAOGGODWAY/SAINWGNGGAEMADNPENK	TONDIM
49 VKEDAPÇAGSOGOAPSTOGSODMAAVSAENTGNGGAATTDKPKNEDEGFONDWPO  49 VKEDAPQAGSOGOAPSTOGSODMAAVSAENTGNGGAATTDKPKNEDEGFONDWPO  49 VKEDAPQAGSOGOAPSTOGSODMAAVSAENTGNGGAATTDKPKNEDEGFONDWPO  49 VKEDAPQAGSOGOAPSTOGSODMAAVSAENTGNGGAATTDKPKNEDEGFONDWPO  49 VKEDAPQAGSOGOAPSTOGSODMAAVSAENTGNGGAATTDKPKNEDEGFONDWPO  49 VKEDAPQAGSOGOAPSTOGSODMAAVSAENTGNGGAATTDKPKNEDEGFONDWPO  49 VKEDAPQAGSOGOAPSTOGSODMAAVSAENTGNGGAATTDKPKNEDEGFONDWPO  49 AKEDAPQAGSOGOAPSTOGSODMAAVSAENTGNGGAATTDKPKNEDEGFONDWPO  49 AKEDAPQAGSOGOAPSTOGSODMAAVSEENTGNGGAATTDKPKNEDEGAONDWPO  49 AKEDAPQAGSOGOAPSTOGSODMAAVSEENTGNGGAATTDKPKNEDEGAONDWPO  49 AKEDAPQAGSOGOAPSTOGSODMAAVSEENTGNGGAATTDKPKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTOGSODMAAVSEENTGNGGAATTDKPKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTOGSODMAAVSEENTGNGGAATTDKPKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTOGSODMAAVSEENTGNGGAATTDKPKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTOGSODMAAVSEENTGNGGAATTDKPKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTOGSODMAAVSEENTGNGGAATTDNFKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTAGSODMAAVSEENTGNGGAATTDNFKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTAGSODMAAVSEENTGNGGAATTDNFKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTAGSODMAAVSEENTGNGGAATTDNFKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTAGSODMAAVSEENTGNGGAATTDNFKNEDEGAONDWPO  40 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDEGPONDWPO  40 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDEGPONDWPO  40 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDEGPONDWPO  40 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDEGPONDWPO  41 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDEGPONDWPONAA  40 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDEGPONDWPONAA  41 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDGPONDWPONAA  42 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDGPONDWPONAA  44 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDGPONDWPONAA  45 AKEDAPQAGSOGOAPSTAGSODMAAVSAENTGNGGAATTDNFKNEDGPONDWPONAA  46 AKEDAPQAGSOGOAPSTAGSOOMAAVSAENTGNGGAATTDNFKNEDGPONDWPONAA  47 ASGAPQAGSOGOAPSTAGSOOMAAVSAENTGNGGAATTDNFKNEDGPONDWPONAA  48 AKEDAPQAGSOGOAPSTAGSOOMAAVSAENTGNG	0	KEDM-TOMGSOGOG	PSTOGSODWANSAISNITGNEGANIUNDKPKNED	GPONDM
49 VKEDAPOAGGOGGAPSTQGSQUAAVSAENTGNGGAATTUNFPKNEDEGPQNDMPQ  49 VKEDAPOAGGOGGAPSTQGSQUAAAVSAENTGNGGAATTUNFPKNEDEGPQNDMPQ  49 VKEDAPOAGGOGGAPSTQGSQUAAAVSAENTGNGGAATTUNFPKNEDEGPQNDMPQ  49 VKEDAPOAGGOGGAPSTQGSQUAAAVSAENTGNGGAATTUNFFKNEDEGPQNDMPQ  49 VKEDAPOAGGOGGAPSTQGSQUAAAVSAENTGNGGAATTUNFFKNEDEGPQNDMPQ  49 VKEDAPOAGGOGGAPSTQGSQUAAAVSAENTGNGGAATTUNFFKNEDEGAQNDMPQ  49 VKEDAPOAGGOGGAPSTQGSQUAAAVSEENTGNGGAATTUNFFKNEDEGAQNDMPQ  49 AKEDAPOAGGOGGAPSAQGGOUMAAVSEENTGNGGAATTUNFFKNEDEGAQNDMPQ  49 AKEDAPOAGGOGGAPSAQGGOUMAAVSEENTGNGGAVTANNFFKNEDEGAQNDMPQ.NAA.  49 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAVTANNFFKNEDEVAQNDMPQ.NAA.  49 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAVTANNFFKNEDEVAQNDMPQ.NAA.  49 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAVTANNFFKNEDEVAQNDMPQ.NAA.  49 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAVTANNFFKNEDEGAQNDMPQ.NAA.  40 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAVTANNFFKNEDEGAQNDMPQ.NAA.  40 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAVTANNFKNEDEGAQNDMPQ.NAA.  40 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAVTANNFKNEDEGAQNDMPQ.NAA.  40 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAVTANNFKNEDEGAQNDMPQ.NAA.  41 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAVTANNFKNEDEGAQNDMPQ.NAA.  42 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  43 AKEDAPOAGGOGGAPSAQGSQUAAAVSEENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  44 AKEDAPOAGGOGGAPSAAGGSQUAAAVSEENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  45 AKEDAPOAGGOGGAPSAAGGSQUAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  46 AKEDAPOAGGOGGAPSAAGGSQUAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  47 AKEDAPOAGGOGGAPSAAGGSQUAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  48 AKEDAPOAGGOGGAPSAAGGSQUAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  49 AKEDAPOAGGOGGAPSAAGGSQUAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  40 AKEAPOADAGGGOGGAPSAAGGSQUAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  40 ANGGAPQADAGGGODMAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  40 ANGGAPQADAGGGODMAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  40 ANGGAPQADAGGGODMAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  40 ANGGAPQADAGGGODMAAAVSAENTGNGGAATTUNFKNEDEGAQNDMPQ.NAA.  40 ANGGAPQADAGGGODMAAAVSAENTGNGGAATTUNFKNEDEGAQND	4	KEDATORGSOCOC	PSTOGSODWAAVSA BINTGNGGAATTOKPKINED	GPONDW
49 VKEDAPOAG CG GAPSTO GS ODMAAVSAENTGNGGAATTDKPKNEDEGP ONDWPO  49 VKEDAPOAG CG CGAPSTO CS ODMAAVSAENTGNGGAATTDKPKNEDEGA ONDWPO  49 AKEDAPOAG CG CGAPSTO CS ODMAAVSENTGNGGAATTDKPKNEDEGA ONDWPO  49 AKEDAPOAG CG CGAPSAAC CG ODMAAVSENTGNGGAATTDKPKNEDEGA ONDWPO  49 AKEDAPOAG CG CGAPSAAC CS ODMAAVSENTGNGGAATTDKPKNEDEGA ONDWPO.NA.  49 AKEDAPOAG CG CGAPSAAC CS ODMAAVSENTGNGGAATTDKPKNEDEVA ONDWPONA.  49 AKEDAPOAG CG CGAPSAAC CS ODMAAVSENTGNGGAATTDKPKNEDEGA ONDWPONA.  40 AKEDAPOAG CG CGAPSAAC CS ODMAAVSAENTGNGGAATTDKPKNEDEGA ONDWPONA.  40 AKEDAPOAG CG CGAPSAAC CS ODMAAVSAENTGNGGAATTDKPKNEDEGA ONDWPONA.  41 AKEDAPOAG CG CGAPSAAC CS ODMAAVSAENTGNGGAATTDKPKNEDEGA ONDWPONA.  42 AKEDAPOAG CG CGAPSAAC CS ODMAAVSAENTGNGGAATTDKPKNEDEGA ONDWPONA.  43 AKEDAPOAG CG CGAPSAAC CS ODMAAVSAENTGNGGAATTDNPRATTDNPRATTOR ONDWPONA.  44 AKEDAPOAG CG CGAPSAAC CS ODMAAVSAENTGNGGAATTDNPRATTOR CGAATTDNPRATTOR CGAATTD	4	EDMONGSOGOG	PSTOGSODWAAVSA BINTGINGGAANUUKPKINED	GPONDMP
49 VKEDAPQAGSQGGAPSTQGSQDWAAVSAENTGNGGAATTDKPKNEDEGPQNDMPQ 49 VKEDAPQAGSQGGAPSTQGSQDWAAVSAENTGNGGAATTDKPKNEDEGPQNDMPQ 49 VKEDAPQAGSQGGAPSTQGSQDWAAVSAENTGNGGAATTDKPKNEDEGPQNDMPQ 49 VKEDAPQAGSQGGAPSTQGSQDWAAVSAENTGNGGAATTDNFKNEDEGAQNDMPQ 49 AKEDAPQAGSQGGAPSTQGSQDWAAVSENTGNGGAATTDNFKNEDEGAQNDMPQ 38 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATTDNFKNEDEGAQNDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATTDNFKNEDEGAQNDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATTDNFKNEDEGAQNDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATTDNFKNEDEVAQNDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATADNFKNEDEVAQNDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATADNFKNEDEVAQNDMPQNAA 40 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATADNFKNEDEVAQNDMPQNAA 40 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATADNFKNEDEGAQDDMPQNAA 40 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATADNFKNEDEGAQDDMPQNAA 40 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATADNFKNEDEGAQDDMPQNAA 40 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATADNFKNEDEGAQDDMPQNAA 41 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATADNFKNEDEGAQDDMPQNAA 42 AKEDAPQAGSQGGAPSAQGSQDWAAVSAENTGNGGAATTDNFKNEDAGAQNDMPQNAA 43 AKEDAPQAGSQGGAPSAQGSQDWAAVSAENTGNGGAATTDNFKNEDAGAQNDMPQNAA 44 AKEDAPQAGSQGGAPSAQGSQDWAAVSAENTGNGGAATTDNFKNEDAGAQNDMPQNAA 45 AKEDAPQAGSQGGAPSAQGSQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA 46 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA 46 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA 46 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA 47 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA 48 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA 49 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA 40 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNFENKDGFQNDMPQNAA 40 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNFENKDGFQNDMPQNAA 40 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNFENKDGFQNDMPQNAAVSAENTGNGGAATTDNFENKDGFQNDMPQNAAVSAENTGNGGAATTDNFENKDGFQNDMPQNDMPQNAAVSAENTGNGGAATTDNFENKDGFQNDMPQNDMPQNDMPQNDMPQNDMAAVSAENTGNGGAATTDNFENKDGFQNDMPQNDMPQNDMPQNDMPQNDMPQNDMPQNDMPQNDMP	-88	EDMONGSOCOG	PSTOGSODWAYWSA BANTGAGGGAATTUDKENED	GPONDMP
26 49 VKEDAPQAGS GGGAPSTQGS GDWAAVSAENTGNGGAATTDNPFNNEDEGPONDWPO 49 VKEDAPQAGS GGGAPSTQGS GDWAAVSAENTGNGGAATTDNPFNNEDEGPONDWPO 49 VKEDAPQAGS GGGAPSTQGS GDWAAVSAENTGNGGAATTDNPFNNEDEGPONDWPO 49 AKEDAPQAGS GGGAPSTQGS GDWAAVSEENTGNGGAATTDNPFNNEDEGAQNDWPO 49 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTDNPFNNEDEGAQNDWPO 49 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTDNPFNNEDEGAQNDWPONAA 49 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTDNPFNNEDEGAQNDWPONAA 69 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTDNPFNNEDEVAQNDWPONAA 69 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTDNPFNNEDEVAQNDWPONAA 69 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTANNFNNEDEVAQNDWPONAA 69 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTANNFNNEDEVAQNDWPONAA 60 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTANNFNNEDEGAQDDWPONAA 61 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTANNFNNEDEGAQDDWPONAA 62 AKEDAPQAGS GGGAPSAQGS GWAAVSEENTGNGGAATTANNFNNEDEGAQDDWPONAA 63 AKEDAPQAGS GGGAPSAAGS GWAAVSEENTGNGGAATTANNFNNEDEGAQDDWPONAA 64 AKEDAPQAGS GGGAPSAAGS GWAAVSEENTGNGGAATTANNFNNEDEGAQDDWPONAA 65 AAGGAPQADTQDATAGES QUMAAVSAENTGNGGAATTANNFNNEDEGAQNDWPONAA 66 AVSGAPQADTQDATAGEGS QUMAAVSAENTGNGGAATTANNFNNEDERGAQNDWPONAA 66 AVSGAPQADTQDATAGEGS QUMAAVSAENTGNGGAATTANNFNNEDERGPONDWPONAA 66 AVSGAPQADTQDATAGEGS QUMAAVSAENTGNGGAATTANNFNNEDERGPONDWPONAA 67 AVSGAPQADTQDATAGEGS QUMAAVSAENTGNGGAATTANNFNNEDERGPONDWPONAA 68 AVSGAPQADTQDATAGEGS QUMAAVSAENTGNGGAATTANNFENKDEGPONDWPONAA 69 AVSGAPQADTQDATAGEGS QUMAAVSAENTGNGGAATTANNFENKDEGPONDWPONAA 60 AVSGAPQADTQDATAGEG QUMAAVSAENTGNGGAATTANNFENKDEGPONDWPONAA 60 AVSGAPQADTQDATAGRG GODWAAVSAENTGNGGAATTANNFENKDEGPONDWPONAA 60 AVSGAPQADAGQDATAGGS QUMAAVSAENTGNGGAATTANNFENKDEGPONDWPONAA 60 AVSGAPQADAGQDATAGGG GOMAAVSAENTGNGGAATTANNFENKDEGPONDWPONAA 60 AVSGAPQADAGQDATAG	31 4	KEDAPOAGSOGOG	PSTOGSODWAAVSAENWGNGGAATWDKPKNED	GPONDWP
15 49 VKEDAPQAGSGGAPSTGGSQUMAAVSAENTGNGGAATTDNPKNEDEGAQNUMPQ  49 AKEDAPQAGSGGGAPSTGGSQUMAAVSAENTGNGGAATTDNPKNEDEGAQNUMPQ  49 AKEDAPQAGSGGGAPSAGGSQUMAAVSAENTGNGGAATTDRFKNEDEGAQNUMPQ  49 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAATDRFKNEDEGAQNUMPQ  49 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAVTADNFKNEDEGAQNUMPQNAA  49 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAVTADNFKNEDEVAQNUMPQNAA  49 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAVTADNFKNEDEVAQNUMPQNAA  40 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAVTADNFKNEDEVAQNUMPQNAA  40 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAVTADNFKNEDEVAQNUMPQNAA  40 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAYTADNFKNEDEGAQUMPPQNAA  40 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAATTDNFKNEDEGAQUDMPQNAA  41 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAATTDNFKNEDEGAQDDMPQNAA  42 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAATTDNFKNEDEGAQDDMPQNAA  43 AKEDAPQAGSGGGAPSAGGSQUMAAVSEENTGNGGAATTDNFKNEDEGAQDDMPQNAA  44 AKEDAPQAGSGGGAPSAGGSQUMAAVSAENTGNGGAATTDNFKNEDEGAQDDMPQNAA  45 AKEDAPQAGSGGGAPSAGGSQUMAAVSAENTGNGGAATTDNFKNEDEGAQDDMPQNAA  46 AKEDAPQADTQDATAGGGQUMAAVSAENTGNGGAATTDNFKNEDEGAQDDMPQNAA  47 AVSGAPQADTQDATAGKGGQUMAAVSAENTGNGGAATTDNFKNEDEGPQNUMPQNAA  48 AKEDAPQAGSGGGAPSAGGGQUMAAVSAENTGNGGAATTDNFKNEDEGPQNUMPQNAA  49 AKEDAPQAGSGGGAPSAGGGQUMAAVSAENTGNGGAATTDNFKNEDEGPQNUMPQNAA  40 AVSGAPQADTQDATAGKGGQUMAAVSAENTGNGGAATTDNFENKDEGPQNUMPQNAA  40 AVSGAPQADTQDATAGKGGQUMAAVSAENTGNGGAATTDNFENKDEGPQNUMPQNAA  40 AKEDAPQAGSGGGGAPSAGGGQUMAAVSAENTGNGGAATTDNFENKDEGPQNUMPQNAA  40 AVSGAPQADTQDATAGKGGQUMAAVSAENTGNGGAATTDNFENKDEGPQNUMPQNAA  40 AVSGAPQADTQDATAGKGGQUMAAVSAENTGNGGAATTDNFENKDEGPQNUMPQNAA  40 AVSGAPQADTQDATAGKGGQUMAAVSAENTGNGGAATTDNFENKDEGPQNUMPQNAA  40 AKEDAPQAGSGGGGGAPSGGGGGAPSGGGGGGGGAATTGNGGGAATTDNFENKDEGPQNUMPQNAA  40 AVSGAPQADTQDATAGKGGQUMAAVSAENTGNGGAATTDNFENKDEGPQNUMPQNAA  40 AVSGAPQADTQDATAGKGGQUMAAVSAENTGNGGAATTDNFENKDEGPQNUMPQNAA  41 AKEDAPQAGSGGGGGAPGGGGGGGGGGGGGGGGGGGGGGGGGGG	26 4	KEDAPOAGSOGOG	PSTOGSODWANSAENTGNGGAATVOKPKNED	GPONDWP
49 VKEDAPOAGSOGOGAPSTOGSODMAAVSABNTGNGGAATTDNPKNEDEGAONDWPO 49 AKEDAPOAGSOGOGAPSTOGSODMAAVSABNTGNGGAATTDNPKNEDEGAONDWPO 49 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATTDNPKNEDEGAONDWPONAA 49 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATTDNPKNEDEGAONDWPONAA 49 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATTANPKNEDEVAONDWPONAA 49 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATANPKNEDEVAONDWPONAA 49 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATANPKNEDEVAONDWPONAA 40 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATANPKNEDEVAONDWPONAA 40 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATANPKNEDEVAONDWPONAA 40 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATANPKNEDEGAODDWPONAA 40 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATANPKNEDEGAODDWPONAA 40 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATANPKNEDEGAODDWPONAA 40 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATTDNPKNEDEGAODDWPONAA 40 AKEDAPPOAGSOGOGAPSAOGSODMAAVSEBNTGNGGAATTDNPKNEDEGAODDWPONAA 40 AKEDAPPOAGSOGOGAPSAOGSODMAAVSABNTGNGGAATTDNPKNEDAGAONDWPONAA 40 AKEDAPPOAGSOGOGAPSAOGSODMAAVSABNTGNGGAATTDNPKNEDAGAONDWPONAA 40 AVSGAPPOADTODATAGKGGODMAAVSABNTGNGGAATTDNPKNEDAGPONDWPONAA 40 AVSGAPPOADTODATAGKGGODMAAVSABNTGNGGAATTDNPENKDEGPONDWPONAA 40 AVSGAPPOADTODATAGKGGODMAAVSABNTGNGGAATTDNPENKDEGPONDWPONDA	800	KEDMPOAGSQGOG	PSTOGSODWAAVSAENFONGGGAAFFIDKPKNED	GPONDMP
49 AKEDAPOAGSOGGAPSAOGSOUAAAVSEDNTGNGGAATTDKPKNEDEGAQNDWPO 49 AKEDAPOAGSOGGAPSAOGSOUAAAVSEDNTGNGGAATTDKPKNEDEGAQNDWPO.NAA 49 AKEDAPOAGSOGGAPSAOGSOUAAAVSEDNTGNGGAVTADKPKNEDEGAQNDWPO.NAA 49 AKEDAPOAGSOGGAPSAOGSOUAAAVSEDNTGNGGAVTADNEKNEDEVAQNDWPO.NAA -76 49 AKEDAPOAGSOGGAPSAOGSOUAAAVSEDNTGNGGAVTADNEKNEDEVAQNDWPO.NAA -8 AKEDAPOAGSOGGAPSAOGSOUMAAVSEDNTGNGGAVTADNEKNEDEVAQNDWPO.NAA -8 AKEDAPOAGSOGGAPSAOGSOUMAAVSENTGNGGAVTADNEKNEDEVAQNDWPO.NAA -8 AKEDAPOAGSOGGAPSAOGSOUMAAVSENTGNGGAATADNEKNEDEGAQDDWPO.NAA -8 AKEDAPOAGSOGGAPSAOGSOUMAAVSENTGNGGAATADNEKNEDEGAQDDWPO.NAA 49 AKEDAPOAGSOGGAPSAOGSOUMAAVSENTGNGGAATADNEKNEDEGAQDDWPO.NAA 40 AKEDAPOAGSOGGAPSAOGSOUMAAVSENTGNGGAATADNEKNEDEGAQDDWPO.NAA 40 AKEDAPOAGSOGGAPSAOGSOUMAAVSENTGNGGAATADNEKNEDEGAQNDWPO.NAA 40 AKEDAPOAGSOGGAPSAOGSOUMAAVSENTGNGGAATADNEKNEDEGAQNDWPO.NAA 40 AKEDAPOAGSOGGAPSAOGSOUMAAVSANTGNGGAATTDNEKNEDEGPQNDWPO.NAA 40 AKEDAPOAGSOGGAPSAOGSOUMAAVSANTGNGGAATTDNEKNEDEGPQNDWPO.NAA 40 AKEDAPOAGSOGGAPSAOGSOUMAAVSANTGNGGAATTDNEKNEDEGPQNDWPO.NAA 41 AKEDAPOAGSOGGAPSAOGSOUMAAVSANTGNGGAATTDNEKNEGEPQNDWPO.NAA 40 AKGAPOADTODATAGKGGOUMAAVSANTGNGGAATTDNEKNEGEPQNDWPO.NAA 40 AVSGAPQADTODATAGKGGOUMAAVSANTGNGGAATTDNEKNEGEPQNDWPO.NAA 40 AVSGAPQADTODATAGKGGOUMAAVSANTGNGGAATTDNEKNEGEPQNDWPO.NAA 41 AKEDAPOAGSOGGGAPSAOGGOUMAAVSANTGNGGAATTDNEKNEGEPQNDWPO.NAA 41 AKEDAPOAGSOGGOAPSAOGGOUMAAVSANTGNGGAATTDNEKNEGEPQNDWPO.NAA 41 AKEDAPOAGSOGGOAPSAOGGOUMAAVSANTGNGGAATTDNEKNEGEPQNDWPO.NAA 41 AKEDAPOAGSOGGOAPSAOGGOUMAAVSANTGNGGAATTDNEKNEGPQNDWPO.NAA 41 AKEDAPOAGSOGGOAPSAOGGOUMAAVSANTGNGGAATTDNEKNEGPQNDWPO.NAA 41 AKEDAPOAGSOGGOAPSAOGGOUMAAVSANTGNGGAATTDNEKNEGPQNDWPO.NAA 40 AVSGAPQADTODATAGKGGOUMAAVSANTGNGGAATTDNEKNEGPQOUNDPO.NAA 40 AVSGAPQADTODATAGKGGOUMAAVSANTGNGGAATTDNEKNEGPQOUNDPO.NAA 40 AVSGAPQADTODATAGKGGOUMAAVSANTGNGGAATTDNEKNEGPQOUNDPO.NAA 41 AKEDAPOAGSOGGOUMAAVSANTGNGGAATTDNEKNEGPQOUNDPO.NAA 41 AKEDAPOAGSOGOGAPSAOGGOUMAAVSANTGNGGAATTDNEKNEGPQOUNDPONDPONDA	15 4	KEDAPOAGS QGOG	PSTOGSODWANSAENTGNGGAATTONPKNED	GAONDWP
49 AKEDAPOAGS QG GAPSAQ GG DUMAAVSE BNTGNGGAAATDKPKNE DEGAQNDMP ONAA 49 AKEDAPOAGS QG GAPSAQ GG DUMAAVSE BNTGNGGAAATDKPKNE DEGAQNDMP ONAA 49 AKEDAPOAGS QG GAPSAQ CS DUMAAVSE BNTGNGGAVTADNP KNE DEGAQNDMP ONAA - 49 AKEDAPOAGS QG GAPSAQ CS DUMAAVSE BNTGNGGAVTADNP KNE DEVAQNDMP ONAA - 88 49 AKEDAPOAGS QG GAPSAQ CS DUMAAVSE BNTGNGGAVTADNP KNE DEVAQNDMP ONAA - 88 49 AKEDAPOAGS QG GAPSAQ CS DUMAAVSE BNTGNGGAVTADNP KNE DEGAQNDMP ONAA - 8 AKEDAPOAGS QG GAPSAQ CS DUMAAVSE BNTGNGGAATTADNP KNE DEGAQNDMP ONAA - 8 AKEDAPOAGS QG GAPSAQ CS DUMAAVSE BNTGNGGAATTADNP KNE DEGAQNDMP ONAA - 8 AKEDAPOAGS QG GAPSAQ CS DUMAAVSE BNTGNGGAATTADNP KNE DEGAQNDMP ONAA - 8 AKEDAPOAGS QG GAPSAQ CS DUMAAVSE BNTGNGGAATTADNP KNE DEGAQNDMP ONAA - 8 AKEDAPOAGS QG GAPSAQ CS DUMAAVS BNTGNGGAATTADNP KNE DEGAQNDMP ONAA - 8 AKEDAPOAGS QG GAPSAQ CS DUMAAVSABNTGNGGAATTDNP KNE DEGAQNDMP ONAA - 8 AKEDAPOAGS QG GAPSAQ CS DUMAAVSABNTGNGGAATTDNP KNE DEGAQNDMP ONAA - 9 AKEDAPOADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP KNE DEGPQ NDMP ONAA - 165 60 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT QDATAGK GQ DUMAAVSABNTGNGGAATTDNP ENK DEGPQ NDMP ONAA - 9 AVSGAPQADT	7	Kedator geoge	PSTOGSQDWAAVSAENTGNGGAATTDKPKNED	GAONDMP
49 AKEDAPQAGSQGQGAPSAQGGQDWAAVSEENTGNGGAVTADNPKNEDEGAQNDMPQNAA 49 AKEDAPQAGSQGQGAPSAQGSQDWAAVSEENTGNGGAVTADNPKNEDEVAQNDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSEENTGNGGAVTADNPKNEDEVAQNDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSEENTGNGGAVTADNPKNEDEVAQNDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSEENTGNGGAATADNPKNEDEVAQNDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSEENTGNGGAATADNPKNEDEGAQDDMPQNAA 49 AKEDAPQAGSQGGAPSAQGSQDWAAVSEENTGNGGAATADNPKNEDEGAQDDMPQNAA 49 VKEDAPQAGSQGGAPSAQGSQDWAAVSEENTGNGGAATADNPKNEDEGAQDDMPQNAA 50 AKEDAPQAGSQGGAPSAQGSQDWAAVSENTGNGGAATADNPKNEDEGAQDDMPQNAA 50 AKEDAPQAGSQGGQPSAGGSQDWAAVSAENTGNGGAATTDNPKNEDEGAQNDMPQNAA 50 ANSGAPQADTQDATAGEGSQDWAAVSAENTGNGGAATTDNPKNEDAGAQNDMPQNAA 50 AVSGAPQADTQDATAGEGSQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 51 60 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 52 60 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 54 60 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 55 60 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 56 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 57 60 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 58 60 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 59 60 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 50 60 AVSGAPQADTQDATAGKGGDWAAVSAENTGNGGAATTDNPENKDGGPQNDMPQNAA	98	Kedaroa geoge	PSAQGGODWAAVSEENTGNGGAAATDKPKNED	GAONDWPONA
49 AKEDAPOAGS QGGAPSAQGS QDWAAVSEENTGNGGAVTADNPKNEDEVAQNDWPQNAA  49 AKEDAPOAGS QGGGAPSAQGS QDWAAVSEENTGNGGAVTADNPKNEDEVAQNDWPQNAA  49 AKEDAPOAGS QGGGAPSAQGS QDWAAVSEENTGNGGAVTADNPKNEDEVAQNDWPQNAA  49 AKEDAPOAGS QGGGAPSAQGS QDWAAVSEENTGNGGAYTADNPKNEDEVAQNDWPQNAA  49 AKEDAPOAGS QGGAPSAQGS QDWAAVSEENTGNGGAATADNPKNEDEVAQNDWPQNAA  40 AKEDAPOAGS QGGAPSAQGS QDWAAVSEENTGNGGAATADNPKNEDEGAQDDWPQNAA  40 AKEDAPOAGS QGGAPSAQGS QDWAAVSEENTGNGGAATADNPKNEDEGAQDDWPQNAA  40 AKEDAPOAGS QGGAPSAQGS QDWAAVSEENTGNGGAATADNPKNEDEGAQDDWPQNAA  40 AKEDAPOAGS QGGAPSAQGS QDWAAVSEENTGNGGAATADNPKNEDEGAQDDWPQNAA  40 AKEDAPOAGS QGGAPSAQGS QDWAAVSAENTGNGGAATTDNPKNEDAGAQNDWPQNAA  40 AKEDAPOADT . ODATAGGS QDWAAVSAENTGNGGAATTDNPKNEDAGAQNDWPQNAA  40 AVSGAPQADT . ODATAGGS QDWAAVSAENTGNGGAATTDNPKNEDEGPQNDWPQNAA  40 AVSGAPQADT . ODATAGKGQDWAAVSAENTGNGGAATTDNPKNEDEGPQNDWPQNAA  40 AVSGAPQADT . ODATAGKGQDWAAVSAENTGNGGAATTDNPKNEDKDGPQNDWPQNAA  40 AVSGAPQADT . ODATAGKGQDWAAVSAENTGNGGAATTDNPKNEDKDGPQPQNDMPQNAA  40 AVSGAPQADT . ODATAGKGGQDWAAVSAENTGNGGAATTDNPKNEDKDGPQPQNDMPQNAA  40 AVSGAPQADT . ODATAGKGGQDWAAVSAENTGNGGAATTDNPKNEDKDGPQPQNDMPQNAA  40 AVSGAPQADT . ODATAGKGGQDWAAVSAENTGNGGAATTDNPKNEDKDGPQPQNAA	38 4	Kedator geogg	PSAQGGODWAAVSEENWGNGGAAATDKPKNED	GAONDMPONA
49 AKEDAPQAGSQGQAPSAQGSQUWAAVSEENTGNGGAVTADNPENNEDEVAQNDMPQNAA  49 AKEDAPQAGSQGQAPSAQGSQUWAAVSEENTGNGGAVTADNPENNEDEVAQNDMPQNAA  49 AKEDAPQAGSQGQAPSAQGSQUWAAVSEENTGNGGAVTADNPENNEDEVAQNDMPQNAA  40 AKEDAPQAGSQGQAPSAQGSQUWAAVSEENTGNGGAATADNPENNEDEAQDDMPQNAA  40 AKEDAPQAGSQGQAPSAQGSQUWAAVSEENTGNGGAATADNPENNEDEGAQDDMPQNAA  41 49 AKEDAPQAGSQGQAPSAQGSQUWAAVSEENTGNGGAATADNPENNEDEGAQDDMPQNAA  42 AKEDAPQAGSQGQAPSAQGSQUWAAVSEENTGNGGAATTDNFENNEDEGAQDDMPQNAA  43 AKEDAPQAGSQGQAPSAQGSQUWAAVSAENTGNGGAATTDNFENNEDAGAQNDMPQNAA  44 AKEDAPQADTQDATAGEGSQUWAAVSAENTGNGGAATTDNFENKDEGAQNDMPQNAA  50 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  51 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  52 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  53 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  54 AKEDAPQAGTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  55 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  56 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  57 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  58 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  59 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  50 AVSGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  51 ANGGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  51 ANGGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  51 ANGGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  52 ANGGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  53 ANGGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  54 ANGGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  55 ANGGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  56 AVGGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA  57 ANGGAPQADTQDATAGKGQDWAAVSAENTGNGGAATTDNFENKDEGPQNDMPQNAA	69	Kedamorge ococ	PSAQGSQDWAAVSEBNTGNGGAVTADNPKNED	VACUADIMECINA
49 AKEDAPQAGSQGOGAPSAQGSQUVAAVSEBNTGNGGAVTADNPKNEDEVAQNDAPQNAA 49 AKEDAPQAGSQGOGAPSAQGSQUVAAVSEBNTGNGGAVTADNPKNEDEVAQNDAPQNAA 36 49 AKEDAPQAGSQGOGAPSAQGSQUVAAVSEBNTGNGGAATADNPKNEDEGAQDDAPQNAA 36 49 AKEDAPQAGSQGOGAPSAQGSQUVAAVSEBNTGNGGAATADNPKNEDEGAQDDAPQNAA 47 49 AKEDAPQAGSQGOGAPSAQGSQUVAAVSEBNTGNGGAATADNPKNEDEGAQDDAPQNAA 28 49 VKEDAPQAGSQGOGAPSTQGSQUVAAVSEBNTGNGGAATADNPKNEDEGAQDDAPQNAA 29 0 60 AAGGAPQADTQDATAGEGSQUVAAVSABNTGNGGAATADNPKNEDAGAQNDAPQNAA 50 0 60 AVSGAPQADTQDATAGEGSQUVAAVSABNTGNGGAATADNPKNEDAGAQNDAPQNAA 18311 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 165 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 24 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 24 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 24 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 25 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 26 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 27 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 32 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 32 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 32 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA 32 60 AVSGAPQADTQDATAGKGGQUVAAVSABNTGNGGAATADNPENKDEGPQNDAPQNAA	3 4	Kedatorcs ococ	PSAQGSQDWAAVSEBNTGNGGAVTADNPKNED	VACIONOMECINAA
8 49 AKEDAPOAGSQGGAPSAQGSQDWAAVSEBNTGNGGAYTADNPKNEDBGAQDDWBQNAA 36 49 AKEDAPOAGSQGGAPSAQGSQDWAAVSEBNTGNGGAATTADNPKNEDBGAQDDWBQNAA 49 AKEDAPOAGSQGGAPSAQGSQDWAAVSEBNTGNGGAATTADNPKNEDBGAQDDWBQNAA 49 AKEDAPOAGSQGGAPSAQGSQNWAAVSEBNTGNGGAATTADNPKNEDBGAQDDWBQNAA 49 VKEDAPOAGSQGGAPSAQGSQNWAAVSBBNTGNGGAATTADNPKNEDBGAQDDWBQNAA 50	-76 4	Kedangageoge	PSAQGSQDWAAVSEENTGNGGAVTADNPKNED	VA ONDWEONA A
49 AKEDAPOAGSOGOGAPSAQGSODMAAVSEENTGNGGAATADNPKNEDEGAODDWPONAA 49 AKEDAPOAGSOGOGAPSAQGSODMAAVSEENTGNGGAATADNPKNEDEGAODDWPONAA 47 49 AKEDAPOAGSOGOGAPSAQGSOMMAAVSEENTGNGGAATADNPKNEDEGAODDWPONAA 58 49 VKEDAPOAGSOGOGAPSAQGSOMMAAVSEENTGNGGAATADNPKNEDEGPONDWPONAA 59 0 60 AAGGAPQADTODATAGEGSODMAAVSAENTGNGGSATTDNPKNEDAGAONDWPONAA 50 0 60 AAGGAPQADTODATAGEGSODMAAVSAENTGNGGAATTDNPKNEDAGAONDWPONAA 50 0 60 AVSGAPQADTODATAGKGGODMAAVSAENTGNGGAATTDNPENKDEGPONDWPONAA 51 60 AVSGAPQADTODATAGKGGODMAAVSAENTGNGGAATTDNPENKDEGPONDWPONAA 51 60 AVSGAPQADTODATAGKGGODMAAVSAENTGNGGAATTDNPENKDEGPONDWPONAA 52 60 AVSGAPQADTODATAGKGGODMAAVSAENTGNGGAATTDNPENKDEGPONDMPONAA 53 60 AVSGAPQADTODATAGKGGODMAAVSAENTGNGGAATTDNPENKDEGPONDMPONAA 54 60 AVSGAPQADTODATAGKGGODMAAVSAENTGNGGAATTDNPENKDEGPONDMPONAA 55 60 AVSGAPQADTODATAGKGGODMAAVSAENTGNGGAATTDNPENKDEGPONDMPONAA 56 60 AVSGAPQADTODATAGKGGODMAAVSAENTGNGGAATTDNPENKDEGPONDMPONAA	8 4	Kedatorge ococ	PSAQGSQDWAAVSEBNWGNGGAVWADNPKNED	VACCINIDATE
49 AKEDAPOAGS QG QAPSAQGQ DWAAVSE ENTGOGATATADNE KNEDEGAQDDWP QWAA 47 49 AKEDAPOAGS QG QAPSAQGS QMMAAVSE ENTGOGGATTADNE KNEDEGAQDDWP QWAA 28 49 VKEDAPQAGS QG QAPSTQGS QMMAAVSE ENTGOGGATTADNE KNEDEGP QNDWP QWAA 29 0 60 AAGGAPQADTQDATAGEGS QD WAAVSAENTGOGGATTTDNE KNEDAGAQNDWP QWAA 49 VKEDAPQADTQDATAGEGS QD WAAVSAENTGOGGATTTDNE KNEDAGAQNDWP QWAA 49 VKSGAPQADTQDATAGKGG QD WAAVSAENTGOGGAATTDNE KNEDEGP QNDWP QWAA 49 AVSGAPQADTQDATAGKGG QD WAAVSAENTGOGGAATTDNE ENKDEGP QND WP QWAA 49 AVSGAPQADTQDATAGKGG QD WAAVSAENTGOGGAATTDNE ENKDEGP QND WP QWAA 50 0 AVSGAPQADTQDATAGKGG QD WAAVSAENTGOGGAATTDNE ENKDEGP QND MP QNAA 50 0 AVSGAPQADTQDATAGKGG QD WAAVSAENTGOGGAATTDNE ENKDEGP QND MP QNAA	-88. 4	Kedatores ococ	PSAQESQDWAAVSEENTGNGGAATADNPKNED	GAODDWPONA
47 49 AKEDAPOAGSQGGAPSAQGSQNMAAVSEBNTGNGGAATADNPKNEDEGPONDMPONAA 28 49 VKEDAPOAGSQGGAPSTQGSQDMAAVSABNTGNGGAATTDNFKNEDEGPONDMPONAA 29 0 60 AAGGAPOADTODATAGEGSQDMAAVSABNTGNGGAATTDNFKNEDAGAQNDMPONAA 90 0 60 AVSGAPOADTODATAGEGSQDMAAVSABNTGNGGAATTDNFKNEDAGAQNDMPONAA 18311 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 165 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 165 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 24 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 24 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 32 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 32 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 32 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 32 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 33 60 AVSGAPOADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 34 AKEDAPOAGSQGGAPFAAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 35 60 AVSGAPQADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA 36 60 AVSGAPQADTODATAGKGGQDMAAVSABNTGNGGAATTDNFENKDEGPQNDMPONAA	36 4	Kedatoacsococ	PSAQGGODWAAVSEENTGNGGAAATDKPKNED	GAONDMPONA
49 VKEDAPQAGSQGQAPSTQGSQDWAAVSABNTGNGGSATTDNPKNEDAGAQNDAAAAAAAAATTDNPKNEDAGAQNDMPQNAAAF62 60 AAGGAPQADTQDATAGEGSQDWAAVSABNTGNGGAATTDNPKNEDAGAQNDMPQNAABOO 60 AVSGAPQADTQDATAGEGSQDWAAVSABNTGNGGAATTDNPKNEDAGAQNDMPQNAABOO 60 AVSGAPQADTQDATAGKGGQDWAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAABBOO 60 AVSGAPQADTQDATAGKGGQDWAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAABBOO 60 AVSGAPQADTQDATAGKGGQDWAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAABBOO 60 AVSGAPQADTQDATAGKGGQDWAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAABBOO 60 AVSGAPQADTQDATAGKGGQDWAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAABACTABN 60 AVSGAPQADTQDATAGKGGQDWAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAAAAAAATTDNPENKDEGPQNDMPQNAAAAAAAATTDNPENKDEGPQNDMPQNAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	47 4	Kedator Geogg	PSAOGSONWAAVSEENTGNGGAATADNPKNED	GAODDWPOKA
60 AAGGAPQADTQDATAGEGSQDMAAVSABNTGNGGAATTDNPKNEDAGAQNDMPQNAA 900 60 AVSGAPQADTQDATAGEGSQDMAAVSABNTGNGGAATTDNPKNEDAGAQNDMPQNAA 18311 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 165 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 25 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 32 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 32 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 32 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 34 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA	28 4	Kedatorge ococ	PSTOGSODWAAVSAENTGNGGSATTDKPKNED	GPONDWPONAA
F62 60 AAGGAPQADTQDATAGEGSQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 900 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 18311 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 165 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA -0 49 AKEDAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 32 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 32 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 32 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA	9 060	AGGAPOADTO	GEGS ODWAAVSA ENTGNGGAATTONPKNED	GAONDMPONA
900 60 AVSGAPOADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMAANA.18311 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.165 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.91 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.24 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.90 49 AKEDAPQAGGQGAPSAQGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.32 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.32 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.32 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.32 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.32 60 AVSGAPQADTQDATAGEGSQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.32 60 AVSGAPQADTQDATAGEGSQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.32 60 AVSGAPQADTQDATAGEGSQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA.32 60 AVSGAPQADTQDATAGEGSQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA	F62 6	AGGAPOADT Q	A GEGSODWAAVSAENFICHGGAAFFIDNPKNED	GAONDWPONA
18311 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 165 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA -0 49 AKEDAPQAGSQGGAPSAQGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA 32 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA actam 60 AVSGAPQADTQDATAGKGGQDMAAVSABNTGNGGAATTDNPENKDEGPQNDMPQNAA	9 006	VSGAPO	GKGGODWAAVSAENTGNGGAATTDNPENKD	GPONDMPONA
165 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA -0 49 AKEDAPQAGSQGGAPSAQGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 32 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA actam 60 AVGGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA	18311 6	VSGAPOA	<b>GKGGQDWAAVSAENTGNGGAATTUDNPENKD</b>	GPONDMPONA
91 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 24 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA -0 49 AKEDAPQAGSQGGAPSAQGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA 32 60 AVSGAPQADTQDATAGKGGQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA actam 60 AVGGAPQADTQDATAGEGSQDMAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA	165 6	VSGAPOR	GKGGQDWAAVSAENTGNGGAATTDNPENKD	GPONDMPONA
24 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA-0 49 AKEDAPQAGSQGGAPSAQGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA-32 60 AVSGAPQADTQDATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA-actam 60 AVGGAPQADTQDATAGKGGODWAAVSAENTGNGGAATTDNPENKDEGPQNDMPQNAA-actam 60 AVGGAPQADTQDATAGEGSQDWAAVSAENTGNGGAATTDNPENKDEAQADT.	91 6	VSGAPO	<b>GKGGQDMAAVSAENTGNGGAATTDNPENKD</b>	GPONDWPONA
-0 49 AKEDAPOAGSOGOGAPSAQGGODMAAVSAENTGNGGAATTDNPENKDEGPONDMPONAA 32 60 AVSGAPOADT, ODATAGKGGODMAAVSAENTGNGGAATTDNPENKDEGPONDMPONAA actam 60 AVGGAPOADT ODATAGEGSODMAAVSAENTGNGGA TTDNFKNEDAGAONDMPONAA	24 . 6	VSGAPO	A GKGGQDWAAVSAENTGNGGAATTDNPEN	POMPMPONA
32 60 AVSGAPQAD ODATAGKGGQDWAAVSAENTGNGGAATTDNPENKDEGPQNDMPONAA actam 60 AVGGAPQAD ODATAGEGSQDWAAVSAENTGNGGA TDKPKNEDAGAQNDMPONAA	<b>4</b>	Kedanaoaggoog	PSAOGGODWAAVSABNTGNGGAATTIDNPEN	POMPLEONA
actam 60 AVGGAPOADE ODATAGEGSODWAAVSAENWGNGGA WOKPKNEDAGAONDWPONAA	32 6	VSGAPOADE 0	A GKGGODWAAVSA ENTGNGGAATTONPENK	PONDMPONA
	actam 6	VGGATOADT OD	TAGEGSODWAAVSAENTGNGGA TTDKPKNED	GAONDWIPONAA

*FIG. 15A*(contd.

DGPSONITLTHCKGD 000 X X X X THE PROPERTY. )нача п п п п п п п  $oldsymbol{n}$ KANTANAN KANTAN  $\phi$ 000000HHHHHH00000000000HHHHH000000 E 9 a 0 9 5 1905 Ö Ø опомыныы

## FIG. 15B(CONTD.)

KERKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
SOUND
COOOCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
00000000000000000000000000000000000000
N N N N N N N N N N N N N N N N N N N

SUBSTITUTE SHEET (RULE 26)

HIVEDESABSSSER	11 YKDKSASSSARFRRSARSRRSLPAEMPLIPVNQADTLIVD	IIYKDKSASSSARFRRSARSRRSDPAEMPLIPVNQADTLIVDGEAVSLTGBSGNI	IIYKDKSASSSFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNI	II YKDKSASSSARFRRSARSRRSDPABMPLIPVNQADTLIVD	IF YRPKITSS ARFRESARSRRSLPAEMPLIPVNQADTLIVDGEAVSLT	IF YKP KITSS ARF RRSARSRRSLPAEMPLIPVNQADILIVDGEAVSLI	IFYKPKPTSSARFRESARSRRSLPAEMPLIPVNQADTLIVDGEAVSL	IFYKPKTTSSARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNI	IFYKPKTISSARFRRSARSRRSIPAEMPLIPVNQAD/TLIVDGEAVSLIGH	IFYKPKTTSSARFRRSARSRRSLPAEMPLTPVNQADTLIVDGEAVSLTGH	IFYKPKTTSSARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGR	IFYRPKITSS. ARFRESARSRRSDPAEMPLIPVNQADTLIVDGEAVSLTGHSGNI	IFYTDKPP RSARSRRSLPAE PLIPVNQAD TLIVDGEAVSLTGYSGNI	IIYKDKSASSAQFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGH	IFYKPKPTSFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGH	IFYKPKPTSFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGESGNI	LFYKPKPKPTS. FARFRRSARSRRSJPAEMPLIPVNQADTLIVDGEAVSLTGH	IFYKPKPTS. FARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNI	IFYRPKPTSFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGH	IFYKPKPTS. FARFRASARSKRSLPAEMPLIPVNQADFLIVDGEAVSLIGHSGNI	II YKDKSTS. SARVRRSARSRRSDPAEMPLIPVNQADTLIVDGEAVSLIGHSGNI	II YKDKSTS SARVRRSARSRRSLPABMPLIPVNQADTLIVDGBAVILTGHSGNI	LIKTOKTPWRSARSRRSDSEBNPETPVNQADVETVDGBAVSLTGBSGNI	HIYOAQPIRSARSRRSIPABMPLIPVNQVDYLIVDGBAVSLIGH	IFYTDKRPWRSARSRRSIPABMPLIPVNQADTLIVDGEAVSLTGHS	IFYTDKPP型RSARSRRSIPABMPLIPVNQADTLIVDGBAVSLTGH	II YKDKSASSSARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGH	II YKDKSASSSARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGH	HIYKDKSASISARFRRSARSRRSIDAEMPLI	II YKDKSASSSARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLIGH	himpersassarerrsarsrrsperenementevnoadplivogbavslighernierp	itykdiksassarfirrsarsrrsderemplipvnoadtlvdg	TEVKPK. TITSSARFRRS	HFW. T. DTPP()SARSRILRRS APPANDA PARTONOM AND COMP
3	222	~	2	0	2	2	2	3	2	7	2	2	3	N	α	ω	$\infty$	ω	$\infty$	α	ω	α	ω	$\infty$	ന	က	თ	თ	9	9	σ	ω	<b>o</b>	g.
99	93-4286	2133	NZ1	22	5 6	0	N	32	36-	3E3	3F26	809	ליז	11	219	田り	216	8	44	C58	63-	GH3	214	GE 28	A109	3-F6	0590	0-1	3P16	249	612	-16	N	L pa

## *FIG. 15С*(соитр.)

Gnyryltygaekleggsyal <mark>rvogepakgemlagtavyngevlhfhtengry yemrgrfa</mark> gnyryltygaekleggsyalrvogepakgemlagtavyngevlhfhtengrp yemrgrfa gnyryltygaekleggsyalrvogepakgemlagtavyngevlhfhtengrp yemrgrfa	on en	GNYRYLTYGAEKTSGGSYALSVOGEPAKGEMLAGTAVYNGEVLHFHTENGKSYPTKGREA GNYRYLTYGAEKTSGGSYALSVOGEPAKGEMLAGTAVYNGEVTHFHTENGESYDTKGREA	KLSGGSYALSVÖ	GNYRYLTYGABKUSGGSYALSVQGEPAKGEMTAGTAVYNGEVLEFETENGRSYPTKGRFA GNYRYLTYGABKUSGGSYALSVOGEPAKGEMTAGTAVYNGEVJHEHTENGESYPTKGETE	GGSYAL	GNIKILTIGAEKUS GGSYALSVOGKPAKGEMLAGTAVYNGEVLEFHTENGRSYPERGREA GNIRYLTIGAEKUS GGSYALSVOGEPAKGEMLAGTAVYNGEVT HFHMENGED YD GGEFF	GGSYALSVOGEPAKGEMIAGTAVYSGEVIHEHTENGRPYPS	GNY KYTTY GABK 1P GGSYALRVOGEPSKGEMTAGTAVYNGEVLHEHTBNGRPSPSRGRFA GNY RYTTY GABK 1P GGSYALRVOGEPSKGEMTAGTAVYNGEVT HEHTBNGHDSPSPST	GGSYALRVOGEPAKGEMLAGAAVYNG	GGSYALRVQGEPAKGEMLAG	on the litterature gostalikvogspak gominagarvyngsverhentenge ydmrerea gnykkynykerokop gosyalikvogsdak gominagarvyngsverhenge og mega	GGSYALRVOGEPAKGEMLAG	GGSYADRIVKG	GNYRYLYYGABKIDEGGSYALRVOGEPAKGEMIAGAAVYNGEVLHFHTBINGRSYPTRGERFA	GGSYALRVOGBPAKGBUTQ	Pargemengeravyng	GNYRYLTYGAEKLSGGSYALSVQGEPAKGEMJAGTAVYNGEVLHFHMENGRP SPSGGRFA	GNYKKTYY GABKASIGGSYAAASVOGBPAKGBMIAGYAVYNGBVAHIBHMBNGRPSPSGGRBA	CALINIA DA DE LA GRANTA GOVERNA DE LA COMPANIA CADA VANCENTA DE LA CORRESA CONVENTA VANCENTA DE LA CORRESA CONVENTA CADA VANCENTA DE LA CORRESA CONVENTA CADA VANCENTA DE LA CORRESA CONVENTA DE LA CORRESA CONVENTA CADA VANCENTA CADA	CANADA MANADA MA	GNYRYLTYGAEKLS GGSYALSVOGEPAKGEWIJAGTAVYNGEVIJETERMENGEPSPSEGERE	gnyrylfygaekls ggsyalsvogepakgemfagtavyngevlefhfengrp ypsrcr	gnyrylyy rabklsgesyalrvogepakgemiagtavyngevlhfhtengepyppsgerfa
2222	սաա	$\omega$	$\alpha$	$\mathbf{x}$	$\mathbf{\omega}$	<b>∞.Γ~</b>	· •	ਨ ਨ	Z.	7 5	<b>.</b> T	Z,	T (	$\sim$	m	m	10 1	O 10	10		***	10	I
2996 93-4286 BZ133	100 100 100 100 100 100 100 100 100 10	00	32	ს ს	GF26	6 C 8	17	2 T 3	216	283	4 () 4 ()	(B)	GH36	2 C	A109	G-F6	05900	91.6	6770	612	97-	223	_1a

## *FIG. 15D*(соитр.)

### FIG. 15E

2996	402	<b>AGKYSYRPTDAEKGGFGVFAGKKEQD</b>
93-4286	402	<b>AGKYSYRPTDAEKGGFGVFAGKKEQD</b>
BZ 133	402	agkysyrp tdaekggfgvfagkkeod
SW 2107	402	<b>AGKYSYRPTDAEKGGFGVFAGKKEQD</b>
A22	403	agkysyrptdaekggfgvfagkkeod
E26	400	agkysyrp tdaekggfgvfagkkeqd
1000	401	agkysyrptdaekggfgvfagkkeod
528	401	<b>AGKYSYRPTDAEKGGFGVFAGKKEQD</b>
E32	401	agkysyrp tdaekggfgvfagkkeod
NG6-88	401	<b>AGKYSYRPTDAEKGGFGVFAGKKEQD</b>
NGE31	401	agkysyrptdaekggfgvfagkkeod
NGF26	401	agkysyrptdaekggfgvfagkkeqd
860800	401	agkysyrp tdaekggfgvfagkkeqd
NGH15	394	agkysyrptdaekggfgvfagkkeqd
C11	398	agkysyrptdaekggfgvfagkkeod
BZ198	467	agkysyrp tdaekggfgvfagkkeqd
NGH38	467	agkysyrptdaekggfgvfagkkeqd
BZ169	463	<b>AGKYSYRPTDAEKGGFGVFAGKKEQD</b>
BZ83	463	<b>AGKYSYRPTDAEKGGFGVFAGKKEQD</b>
H44-76	463	<b>AGKYSYRPTDAEKGGFGVFAGKKEQD</b>
MC58	463	<b>AGKYSYRPTDAEKGGFGVFAGKKEQD</b>
NG3-88	461	agkysyrptdaekggfgvfagkkeqd
NGH36	461	agkysyrptdaekggfgvfagkkeod
BZ147	456	agkysyrptdaekggfgvfagkkeod
NGE28	455	AGKYSYRPTDAEKGGFGVFAGKKEOD
FA1090	404 404	AGKYSYRPTDAEKGGFGVFAGKKERD AGKYSYRPTDAEKGGFGVFAGKKERD
NG-F62	472	AGKYSYRPTDAEKGGFGVFAGKK <u>©R</u> D AGKYSYRPTDAEKGGFGVFAGKKEOD
205900	472	AGRYSYRPTDAEKGGFGVFAGKKEOD AGRYSYRPTDAEKGGFGVFAGKKEOD
90-18311	472	AGKYSYRPTDAEKGGFGVFAGKKEOD
NGP165		
Z2491	472 472	AGKYSYRPTDAEKGGFGVFAGKKEQD AGKYSYRPTDAEKGGFGVFAGKKEOD
F6124	463	
297-0	463	AGKYSYRPTDAEKGGFGVFAGKKEQD AGKYSYRPTDAEKGGFGVFAGKKEOD
BZ232	468	AGKYSYRPTDAEKGGFGVFAGKKEOD
N_lactam	400	MONTO ENT TO MENGOT GAS HOVE TO

8497

111. AVANFGEKSEVVIPQOEVHVVERIGEFHRALTAGINILIPFIDRVAYRHSIKEIPLDVESQVCITRRNYTOL

112. AVANFGEKSEVVIPQOEVHVVERIGREHRALTAGINILIPFIDRVAYRHSIKEIPLDVESQVCITRRNYTOL

113. AVANFGEKSEVVIPQOEVHVVERIGREHRALTAGINILIPFIDRVAYRHSIKEIPLDVESQVCITRRNYTOL

114. AVANFGEKSEVVIPQOEVHVVERIGREHRALTAGINILIPFIDRVAYRHSIKEIPLDVESQVCITRRNYTOL

115. AVANFGEKSEVVIPQOEVHVVERIGREHRALTAGINILIPFIDRVAYRHSIKEIPLDVESQVCITRRNYTOL

116. AVANFGEKSEVVIPQOEVHVVERIGREHRALTAGINILIPFIDRVAYRHSIKEIPLDVESQVCITRRNYTOL


117. AVANFGEKSEVVIPQOEVHVERIGREHRALTAGINILIPFIDRVAYRHSIKEIPLDVESQVCITRR MEFFILLS MEF NGP165 NGH15 NGH36 90-18311 93-4286 BZZ169 NGF26 NGH38 SWZ107 BZZ32 BZZ83 44-76 MC58 E26 BZL98 NG3-88 Ng-F62 Ng-SN4 FA1090 205900 22491 860800 NG6-88 NGE31 2996 1000 BZ147 528 297-0

SUBSTITUTE SHEET (RULE 26)

SALDEAAGAWGVKVLRYEIKI SALDEAAGAWGVKVLRYEIKI VALDEAAGAWGVKVLRYEIKI VSALDEAAGAWGVKVLRYEIKI VSALDEAAGAWGVKVLRYEIKI VSALDEAAGAWGVKVLRYEIKI VSALDEAAGAWGVKVLRYEIKI VSALDEAAGAWGVKVLRYEIKI VSALDEAAGAWGVKVLRYEIKI 81 TVDGIIYEQVTDPKLASYGSSNYIMAITQLAQTTLRSVIGRMELDKTFEERDEINSHVVSALDE
81 TVDGIIYEQVTDPKLASYGSSNYIMAITQLAQTTLRSVIGRMELDKTFEERDEINSHVVSALDE
81 TVDGIIYEQVTDPKLASYGSSNYIMAITQLAQTTLRSVIGRMELDKTFEERDEINSTVVAALDE
81 TVDGIIYEQVTDPKLASYGSSNYIMAITQLAQTTLRSVIGRMELDKTFEERDEINSTVVSALDE
81 TVDGIIYEQVTDPKLASYGSSNYIMAITGLAAQTTLRSVIGRMELDKTFEERDEINSTVVSALDE
81 TVDGIIYEQVTDPKLASYGSSNYIMAITGLAAQTTLRSVIGRMELDKTFEERDEINSTVVSALDE
81 TVDGIIYEQVTDPKLASYGSSNYIMAITQLAAQTTLRSVIGRMELDKTFEERDEINSTVSALDEINSTVVSALDE
81 TVDGIIYEQVTDPKLASYGSSNYIMAITGLAAGTGINGTLAAGTGINGTNYTOTTVSA NGP165 NGH15 NGH36 90-18311 93-4286 2996 86080 NG6-88 NGF169 NGF26 NGF26 NGF38 SW2107 BZ232 BZ232 BZ232 BZ198 NG3-88 297-0 1000 BZ147 NG-SN4 FA1090 205900 Z2491 NGE28 F6124 E32 NGE31

## F1G. 16A(contd.)

### F/G. 16B



SUBSTITUTE SHEET (RULE 26)

F1G. 16B(CONTD.)

	NA GALLANGA SA	TAEO Y VAAFUNLAKE SNTLIMPANVADIGSLISA EMK	PAFINITARESNT LIMPANVADIGSLISAGMK	KESNTLIMPANVADIGSLISACHKIIDS	lktaeqyvaafnnlakesntlimpanvadigslisagmkiyds		ktaeoyvaafnnlaresntlimpanvadigslisagmr	ю	PPOGGADAVNLKTAEQYVAAFINNLAKESINTLTMPANVADIGSLISAGMKTTDSSKTAK+	avnektaeoxu	: 10gggadavnikki aeqyvarfinijaresntijimpanvadi gslisagmki idssktakk	ggadavnekiaeoyv	DAVNE	:Toggadavnlkiaeoxvaafnnlaresntlimpanvadigslisagmkiidssktarp	Poggadavnikktaeqxvaafnniaresntiimpanvadigslisagmktidssktake	Toggadavnektaeqvvaafnnearesntlimpanvadigslisagmkiidssktakk	Toggadavnikiaeoxvaafnniaresntlimpanvadigslisagmkiidssktak*	Toggadavnikiaeoyvaaenniaresntlimpanvadigslisagmkiidssktak+	Toggadavnikiaeoyvaafinniaresntlimpanvadigslisagmkiidssktakr	Toggadavniktaeqyvaafnnlakesntlimpanvadigslisagmkiidssktak	aeovvaaennea	TOGGADAVNIKIAEOYVAAFNNIAKESNTIIMPANVADIGSLISAGMKIIDSSKTAK*	TOGGROATNE	3		TOGGADAVNLKI AEQYVAAFNNLAKESNTLIMPANVADIGSLISAGMKIIDSSKTAK:	SYLVIE		TOGGADAVNLKI REQYVAAFNNLAKESNTLIMPANVADIGSLI SAGMKI IDSSKTAK	CYVARENNIARESNIED MERNYADI GSELISAGE	E. The Municipal Little And Andreas
AVNEKTAEDYVA		APALOTOGGADAVNEKTABOYV	<b>PTOGGADAVNEKI AEDYV</b>	<u>Peggadavnuria</u>	aardtoggadavnektae	anaeriro taalotoggadavalkiae	anaeatro taralo toggadavnik;	<b>Otoggadawner</b>	anaea Iro taaal	anabatrotaar	ANADA KOTABAL	anasa ketaareeteggadanne	DAVNE	anabatro taaalotoggadavnista	anaeatrotaarloto	anaeatrotaaaloto	anaeatro taaalo to	anaeat rotaaalotoggadavni	Taralotog	aeanaeatro taralo toggada vniktaeo yva	aeanaea iro i aaalotoggadavnik i aeoyva	taralotoge	TOGGROATNE	*		anaeatroianaloto		anaeatro taralotoggadavni	ranarorogenda Boggan	AERNAEMIKULARAKUTUGGADAVNIKTAEUTVA BEBNAEMIROTABALOTOGGADAVNIKTAGOVUN	
241	4	4	4	4	4	4	4	4	4	4	7	4	4	4	4	4.	♥ '	₹.	4	♥ '	4	4	4	9	₲,	4.	4	ጥ '	₹ ₹	* 7	•
NGE28 F6124	32	田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田田	9	608	8-95	216	GF2	GH38	£23	22	ო 8 2	4-7	ပ္ပ	2 6	2198	O	97-	000	214	28	145 145	다 ( 또 ()	GH36	4 1	876-5	<b>9-F6</b>	g-sw	A109	0530	4 0	1

( )

726 FIG. 17	1 MTIYFKNGFYDDTLGGIPEGAVAVRAEEYAALLAGQAQGGQIAADSDGRPVLTPPRPS TY 1 MTIYFKNGFYDDTLGGIPEGAVAVRAEEYAALLAGQAQGGQIAADSDGRPVLTPPRPS TY 1 MTIYFKNGFYDDTLGSIPEGAVAVRAEEYAALLAGQAQGGQIAADSDGRPVLTPPRPS TY 2 ~~~~~~NGFYDDTLGSIPEGAVAVRAEEYAALLAGQAQGGQIAADSDGRPVLTPPRPS TY 3 1 MTIYFKNGFYDDTLGSIPEGAVAVRAEEYAALLAGQAQGGQIAADSDGRPVLTPPRPS TY 4 ~~~~~~~NGFYDDTLGSIPEGAVAVRAEEYAALLAGQAQGGQIAADSDGRPVLTPPRPS TY 5 1 MTIYFKNGFYDDTLGSIPEGAVAVRAEEYAALLAGQAQGGQIAADSDGRPVLTPPRPS TY 6 1 ~~~ISKMGFYDDTLGSIPEGAVAVRAEEYAALLAGQTQGGQIAADSDGRPVLTPPRPS TY 7 2 IYFKNGFYDDTLGSIPEGAVAVRAEEYAALLAGQTQGGQIAADSDGRPVLTPPRPS TY	61 HEWDGKKWEIGEAAAARFAEQKTATAFRLAAKADELKNSLLAGYPQVEIDSFYRQEKEA 61 HEWDGKKWEIGEAAAARFAEQKTATAFRLAAKADELKNSLLAGYPQVEIDSFYRQEKEA 61 HEWDGKKWEIGEAAAARFAEQKTATAFRLAAKADELKNSLLAGYPQVEIDSFYRQEKEA 55 HEWDGKKWKISKAAAAARFAEQKTATAFRLAEKADELKNSLLAGYPQVEIDSFYRQEKEA 61 HEWDGKKWKISKAAAAARFAEQKTATAFRLAEKADELKNSLLAGYPQVEIDSFYRQEKEA 61 HEWDGKKWKISKAAAAARFAEQKTATAFRLAEKADELKNSLLAGYPQVEIDSFYRQEKEA 62 HEWDGKKWEIGEAAAAARFAEQKTATAFRLAAKADELKNSLLAGYPQVEIDSFYRQEKEA 63 HEWDGKKWEIGEAAAAARFAEQKTATAFRLAAKADELKNSLLAGYPQVEIDSFYRQEKEA
	10000 CC111 2996 BZ133 MG58 BZ232	1000 C11 C211 2996 BZ133 MGH38 BZ232

F1G. 17(contd.)

LARQADNNAPTPMLAQIAAT RGVELDVLIEKV EKSARLAVAAGAIIGKRQQLEDK LARQADNNAPTPMLAQIAAT RGVELDVLIEKV EKSARLAVAAGAIIGKRQQLEDK LARQADNNAPTPMLAQIAAARGVELDVLIEKV EKSARLAVAAGAIIGKRQQLEDK LARQADNNAPTPMLAQIAAARGVELDVLIEKV EKSARLAVAAGAIIGKRQQLEDK LARQADNNAPTPMLAQIAAARGVELDVLIEKV EKSARLAVAAGAIIGKRQQLEDK LARQADNNAPTPMLAQIAAARGVELDVLIEKV EKSARLAVAAGAIIGKRQQLEDK LARQADNNAPTPMLAQIAAARGVELDVLIEKV EKSARLAVAAGAIIGKRQQLEDK LARQADNNAPTPMLAQIAAARGVELDVLIEKV EKSARLAVAAGAIIGKRQQLEDK	LNT ISTAPGLDALEKEIEEWTLNIG LNT ISTAPGLDALEKEIEEWTLNIG LNA ISTAPGLDALEKEIEEWTLNIG LNA ISTAPGLDALEKEIEEWTLNIG LNT ISTAPGLDALEKEIEEWTLNIG LNT ISTAPGLDALEKEIEEWTLNIG LNT ISTAPGLDALEKEIEEWTLNIG LNA IBTAPGLDALEKEIEEWTANA
44454486 4444444444444444444444444444444	11111111 1111111111111111111111111111
10000 C111 C211 B2133 MC58 NGH38	1000 F6124 C111 2996 BZ133 MCF38 NGH38


į	
5 C C C C C C C C C C C C C C C C C C C	
7 Y	4
	Tresh Just Charle
9	WRITE THE RESIDENCE OF THE PARTY OF THE PART
NGP165	DCGTAN
BZ133	nkkylpraalcotaaatlaacoskstopppdasvingpdrpygtpacpapacyvyjägggavytvyphislphmaaodpakslosprigcaniknrogwddv
90-18311	HKKYDPRAALCGTAA
7	WERESTOR REARING COTTON
H3	Meryderaalcolaa
297-0	Voc(GTAN
NGE 31	MKKYLPRAALCGIAA
528	MKKYOPRAALYGTAA
2996	WKKY10PRABUYGTAA
9	MKKYOPRAADYGTAA
BZ198	MKRYDPRAADY(GYAA)
3,	WKKWOPBAADYOTAA
BZ169	MERCY OF REAL STAY (C) FROM
NGF 26	MERSYPERBANDY GRAM
BZ232	ATTENDED TO A TOTAL OF THE PARTY.
BZ83	WIRESTON BANKO CONTRA
44-76	WIRESTOPPINANOY OF BAN
MC58	WERVINE RAMANY (GYANA)
B2147	mkrycpraacy Wkrycpraacy Wrycpraacy
NGH36	mkrycprajly gtaaatcaacobkbiotpopdtbvinopdrpvoipdagtfvig
ы	i akkyjpraalygtaaatlaacoskstotpboddsvingbdrbvgtpdpagttvegggggavytvvphlslphmaeqddfalcarlgrngghgdv
00	STREET STORY STANDARD STANDARD
205900	Wrryibralcotrarican
249	STATES OF RESIDENCE STATES OF STATES
N	MKKYIPRANSYOTANAY GA
860800	WERY OFRANCO: ABAY OR
E32	WEST OF PRINTING CONTINUE OF THE
NGH15	wrrydfraat <mark>c</mark> gtaaatear
SW2107	i mkkylpraalijolaaatlaacobkbiotbodfbvinopdrpvotpodagtiväggggavytuvpblslphwaaqdpakelgbfrlgcanlkneggwodv
N_lactam	i mkrhippraalygtaaatlaacobkbiotpbiotbiilkgpdrpagtrugggggavytuvphibidhwaaqdpakbiocerlicrniknrqgwodu

919

FIG. 18A

CAGAP OTPVHSPOAKEPERYPTPWQVAGNGELAGTVTGYYEPVLKGDGRRYAFARPIYGIPDDPISVPLPAGLRGGRALVRIRGTGTRNSGTIDNA
CAGAP OTPVHSPOAKEPERYPTPWQVAGNGELAGTVTGYYEPVLKGDDRRYAGARPIYGIPDDPISVPLPAGLRSGRALVRIRGTGTRNSGTIDNA
CAGAP OTPVHSPOAKGPFERYPTPWQVAGNGELAGTVTGYYEPVLKGDDRRYAGARPIYGIPDDPISVPLPAGLRSGRALVRIRGTGKNSGTIDNA
CAGAP OTPVHSPOAKGPFERYPTPWQVAGNGELAGTVTGYYEPVLKGDDRRYAGARPPIYGIPDDPISVPLPAGLRSGRALVRIRGTGKNSGTIDNA
CAGAP OTPVHSPQAKGPFERYPTPWQVAGNGELAGTVTGYYEPVLKGDDRRYAGARPPIYGIPDDPISVPLPAGLRSGRALVRIRGTGKNSGTIDNA
CAGAP OTPVHSPQAKGPFERYPTPWQVAGNGSLAGTVTGYYEPVLKGDDRRYAGARPPIYGIPDDPISVPLPAGLRSGRALVRIRGTGKNSGTIDNA
CAGAP OTPVHSPQAKGPFERYPTPWQVAGNGSLAGTVTGYYEPVLKGDDRRYAGARPPIYGIPDDPISVPLAGGRAGFRATVRIRGTGKNSGTIDNA
CAGAP OTPVHSPQAKGPFERYPTPWQVAGNGSLAGTVTGYYEPVLKGDDRRYAGARPPIYGIPDDPISVPLAGGRAFGRATVRIRGTGKNSGTIDNA
CAGAP OTPVHSPQAKGPFERYPTPWQVAGNGSLAGTVTGYYEPVLKGDDRRYAGARPPIYGIPDDPISVPLAGGRAFGRATVRIRGTGKNSGTIDNA
CAGAP OTPVHSPQAKGPFERYPTPWQVAGNGSLAGTVTGYYEPVLKGDDRRYAGARPPIYGIPDDPISVAGKSGKALVRIRGTGKNSGTIDNA
CAGAP OTPVHSPQAKGPFERYPTPWGVAGNGSLAGTVTGYYEPVLKGDDRRYAGARPPIYGIPDDPISGTGKNSGTALVRIRGTGKNSGTIDNA
CAGAP OTPVHSPQAKGPFERYPTPWGVAGNGSLAGTGYTGYNGTGKNSTRYTDAGNSTYNGTGKNSGTALNAT NG-SN4 FA1090 NG-F62 F6124 F26 NGP165 B2133 99-18311 l_lactam MGH38 297-0 297-0 528 2996 NG6-88 BZ198 NG726 BZ232 BZ232 A44-76 MC58 MC58 MC58 1000 205900 22491 008091

# FIG. 18A(CONTD.




# FIG. 18E

89/97

90-18311 93-4286 NGH38 297-0 NGE31 528 NGP165 BZ133 2996 NG6-88 BZ16-88 BZ169 NG3-88 BZ23-23 BZ23-23 BZ23-23 BZ23-24 A4-76 NG28 NG28

FIG. 18B(contd.)

FIG. 18C





IKKI IFAALGAAAVGTASAATYKVDEYHANARFAIDHFNTSTNVGGFYGLTGSVEFDQAK IKKI IFAALAAAA STASAATYKVDEYHANARFAIDHFNTSTNVGGFYGLTGSVEFDQAK IKKI IMAALAAAA GTASAATYKVDEYHANARFSIDHFNTSTNVGGFYGLTGSVEFDQAK RDGK IDITI PVANLQSGSQHF TDHLKSADI FDAAQY PDIRFVSTKFNFNGKKLVSVDGNL DGKIDITIPVANLQSGSQHFTDHLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVDGNL DGKIDITIPVANLOSGSOHFTDHLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVDGNL MKKILFAALAAAAVGTASAATYKVDEYHANARFAIDHFNTSTNVGGFYGLTGSVEFDQAK MANL QSGSQHFTDHLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVDGNI GKIDITIPVANLQSGSQHFTDHLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVDGN GKIDITIPVANLOSGSQHFIDHLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVDGN DGKIDITI PVANLQSGSQHFTDHLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVDGN <u>MKKI IFAALAAAAVGTASAATYKVDEYHANARFAIDHFNTSTNVGGFYGLTGSVEFD</u> MKKI IFAALAAAAVGTASAATYKVDEYHANARFAIDHFNTSTNVGGFYGLTGSVEFD KK LI FAALAAAAVGTASAA TYK VDEY HANARFAI DHFNTSTNVGGFYGLTGSVEFD kkti iaalaaavgtasaatxkvdeyhanarfaidhfntstnvggfygltgsvefd OSGSOHF TDHLKSADIFDAAQYPDIRFVSTKFNFNGKKLVSVD GKIDITIP GKIDITI 149 149 199 199 199 99 2996 BZ13 NGH3 MC58 F6124 BZ23 C11 2996 BZ13: BZ23; NGH3 N 100 100 MC5


FIG. 19(contd.)

TMHGKTAPVKLKAEKFNCYQSPMBKTEVCGGDFSTTIDRTKWGVDYLVNVGMTKSVRIDI	TMHCKTAP	1 TMHGKTAPVKLKAEKFNCYQSPMAKTEVCGGDFSTTIDRTKWGVDYLVNVGMTKSVRIDI	TMHGKTAP	TMHGKTAP	TWHGKTAP	TMHGKTAP	1 TMHGKTAPVKLKAEKFNCYQSPM <mark>L</mark> KTEVCGGDFSTTIDRTKWGMDYLVNVGMTKSVRIDI	1 QIEANKQ~	1 OTENANKO~		1 QIBAAKQ~	1 OIBAAKO~	1 Oldsanko~		1 QIBAAKQ~
~	7	~	~	~	~	~	121	$\infty$	$\boldsymbol{\omega}$	$\infty$	$\boldsymbol{\omega}$	$\boldsymbol{\omega}$	$\boldsymbol{\omega}$	181	œ
1000	4	9	213	223	Ö	C58	F6124	00	7	9	Z13	BZ232	GH3	58	F6124

93/97 FIG. 20A Orf 4 (33 kD)










SUBSTITUTE SHEET (RULE 26)

WO 00/66741 PCT/IB00/00642


94/97 FIG. 20B 225 (27kD)*









*95/97 FIG. 20C* 235 (23 kD)










()

WO 00/66741 PCT/IB00/00642

*9497 FIG. 20D* 519 (35 kD)











( )

*97/97 FIG. 20E* 919 (48kD)









# (19) World Intellectual Property Organization International Bureau





#### (43) International Publication Date 9 November 2000 (09.11.2000)

**PCT** 

# (10) International Publication Number WO 00/66741 A3

- (51) International Patent Classification⁷: C12N 15/31, C07K 14/22, C12Q 1/68, G01N 33/53, A61K 39/095
- (21) International Application Number: PCT/IB00/00642
- (22) International Filing Date: 28 April 2000 (28.04.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

9910168.5 0005728.1 30 April 1999 (30.04.1999) GB 9 March 2000 (09.03.2000) GB

- (71) Applicant (for all designated States except US): CHIRON S.P.A. [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): RAPPUOLI, Rino [IT/IT]; Chiron S.p.A., Via Fiorentina, 1, I-53100 Siena (IT).
- (74) Agents: HALLYBONE, Huw, George et al.; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- (88) Date of publication of the international search report: 13 June 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

66741 A3

(54) Title: CONSERVED NEISSERIAL ANTIGENS

(57) Abstract: To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of Neisseria, particularly N. meningitidis and N.gonorrhoeae.

#### INTERNATIONAL SEARCH REPORT

ntional Application No PLI/IB 00/00642

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/31 C07K14/22

C12Q1/68

G01N33/53

A61K39/095

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K C12N C12Q G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, STRAND

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	COONEY ET AL.: "Three contiguous lipoprotein genes in Pasteurella haemolytica A1 which are homologous to a lipoprotein gene in Haemophilus influenza Type b" INFECTION AND IMMUNITY, vol. 61, no. 11, November 1993 (1993-11), pages 4682-4688, XP002148894 abstract page 4682, column 1 figures 3,4	1,3-15

	A dictar admity members are insteo in armex.
<ul> <li>Special categories of cited documents:</li> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" earlier document but published on or after the international filing date</li> <li>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or other means</li> <li>"P" document published prior to the international filing date but later than the priority date claimed</li> </ul>	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family
Date of the actual completion of the international search  29 September 2000	Date of mailing of the international search report  2 2 12 2000
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  van Klompenburg, W

Form PCT/ISA/210 (second sheet) (July 1992)

#### INTERNATIONAL SEARCH REPORT

International Application No
PUT/IB 00/00642

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE SWISSPROT [Online] ACC. No.: p28635, 1 December 1992 (1992-12-01) GERVAIS ET AL.: "putative lipoprotein yaec precursor" XP002148895 abstract	1,3-11, 15
×	EP 0 273 116 A (MAX PLANCK GESELLSCHAFT) 6 July 1988 (1988-07-06) page 3, line 12 - line 25 page 3, line 42 - line 47 claims 1-23; figure 1; examples 1-4	1-7
(	WO 96 29412 A (IAF BIO VAC INC ;BRODEUR BERNARD R (CA); MARTIN DENIS (CA); HAMEL) 26 September 1996 (1996-09-26) page 5, line 24 -page 6, line 12 claims 1-90; figures 11,12,15; examples 4,7,9; table 2	1-7
	PETTERSSON A ET AL: "Sequence variability of the meningococcal lactoferrin-binding protein LbpB" GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 231, no. 1-2, 29 April 1999 (1999-04-29), pages 105-110, XP004166783 ISSN: 0378-1119 page 105, column 2 page 109, column 2 -page 110, column 1; figures 1,2	1-7
,х	WO 99 24578 A (PIZZA MARIAGRAZIA ;SCARLATO VINCENZO (IT); RAPPUOLI RINO (IT); CHI) 20 May 1999 (1999-05-20) cited in the application page 164, line 42 -page 169, line 34	1-15

3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# ernational application No. PCT/IB 00/00642

#### INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 c	of final at the state of
To a continuation of item 1	of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the	ne following reasons:
Claims Nos.:     because they relate to subject matter not required to be searched by this Authority, namely:	
Claims Nos.:     because they relate to parts of the International Application that do not comply with the prescribed require an extent that no meaningful International Search can be carried out, specifically:	ements to such
Claims Nos.:     because they are dependent claims and are not drafted in accordance with the second and third sentence	es of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
,	
see additional sheet	
1. As all required additional search fees were timely paid by the applicant, this International Search Report of searchable claims.	overs all
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not of any additional fee.	invite payment
3. As only some of the required additional search fees were timely paid by the applicant, this International Se covers only those claims for which fees were paid, specifically claims Nos.:	arch Report
4. X No required additional search fees were timely paid by the applicant. Consequently, this International Sear restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-15 all partially	ch Report is
Remark on Protest  The additional search fees were accompanied by the companied by the comp	
Remark on Protest  The additional search fees were accompanied by the a	applicant's protest.
No protest accompanied the payment of additional sea	ırch fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-15, all partially

A protein comprising a conserved fragment of ORF4 with SEQ ID NOs: 22-53. The above mentioned protein for use as a medicament. A nucleic acid encoding the above mentioned protein. The use of the above mentioned protein or nucleic acid in the manufacture of a medicament. The use of the above mentioned protein or nucleic acid in the manufacture of a multi-specific diagnostic reagent.

- 2. Claims: 1-15, all partially
  Idem for ORF40 with SEQ ID NOs: 1-21
- 3. Claims: 1-15, all partially
  Idem for ORF46 with SEQ ID NOs: 182-187
- 4. Claims: 1-15, all partially

  Idem for protein 225 for SEQ ID NOs: 54-87
- 5. Claims: 1-15, all partially

  Idem for protein 235 with SEQ ID NOs: 88-118
- 6. Claims: 1-15, all partially

  Idem for protein 287 for SEQ ID NOs: 119-124
- 7. Claims: 1-15, all partially

  Idem for protein 519 with SEQ ID NOs: 125-146
- 8. Claims: 1-15, all partially

  Idem for protein 726 with SEQ ID NOs: 188-195
- 9. Claims: 1-15, all partially

  Idem for protein 919 with SEQ ID NOs: 147-181
- 10. Claims: 1-15, all partially

( )

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Idem for protein 953 with SEQ ID NOs: 196-203

11. Claims: 1-15 all partially

A protein comprising a conserved fragment of a Neisserial protein not covered by the above mentioned inventions. medicament. A nucleic acid encoding the above mentioned protein. The use of the above mentioned protein or nucleic acid in the manufacture of a medicament. The use of the above mentioned protein or nucleic acid in the manufacture of a multi-specific diagnostic reagent.

page 2 of 2

### INTERNATIONAL SEARCH REPORT

nformation on patent family members

Intravional Application No
PC (/ IB 00/00642

Patent document cited in search report	Publication date	Patent family member(s)	Publication date		
EP 0273116 A	06-07-1988	NONE			
WO 9629412 A	26-09-1996	AU 716225 B AU 4934396 A BR 9607651 A CA 2215161 A CZ 9702914 A EP 0815234 A HU 9702387 A JP 11500624 T NO 974264 A PL 322363 A SI 9620035 A SK 125597 A	24-02-2000 08-10-1996 17-11-1998 26-09-1996 14-01-1998 07-01-1998 28-05-1998 19-01-1999 13-11-1997 19-01-1998 31-12-1998 03-06-1998		
WO 9924578 A	20-05-1999	AU 9363798 A EP 1029052 A	31-05-1999 23-08-2000		

Form PCT/ISA/210 (patent family annex) (July 1992)

BNSDOCID: <WO_____0066741A3_I_>